var title_f17_45_18128="PET rate of transport";
var content_f17_45_18128=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F83816&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F83816&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 577px\">",
"   <div class=\"ttl\">",
"    Peritoneal Equilibration Test (PET): Rate of transport",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 557px; height: 655px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data originally published in Peritoneal Dialysis International. Reproduced with permission from: Twardowski ZJ, Nolph KD, Khanna R, et al. Peritoneal equilibration test. Perit Dial Bull 1987; 7:138. Copyright &copy; 1987.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_45_18128=[""].join("\n");
var outline_f17_45_18128=null;
var title_f17_45_18129="Quick start method";
var content_f17_45_18129=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F56863&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F56863&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 613px\">",
"   <div class=\"ttl\">",
"    Quick start approach to initiation of new birth control method: pill, patch, ring, injection",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 593px; height: 647px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Because hormonal EC is not 100 percent effective, check urine pregnancy test two weeks after EC use.",
"     <br>",
"      &bull; If pregnancy test is positive, provide options counseling.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: RHEDI/The Center for Reproductive Health Education In Family Medicine, Montefiore Medical Center, New York City. Copyright &copy;2007 RHEDI.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_45_18129=[""].join("\n");
var outline_f17_45_18129=null;
var title_f17_45_18130="Large endometrial polyp";
var content_f17_45_18130=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F74624&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F74624&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 491px\">",
"   <div class=\"ttl\">",
"    Elongated polyp in 55-year-old woman who presented with postmenopausal bleeding",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 471px; height: 238px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Sagittal transvaginal sonogram shows lobular 9- to 20-mm-thick endometrium (cursors and arrows) (A). Sagittal sonohysterogram shows 2.3-cm elongated angular polyp (arrow) with 0.8-cm stalk and small 0.7-cm polyp (arrowhead) (B).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from Joizzo, JR, Chen, MY, Riccio, GJ, Endometrial Polyps: Sonohysterographic Evaluation. AJR Am J Roentgenol 2001; 176:617. Copyright &copy; 2001 American Journal of Roentgenology.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_45_18130=[""].join("\n");
var outline_f17_45_18130=null;
var title_f17_45_18131="Baby position PI";
var content_f17_45_18131=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F72643&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F72643&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 499px\">",
"   <div class=\"ttl\">",
"    Different baby positions in the uterus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 479px; height: 697px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Before birth, babies lie in the uterus in different positions. Most babies lie with their head down and close to the vagina (as shown in A). But some babies lie with their legs, buttocks, or shoulders down. Doctors call it \"breech\" if a baby's legs or buttocks are closest to the vagina (as shown in B).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_45_18131=[""].join("\n");
var outline_f17_45_18131=null;
var title_f17_45_18132="NB lung fluid clearance";
var content_f17_45_18132=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F57746&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F57746&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 634px\">",
"   <div class=\"ttl\">",
"    Resorption of alveolar fluid at birth: Cellular mechanisms",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 614px; height: 310px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Na enters the cell through the apical surface of both ATI and ATII cells via amiloride-sensitive epithelial Na channels (ENaC), both highly selective channels (HSC) and nonselective channels (NSC), and via cyclic nucleotide gated channels (seen only in ATI cells). Electroneutrality is conserved with chloride movement through cystic fibrosis transmembrane conductance regulator (CFTR) or through chloride channels (CLC) in ATI and ATII cells, and/or paracellularly through tight junctions. The increase in cell Na stimulates Na-K-ATPase activity on the basolateral aspect of the cell membrane, which drives out three Na ions in exchange for two K ions, a process that can be blocked by the cardiac glycoside ouabain. If the net ion movement is from the apical surface to the interstitium, an osmotic gradient would be created, which would in turn direct water transport in the same direction, either through aquaporins or by diffusion.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reprinted with permission from: Jain L. Respiratory morbidity in late-preterm infants: prevention is better than cure. Am J Perinatol 2008; 25:75. Copyright &copy; 2008 Thieme Medical Publishers, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_45_18132=[""].join("\n");
var outline_f17_45_18132=null;
var title_f17_45_18133="Rasagiline: Patient drug information";
var content_f17_45_18133=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Rasagiline: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/13/24791?source=see_link\">",
"     see \"Rasagiline: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F2985038\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Azilect&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F14476718\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Azilect&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10028849\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10028851\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2692011",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat Parkinson's disease.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10028850\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702857",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to rasagiline or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703859",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have taken certain drugs used for low mood (depression) like isocarboxazid, phenelzine, or tranylcypromine or drugs used for Parkinson's disease like selegiline or rasagiline in the last 14 days. Taking this drug within 14 days of those drugs can cause very bad high blood pressure. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701004",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Stop fluoxetine for at least 5 weeks before starting this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701346",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you cannot follow the diet needed when taking this drug. See How Is This Drug Best Taken? for more details.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10028855\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697179",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have been taking this drug for many weeks, talk with your doctor before stopping. You may want to slowly stop this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697845",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid aged cheeses that have lots of tyramine. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698416",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood pressure and heart rate checked often. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697633",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell dentists, surgeons, and other doctors that you use this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697111",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are taking this drug and have high blood pressure, talk with your doctor before using OTC products that may raise blood pressure. These include cough or cold drugs, diet pills, stimulants, ibuprofen or like products, and some natural products or aids.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696620",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, or mixed drinks. Alcohol may cause very high blood pressure even 2 weeks after the drug is stopped.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697564",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Limit your use of caffeine (for example, tea, coffee, cola) and chocolate. Use with this drug may cause nervousness, shakiness, and a fast heartbeat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10028856\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698060",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling lightheaded, sleepy, having blurred eyesight, or a change in thinking clearly. Avoid driving and doing other tasks or actions that call for you to be alert or have clear eyesight until you see how this drug affects you.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling dizzy. Rise slowly over a few minutes when sitting or lying down. Be careful climbing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698195",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Joint pain.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10028858\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698655",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A fast heartbeat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699057",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Big change in balance.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699058",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in thinking clearly and with logic.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699112",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very nervous and excitable.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699028",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad flushing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699031",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705902",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Strong urges that are hard to control (such as gambling or sex).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10028853\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696213",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use this drug early in the day to stop sleep problems.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694863",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Follow a diet plan. Some foods and drinks taken with higher doses of this drug may cause very risky effects such as sudden high blood pressure. To avoid these problems, get a list of foods to avoid.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698545",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a diary of your signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10028854\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10028859\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10028860\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11849 Version 33.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1102-211.167.112.15-0980553D96-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_45_18133=[""].join("\n");
var outline_f17_45_18133=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2985038\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14476718\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028849\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028851\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028850\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028855\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028856\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028858\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028853\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028854\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028859\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028860\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?24/13/24791?source=related_link\">",
"      Rasagiline: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f17_45_18134="Treatment of calcium pyrophosphate crystal deposition disease";
var content_f17_45_18134=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment of calcium pyrophosphate crystal deposition disease",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/45/18134/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/45/18134/contributors\">",
"     Michael A Becker, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/45/18134/contributors\">",
"     Lawrence M Ryan, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/45/18134/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/45/18134/contributors\">",
"     H Ralph Schumacher, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/45/18134/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/45/18134/contributors\">",
"     Paul L Romain, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?17/45/18134/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 12, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H272267591\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Precipitation of crystals of calcium pyrophosphate dihydrate (CPPD) in connective tissues may be asymptomatic or may be associated with several clinical syndromes. These disorders, including an acute and chronic inflammatory arthropathy, as well as radiographic calcification, comprise the spectrum of calcium pyrophosphate crystal deposition disease [",
"    <a class=\"abstract\" href=\"UTD.htm?17/45/18134/abstract/1-3\">",
"     1-3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Treatment of the CPPD crystal deposition diseases is discussed here. The pathogenesis, etiology, clinical manifestations, and diagnosis of this disorder are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/14/6375?source=see_link\">",
"     \"Pathogenesis and etiology of calcium pyrophosphate crystal deposition disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/38/7785?source=see_link\">",
"     \"Clinical manifestations and diagnosis of calcium pyrophosphate crystal deposition disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H272267598\">",
"    <span class=\"h1\">",
"     TERMINOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The names traditionally used for CPPD crystal deposition diseases include pseudogout, chondrocalcinosis, and pyrophosphate arthropathy. A European League Against Rheumatism (EULAR) consensus panel has suggested alternative terminology and has reviewed diagnostic approaches to these conditions [",
"    <a class=\"abstract\" href=\"UTD.htm?17/45/18134/abstract/4\">",
"     4",
"    </a>",
"    ]. The clinical syndromes, findings, and limitations of these terms, together with the nomenclature proposed by EULAR include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pseudogout &mdash; Pseudogout accurately describes acute attacks of CPPD crystal-induced synovitis, which clinically resemble urate gout. However, the majority of individuals with CPPD crystal deposition never experience such episodes. The EULAR consensus panel prefers the term &ldquo;acute calcium pyrophosphate (CPP) crystal arthritis&rdquo; instead of pseudogout.",
"     </li>",
"     <li>",
"      Chondrocalcinosis &mdash; Chondrocalcinosis refers to radiographic calcification in hyaline",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      fibrocartilage. It is commonly present in patients with CPPD crystal deposition disease but is neither absolutely specific for CPPD nor universal among affected patients. The EULAR group designates this finding as &ldquo;cartilage calcification (CC).&rdquo;",
"     </li>",
"     <li>",
"      Pyrophosphate arthropathy &mdash; Pyrophosphate arthropathy is the term sometimes used for the joint disease or radiographic abnormalities accompanying CPPD crystal deposition. Although this name has little justification in terms of the pathologic anatomy of the disorder, evidence of aberrant inorganic pyrophosphate metabolism in the pathogenesis of CPPD crystal deposition disease may legitimize use of this term.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The term &ldquo;calcium pyrophosphate deposition&rdquo; (also abbreviated as &ldquo;CPPD&rdquo;) is proposed by the EULAR task force as the umbrella term for all instances of calcium pyrophosphate crystal occurrence.",
"   </p>",
"   <p>",
"    The EULAR consensus panel has rigorously reviewed the literature regarding CPPD crystal deposition, has proposed changes in nomenclature, has summarized levels of evidence regarding diagnosis, and has made recommendations for management [",
"    <a class=\"abstract\" href=\"UTD.htm?17/45/18134/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. A commentary has been published concerning the EULAR committee recommendations, which is co-authored by one of the authors of this topic review, that generally supports use of the new terms [",
"    <a class=\"abstract\" href=\"UTD.htm?17/45/18134/abstract/6\">",
"     6",
"    </a>",
"    ]. However, these terms are not widely accepted, and we have, therefore, retained use of the traditional terminology while providing the proposed terms in parentheses following the traditional names for these conditions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H272267743\">",
"    <span class=\"h1\">",
"     GENERAL APPROACH",
"    </span>",
"    &nbsp;&mdash;&nbsp;If a disease associated with CPPD deposition is present, specific therapy directed at the underlying disorder should be initiated even though it usually does not reverse CPPD crystal deposition disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/38/7785?source=see_link&amp;anchor=H21#H21\">",
"     \"Clinical manifestations and diagnosis of calcium pyrophosphate crystal deposition disease\", section on 'Screening for associated diseases'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Otherwise, therapies are utilized for the treatment of pseudogout, chronic crystal deposition, or degenerative joint disease as necessitated by the clinical presentation. These treatment approaches are based upon clinical experience and not upon controlled trials. The aforementioned EULAR panel has made a careful analysis of the scant literature supporting treatment strategies [",
"    <a class=\"abstract\" href=\"UTD.htm?17/45/18134/abstract/5\">",
"     5",
"    </a>",
"    ]. In general, their recommendations concur with ours, but the limitations of these recommendations and the importance of further clinical research in CPPD crystal deposition disease have also been noted [",
"    <a class=\"abstract\" href=\"UTD.htm?17/45/18134/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ACUTE PSEUDOGOUT (\"ACUTE CPP CRYSTAL ARTHRITIS\")",
"    </span>",
"    &nbsp;&mdash;&nbsp;One approach or, more often, a combination of approaches is appropriate for the treatment of acute attacks of pseudogout (",
"    <a class=\"graphic graphic_algorithm graphicRef56111 \" href=\"UTD.htm?29/17/29982\">",
"     algorithm 1",
"    </a>",
"    ). These include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Removal of crystals by thorough joint aspiration",
"     </li>",
"     <li>",
"      Administration of a nonsteroidal antiinflammatory drug (NSAID) or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32983?source=see_link\">",
"       colchicine",
"      </a>",
"      during the period of acute inflammation. Oral or systemic glucocorticoids can be used if there are contraindications to the use of colchicine and NSAIDs.",
"     </li>",
"     <li>",
"      Intraarticular injection of a glucocorticoid preparation (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/14/30951?source=see_link\">",
"       \"Intraarticular and soft tissue injections: What agent(s) to inject and how frequently?\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Joint immobilization",
"     </li>",
"     <li>",
"      Ice or cool pack application",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Recommendation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Whenever possible, we prefer joint aspiration (both for diagnosis and for treatment) combined with intraarticular glucocorticoid injection. For injections into large joints, including the shoulders, we use",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/38/39520?source=see_link\">",
"     triamcinolone",
"    </a>",
"    acetonide (1 mL, 40 mg) mixed with 1 or 2 mL of 1 percent procaine.",
"   </p>",
"   <p>",
"    When smaller joints of the lower or upper extremities are involved, smaller doses of the respective glucocorticoid preparations can be utilized. We also restrict weightbearing or routine joint use in all patients for 48 to 72 hours, employing splints when necessary. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/52/23368?source=see_link\">",
"     \"Joint aspiration or injection in adults: Technique and indications\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/14/30951?source=see_link\">",
"     \"Intraarticular and soft tissue injections: What agent(s) to inject and how frequently?\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    When more than two joints are inflamed, joint injection is usually an impractical approach. In this setting, medical therapy is warranted, using agents used for the treatment of acute gout (",
"    <a class=\"graphic graphic_algorithm graphicRef56111 \" href=\"UTD.htm?29/17/29982\">",
"     algorithm 1",
"    </a>",
"    ). The following approaches are described in detail elsewhere (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/24/17800?source=see_link\">",
"     \"Treatment of acute gout\"",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An oral nonsteroidal antiinflammatory drug or oral",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32983?source=see_link\">",
"       colchicine",
"      </a>",
"      is preferred.",
"     </li>",
"     <li>",
"      If oral medications are precluded by the patient&rsquo;s postoperative status or by age, prior NSAID-related toxicity, or",
"      <span class=\"nowrap\">",
"       renal/hepatic",
"      </span>",
"      dysfunction, systemic glucocorticoids or adrenocorticotropic hormone (ACTH) can be given, although this approach has been less well-studied than in gouty arthritis.",
"     </li>",
"     <li>",
"      Although intravenous",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32983?source=see_link\">",
"       colchicine",
"      </a>",
"      can reduce the inflammation of pseudogout, the potential dangers of this approach have led to withdrawal of approval in the United States for the distribution of colchicine for administration by the intravenous route.",
"     </li>",
"     <li>",
"      Interleukin (IL)-1 inhibitors show promise for suppressing crystal-induced inflammation, but data are not available to support treatment of acute pseudogout with these agents.",
"     </li>",
"     <li>",
"      Observational studies involving a total of 15 patients suggest that low-dose",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      may be useful in instances of refractory calcium pyrophosphate crystal-induced inflammation, either pseudogout or pseudo-rheumatoid arthritis [",
"      <a class=\"abstract\" href=\"UTD.htm?17/45/18134/abstract/7,8\">",
"       7,8",
"      </a>",
"      ]. In contrast, a lack of efficacy was seen in a smaller experience with three patients [",
"      <a class=\"abstract\" href=\"UTD.htm?17/45/18134/abstract/9\">",
"       9",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     PROPHYLAXIS FOR PSEUDOGOUT (\"ACUTE CPP CRYSTAL ARTHRITIS\")",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients suffering recurrent attacks of pseudogout, several reports indicate that oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32983?source=see_link\">",
"     colchicine",
"    </a>",
"    daily may be effective as a prophylactic agent at a usual dose of 0.6 mg twice daily. In one series of 10 patients with recurrent episodes of pseudogout, colchicine treatment was associated with a marked reduction in the number of episodes at one year compared with the year prior to the initiation of therapy (10 versus 32 episodes) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/45/18134/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Recommendation",
"    </span>",
"    &nbsp;&mdash;&nbsp;We suggest prophylaxis with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32983?source=see_link\">",
"     colchicine",
"    </a>",
"    for patients with three or more attacks of pseudogout annually as long as the guidelines for safe use of this agent are followed with respect to renal and hepatic function, to drug intolerance, and to potential drug interactions. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/26/36266?source=see_link\">",
"     \"Prevention of recurrent gout\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If the recommended dose of 0.6 mg twice daily results in abdominal distress or diarrhea, side effects that commonly occur among older patients, a reduction in dose to 0.6 mg once daily or even every other day may increase",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32983?source=see_link\">",
"     colchicine",
"    </a>",
"    tolerability. However, evidence for reduction of pseudogout flare incidence with doses lower than 0.6 mg twice daily is lacking.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3678803\">",
"    <span class=\"h1\">",
"     PSEUDO-RHEUMATOID ARTHRITIS (\"CHRONIC CPP CRYSTAL INFLAMMATORY ARTHRITIS\")",
"    </span>",
"    &nbsp;&mdash;&nbsp;A small portion of patients with CPPD deposition disease exhibit features of chronic joint inflammation that may mimic rheumatoid arthritis. After careful analysis of the scant available data, the European League Against Rheumatism consensus panel has formulated provisional treatment recommendations for pseudo-rheumatoid arthritis [",
"    <a class=\"abstract\" href=\"UTD.htm?17/45/18134/abstract/5\">",
"     5",
"    </a>",
"    ]. In order of preference, their suggestions were nonsteroidal antiinflammatory drug (with gastroprotection when indicated)",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32983?source=see_link\">",
"     colchicine",
"    </a>",
"    as first choices, followed by low-dose glucocorticoid,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/26/2471?source=see_link\">",
"     hydroxychloroquine",
"    </a>",
"    . Their mean strength of recommendation was 79 on a 0 to 100 mm visual analogue scale.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     CHRONIC AND PROGRESSIVE CPPD CRYSTAL DEPOSITION",
"    </span>",
"    &nbsp;&mdash;&nbsp;In contrast to the relatively routine success in the treatment of pseudogout attacks, there is no proven effective therapy to prevent progressive CPPD crystal deposition or to remove crystals already deposited. In this regard, the potential therapeutic use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/18/37157?source=see_link\">",
"     probenecid",
"    </a>",
"    , an inhibitor of transmembrane anion transport, to retard extracellular pyrophosphate elaboration [",
"    <a class=\"abstract\" href=\"UTD.htm?17/45/18134/abstract/11,12\">",
"     11,12",
"    </a>",
"    ] is an intriguing idea that is under investigation.",
"   </p>",
"   <p>",
"    Even among patients with associated metabolic disorders, such as hemochromatosis, hyperparathyroidism, or hypothyroidism, successful treatment of the metabolic disorder has not resulted in reversal of cartilage calcification, and new calcifications have developed in some individuals [",
"    <a class=\"abstract\" href=\"UTD.htm?17/45/18134/abstract/13-16\">",
"     13-16",
"    </a>",
"    ]. However, some instances of spontaneous resolution of the presumed CPPD crystal deposits have been reported.",
"   </p>",
"   <p>",
"    Some studies have reported success with different therapeutic approaches:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Long-term administration of magnesium in some patients with chronic hypomagnesemia may decrease meniscal calcification [",
"      <a class=\"abstract\" href=\"UTD.htm?17/45/18134/abstract/17\">",
"       17",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Symptomatic improvement was noted in some patients with sporadic CPPD crystal deposition during a controlled trial of magnesium carbonate supplementation, but radiographic improvement was not detected [",
"      <a class=\"abstract\" href=\"UTD.htm?17/45/18134/abstract/18\">",
"       18",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In patients with persistent clinical manifestations of CPPD crystal deposition despite correction of associated metabolic disorders, management of the joint disease follows the recommendations for that of idiopathic CPPD crystal deposition disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     JOINT DEGENERATION (\"OA WITH CPPD\")",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment approaches for patients in whom joint degeneration is the major manifestation of CPPD crystal deposition disease and is unaccompanied by episodic pseudogout are the same as those employed for osteoarthritis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/30/2538?source=see_link\">",
"     \"Nonpharmacologic therapy of osteoarthritis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/23/14714?source=see_link\">",
"     \"Pharmacologic therapy of osteoarthritis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/9/12440?source=see_link\">",
"     \"Surgical therapy of osteoarthritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?10/9/10386?source=see_link\">",
"       \"Patient information: Pseudogout (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?33/15/34033?source=see_link\">",
"       \"Patient information: Pseudogout (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2086999\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Treatment of calcium pyrophosphate (CPPD) deposition diseases is based largely upon clinical experience in both CPPD deposition disease and gout, given the lack of randomized trials in this disorder. In patients with an underlying disorder associated with CPPD deposition, specific therapy directed at the underlying disorder should also be initiated, although it usually does not reverse CPPD crystal deposition disease. (See",
"      <a class=\"local\" href=\"#H272267743\">",
"       'General approach'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H3\">",
"       'Recommendation'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H6\">",
"       'Chronic and progressive CPPD crystal deposition'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients with pseudogout (acute calcium pyrophosphate crystal arthritis) with no more than two acutely inflamed joints, we prefer joint aspiration and intraarticular glucocorticoid injection as initial treatment. For injections into large joints, including the knees and shoulders, we use",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/38/39520?source=see_link\">",
"       triamcinolone",
"      </a>",
"      acetonide (1 mL, 40 mg) mixed with 1 or 2 mL of 1 percent procaine. When smaller joints are involved, smaller doses of the respective glucocorticoid preparations can be utilized. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Acute pseudogout (\"acute CPP crystal arthritis\")'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H3\">",
"       'Recommendation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients with pseudogout (acute calcium pyrophosphate crystal arthritis) who are not treated with arthrocentesis and injection, we prefer to treat with nonsteroidal antiinflammatory drugs (NSAIDs), and, if NSAIDs are contraindicated, we use oral",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32983?source=see_link\">",
"       colchicine",
"      </a>",
"      . Systemic glucocorticoids are used if NSAIDs and colchicine are contraindicated. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Acute pseudogout (\"acute CPP crystal arthritis\")'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H3\">",
"       'Recommendation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest prophylaxis with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32983?source=see_link\">",
"       colchicine",
"      </a>",
"      for patients with three or more attacks of pseudogout annually, with appropriate dose adjustment for renal and hepatic dysfunction, for drug intolerance, and for potential drug interactions. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/26/36266?source=see_link\">",
"       \"Prevention of recurrent gout\"",
"      </a>",
"      and",
"      <a class=\"local\" href=\"#H4\">",
"       'Prophylaxis for pseudogout (\"acute CPP crystal arthritis\")'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H5\">",
"       'Recommendation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients with pseudo-rheumatoid arthritis (chronic calcium pyrophosphate crystal inflammatory arthritis), we use NSAIDs",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32983?source=see_link\">",
"       colchicine",
"      </a>",
"      , followed, if needed, by low-dose glucocorticoids,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/26/2471?source=see_link\">",
"       hydroxychloroquine",
"      </a>",
"      , consistent with the recommendations for treatment of CPPD crystal deposition disease of the European League Against Rheumatism (EULAR) task force. (See",
"      <a class=\"local\" href=\"#H3678803\">",
"       'Pseudo-rheumatoid arthritis (\"chronic CPP crystal inflammatory arthritis\")'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The treatment approaches for patients in whom joint degeneration is the major manifestation of CPPD crystal deposition disease and is unaccompanied by episodic pseudogout are the same as those employed for osteoarthritis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/30/2538?source=see_link\">",
"       \"Nonpharmacologic therapy of osteoarthritis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?14/23/14714?source=see_link\">",
"       \"Pharmacologic therapy of osteoarthritis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/9/12440?source=see_link\">",
"       \"Surgical therapy of osteoarthritis\"",
"      </a>",
"      and",
"      <a class=\"local\" href=\"#H7\">",
"       'Joint degeneration (\"OA with CPPD\")'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/45/18134/abstract/1\">",
"      McCarty DJ. Calcium pyrophosphate dihydrate crystal deposition disease--1975. Arthritis Rheum 1976; 19 Suppl 3:275.",
"     </a>",
"    </li>",
"    <li>",
"     Rosenthal AK, Ryan LM, McCarty DJ. Calcium pyrophosphate crystal deposition disease, pseudogout, and articular chondrocalcinosis. In: Arthritis and Allied Conditions, 15th, Koopman WJ, Moreland LW (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2005. p.2373.",
"    </li>",
"    <li>",
"     Rosenthal AK. Pseudogout: Presentation, natural history, and associated conditions. In: Crystal-Induced Arthropathies: Gout, Pseudogout, and Apatite-Associated Syndromes, Wortmann RL, Schumacher HR Jr, Becker MA, Ryan LM (Eds), Taylor and Francis Group, New York 2006. p.99.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/45/18134/abstract/4\">",
"      Zhang W, Doherty M, Bardin T, et al. European League Against Rheumatism recommendations for calcium pyrophosphate deposition. Part I: terminology and diagnosis. Ann Rheum Dis 2011; 70:563.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/45/18134/abstract/5\">",
"      Zhang W, Doherty M, Pascual E, et al. EULAR recommendations for calcium pyrophosphate deposition. Part II: management. Ann Rheum Dis 2011; 70:571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/45/18134/abstract/6\">",
"      Rosenthal AK, Ryan LM. Crystal arthritis: calcium pyrophosphate deposition-nothing 'pseudo' about it! Nat Rev Rheumatol 2011; 7:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/45/18134/abstract/7\">",
"      Andres M, Sivera F, Pascual E. Methotrexate is an option for patients with refractory calcium pyrophosphate crystal arthritis. J Clin Rheumatol 2012; 18:234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/45/18134/abstract/8\">",
"      Chollet-Janin A, Finckh A, Dudler J, Guerne PA. Methotrexate as an alternative therapy for chronic calcium pyrophosphate deposition disease: an exploratory analysis. Arthritis Rheum 2007; 56:688.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/45/18134/abstract/9\">",
"      Doan TH, Chevalier X, Leparc JM, et al. Premature enthusiasm for the use of methotrexate for refractory chondrocalcinosis: comment on the article by Chollet-Janin et al. Arthritis Rheum 2008; 58:2210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/45/18134/abstract/10\">",
"      Alvarellos A, Spilberg I. Colchicine prophylaxis in pseudogout. J Rheumatol 1986; 13:804.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/45/18134/abstract/11\">",
"      Rosenthal AK, Ryan LM. Probenecid inhibits transforming growth factor-beta 1 induced pyrophosphate elaboration by chondrocytes. J Rheumatol 1994; 21:896.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/45/18134/abstract/12\">",
"      Ryan LM. The ank gene story. Arthritis Res 2001; 3:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/45/18134/abstract/13\">",
"      Hamilton EB, Bomford AB, Laws JW, Williams R. The natural history of arthritis in idiopathic haemochromatosis: progression of the clinical and radiological features over ten years. Q J Med 1981; 50:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/45/18134/abstract/14\">",
"      Van Geertruyden J, Kinnaert P, Frederic N, et al. Effect of parathyroid surgery on cartilage calcification. World J Surg 1986; 10:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/45/18134/abstract/15\">",
"      Glass JS, Grahame R. Chondrocalcinosis after parathyroidectomy. Ann Rheum Dis 1976; 35:521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/45/18134/abstract/16\">",
"      Pritchard MH, Jessop JD. Chondrocalcinosis in primary hyperparathyroidism. Influence of age, metabolic bone disease, and parathyroidectomy. Ann Rheum Dis 1977; 36:146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/45/18134/abstract/17\">",
"      Smilde TJ, Haverman JF, Schipper P, et al. Familial hypokalemia/hypomagnesemia and chondrocalcinosis. J Rheumatol 1994; 21:1515.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/45/18134/abstract/18\">",
"      Doherty M, Dieppe PA. Double blind, placebo controlled trial of magnesium carbonate in chronic pyrophosphate arthropathy. Ann Rheum Dis 1983; 42(Suppl):106.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1671 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-180.241.123.62-C1AFB1FE5C-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_45_18134=[""].join("\n");
var outline_f17_45_18134=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H2086999\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H272267591\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H272267598\">",
"      TERMINOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H272267743\">",
"      GENERAL APPROACH",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ACUTE PSEUDOGOUT (\"ACUTE CPP CRYSTAL ARTHRITIS\")",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Recommendation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      PROPHYLAXIS FOR PSEUDOGOUT (\"ACUTE CPP CRYSTAL ARTHRITIS\")",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Recommendation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3678803\">",
"      PSEUDO-RHEUMATOID ARTHRITIS (\"CHRONIC CPP CRYSTAL INFLAMMATORY ARTHRITIS\")",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      CHRONIC AND PROGRESSIVE CPPD CRYSTAL DEPOSITION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      JOINT DEGENERATION (\"OA WITH CPPD\")",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2086999\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"RHEUM/1671\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"RHEUM/1671|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?29/17/29982\" title=\"algorithm 1\">",
"      Treatment of pseudogout involving more than two joints",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/38/7785?source=related_link\">",
"      Clinical manifestations and diagnosis of calcium pyrophosphate crystal deposition disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/14/30951?source=related_link\">",
"      Intraarticular and soft tissue injections: What agent(s) to inject and how frequently?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/52/23368?source=related_link\">",
"      Joint aspiration or injection in adults: Technique and indications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/30/2538?source=related_link\">",
"      Nonpharmacologic therapy of osteoarthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/14/6375?source=related_link\">",
"      Pathogenesis and etiology of calcium pyrophosphate crystal deposition disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?33/15/34033?source=related_link\">",
"      Patient information: Pseudogout (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?10/9/10386?source=related_link\">",
"      Patient information: Pseudogout (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/23/14714?source=related_link\">",
"      Pharmacologic therapy of osteoarthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/26/36266?source=related_link\">",
"      Prevention of recurrent gout",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/9/12440?source=related_link\">",
"      Surgical therapy of osteoarthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/24/17800?source=related_link\">",
"      Treatment of acute gout",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f17_45_18135="The adult patient with brittle diabetes mellitus";
var content_f17_45_18135=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   The adult patient with brittle diabetes mellitus",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/45/18135/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/45/18135/contributors\">",
"     David K McCulloch, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/45/18135/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/45/18135/contributors\">",
"     David M Nathan, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/45/18135/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/45/18135/contributors\">",
"     Jean E Mulder, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?17/45/18135/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 17, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Almost all diabetic patients experience swings in blood glucose levels, which are larger and less predictable than in nondiabetics. When these swings become intolerable and cause disruption to the person's daily life",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    prolonged hospitalization, the person is labeled as having \"labile\" or \"brittle\" diabetes. Although brittle diabetes is uncommon (less than 1 percent of insulin-taking diabetic patients) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/45/18135/abstract/1\">",
"     1",
"    </a>",
"    ], it can cause a considerable burden on hospital, social, and family resources due to multiple hospital admissions.",
"   </p>",
"   <p>",
"    The clinical manifestations, diagnosis, and management of brittle diabetes will be reviewed here. General principles of insulin therapy in diabetes mellitus are reviewed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/55/15225?source=see_link\">",
"     \"General principles of insulin therapy in diabetes mellitus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/20/24906?source=see_link\">",
"     \"Insulin therapy in adults with type 1 diabetes mellitus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/24/30089?source=see_link\">",
"     \"Insulin therapy in type 2 diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2935179\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most experts would define brittle diabetes as severe instability of blood glucose levels with frequent and unpredictable episodes of hypoglycemia",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    ketoacidosis that disrupt quality of life. The unpredictable episodes of hypoglycemia",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    ketoacidosis are due to an absolute insulin dependency (undetectable C-peptide levels). Thus, brittle diabetic patients virtually always have type 1 diabetes.",
"   </p>",
"   <p>",
"    The majority of the published clinical literature regarding brittle diabetes is old with few modern-day descriptions of brittle diabetes encompassing the era of intensive insulin therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?17/45/18135/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. With the availability of basal and bolus insulin regimens, using long and rapid-acting insulin analogs or insulin pump therapy, there has been substantial improvement in the ability to treat most patients with type 1 diabetes effectively [",
"    <a class=\"abstract\" href=\"UTD.htm?17/45/18135/abstract/3\">",
"     3",
"    </a>",
"    ]. Although most clinical experts in the management of type 1 diabetes continue to see patients with brittle diabetes mellitus, many of whom have a substantial behavioral or iatrogenic contribution to their brittle state, the modern day course of such patients has not been well described.",
"   </p>",
"   <p>",
"    Three clinical presentations of brittle diabetes have been described: (1) predominant hyperglycemia with recurrent ketoacidosis, (2) predominant hypoglycemia, and (3) mixed hyper- and hypoglycemia [",
"    <a class=\"abstract\" href=\"UTD.htm?17/45/18135/abstract/4\">",
"     4",
"    </a>",
"    ]. Frequent hypoglycemia, even if asymptomatic, causes both defective glucose counterregulation and hypoglycemia unawareness and thus a vicious cycle of recurrent hypoglycemia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/60/29638?source=see_link&amp;anchor=H12#H12\">",
"     \"Physiologic response to hypoglycemia in normal subjects and patients with diabetes mellitus\", section on 'Hypoglycemia-associated autonomic failure'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with brittle diabetes have wide swings in their blood sugar levels and report differing blood sugar responses to the same dose and type of insulin. Historically, glycated hemoglobin (A1C) levels are typically elevated (10 to 14 percent), and acute (ketoacidosis, severe hypoglycemia) and chronic (neuropathy, nephropathy, retinopathy) diabetes complications are common [",
"    <a class=\"abstract\" href=\"UTD.htm?17/45/18135/abstract/1,5\">",
"     1,5",
"    </a>",
"    ]. Most patients are in their twenties and thirties, although the elderly may also have brittle diabetes [",
"    <a class=\"abstract\" href=\"UTD.htm?17/45/18135/abstract/6\">",
"     6",
"    </a>",
"    ]. Although some patients are able to control their blood sugars with time, the overall mortality rate for patients with brittle diabetes is high, ranging from 20 to 50 percent in series from specialist centers [",
"    <a class=\"abstract\" href=\"UTD.htm?17/45/18135/abstract/1,2,7,8\">",
"     1,2,7,8",
"    </a>",
"    ]. In one series, the causes of death were chronic renal failure, DKA, hypoglycemia, and subarachnoid hemorrhage [",
"    <a class=\"abstract\" href=\"UTD.htm?17/45/18135/abstract/2\">",
"     2",
"    </a>",
"    ]. The age at death ranged from 27 to 45 years. In contrast to an older review which found an equal prevalence in men and women [",
"    <a class=\"abstract\" href=\"UTD.htm?17/45/18135/abstract/1\">",
"     1",
"    </a>",
"    ], all of the other series found a predominance of young women, and one noted a significant increase in microvascular diabetic complications (67 versus 25 percent in stable diabetic controls) and pregnancy complications (46 versus 7 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/45/18135/abstract/8\">",
"     8",
"    </a>",
"    ]. Among survivors, the insulin dose tended to drop over time, and episodes of ketoacidosis and severe hypoglycemia became less frequent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4990844\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Brittle diabetes is labile or unstable diabetes, which requires frequent",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    prolonged hospitalizations for ketoacidosis or severe hypoglycemia [",
"    <a class=\"abstract\" href=\"UTD.htm?17/45/18135/abstract/4\">",
"     4",
"    </a>",
"    ]. Thus, the diagnosis of brittle diabetes is established when a patient with absolute insulin deficiency (type 1 or rarely long-standing type 2 diabetes mellitus) has frequent episodes of severe hyper",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    hypoglycemia, requiring frequent hospitalizations and preventing a normal lifestyle.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2935579\">",
"    <span class=\"h1\">",
"     ETIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are multiple causes of brittle diabetes. The major cause of brittle diabetes is non-physiologic matching of",
"    <span class=\"nowrap\">",
"     meals/exercise",
"    </span>",
"    and insulin administration either by clinicians or patients. Potential physiological causes include malabsorption, delayed gastric emptying due to autonomic neuropathy, impairment of behavioral and counterregulatory responses to falling plasma glucose concentrations, use of certain drugs (alcohol, antipsychotics), systemic insulin resistance, and abnormal insulin absorption or degradation [",
"    <a class=\"abstract\" href=\"UTD.htm?17/45/18135/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Several studies from specialist referral centers in the late 1970s and early 1980s focused on possible physiological mechanisms for the brittleness, and tried mechanistic approaches to overcome the problem by using continuous subcutaneous [",
"    <a class=\"abstract\" href=\"UTD.htm?17/45/18135/abstract/9\">",
"     9",
"    </a>",
"    ], intramuscular, intravenous [",
"    <a class=\"abstract\" href=\"UTD.htm?17/45/18135/abstract/10\">",
"     10",
"    </a>",
"    ] or intraperitoneal insulin infusions [",
"    <a class=\"abstract\" href=\"UTD.htm?17/45/18135/abstract/11,12\">",
"     11,12",
"    </a>",
"    ], or the closed-loop artificial pancreas (Biostator) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/45/18135/abstract/13\">",
"     13",
"    </a>",
"    ]. However, with increasing study, it has become clear that the vast majority of cases appear to be due to psychological factors, with patient-centered behavioral issues often underlying the poor glycemic control [",
"    <a class=\"abstract\" href=\"UTD.htm?17/45/18135/abstract/1,7,8,14\">",
"     1,7,8,14",
"    </a>",
"    ]. When &ldquo;brittle&rdquo; diabetic patients were studied in a controlled environment with regimented meals and exercise and insulin dosing choices made by and administered by the health care team, their labile glycemic state often improved and they were no longer brittle. As an example, in an attempt to estimate the prevalence and causes of brittle diabetes, a questionnaire was sent to all diabetes clinics in the United Kingdom [",
"    <a class=\"abstract\" href=\"UTD.htm?17/45/18135/abstract/14\">",
"     14",
"    </a>",
"    ]. Among the 414 patients with brittle diabetes identified (prevalence of 2.9 per 1000 insulin-treated patients), the responding clinicians believed that 93 percent of cases were due to psychological problems. Some of these problems may be short-lived and related to a stressful situation (unhappiness at school or home), which causes the patient to neglect their diabetes care. In other, rarer settings, a patient may deliberately mismanage his or her diabetes (factitious brittle diabetes) in order to remain in the hospital [",
"    <a class=\"abstract\" href=\"UTD.htm?17/45/18135/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    After eliminating the behavioral aspects of brittle diabetes and improving the physiologic match between insulin delivery and insulin requirements, there are still a small number of patients with type 1 diabetes who will remain inexplicably brittle. With further investigation, erratic meal absorption from gastroparesis or with unrecognized celiac disease may be identified. In some patients, perhaps owing to high levels of anti-insulin antibodies from prior use of animal species insulins, the absorption or biologic activity of insulin may be unpredictable.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2935572\">",
"    <span class=\"h1\">",
"     EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;A careful evaluation should be performed in patients with brittle diabetes to differentiate among the various causes [",
"    <a class=\"abstract\" href=\"UTD.htm?17/45/18135/abstract/3,16\">",
"     3,16",
"    </a>",
"    ]. In evaluating a patient with brittle diabetes, it is important to take a detailed history to include several specific points, such as the duration of diabetes, a description of all episodes of ketoacidosis and severe hypoglycemia, presence of diabetes complications (particularly autonomic neuropathy), and prescribed insulin regimens. It should also be determined if there was a period of \"stable\" diabetes preceding the brittleness, and what happened in the patient's life circumstances coincident with the onset of brittleness. Because psychosocial factors are an important contributor to disease instability, psychosocial assessment is an important component of the evaluation, particularly for patients with brittle diabetes in whom diabetes education and intensive insulin therapy fail to reduce the episodes of ketoacidosis and hypoglycemia. (See",
"    <a class=\"local\" href=\"#H2934997\">",
"     'Management'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    For patients with recurrent episodes of severe hypoglycemia, a number of conditions should be considered:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Gastroparesis can lead to a severe mismatch between food absorption and insulin absorption, causing unexplained hypoglycemia [",
"      <a class=\"abstract\" href=\"UTD.htm?17/45/18135/abstract/5\">",
"       5",
"      </a>",
"      ]. Gastric emptying studies",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      a trial of medical therapy may be helpful in this setting. Evaluation of gastroparesis is reviewed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/25/24985?source=see_link&amp;anchor=H7#H7\">",
"       \"Diabetic autonomic neuropathy of the gastrointestinal tract\", section on 'Methods to measure gastric emptying'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Celiac disease can cause erratic absorption of meals, causing unexplained hypoglycemia. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/44/40650?source=see_link\">",
"       \"Pathogenesis, epidemiology, and clinical manifestations of celiac disease in adults\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?14/2/14377?source=see_link\">",
"       \"Diagnosis of celiac disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The protective response to hypoglycemia is impaired in many patients with type 1 diabetes and in some patients with long-standing (absolute endogenous insulin deficient) type 2 diabetes. Impaired glucose counterregulation is a major risk factor for recurrent hypoglycemia. In addition, previous episodes of hypoglycemia further impair glucose counterregulation and cause hypoglycemia unawareness, causing a vicious cycle of recurrent hypoglycemia in which recurrent episodes of hypoglycemia make subsequent episodes more likely. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/60/29638?source=see_link&amp;anchor=H7#H7\">",
"       \"Physiologic response to hypoglycemia in normal subjects and patients with diabetes mellitus\", section on 'Response to hypoglycemia in diabetes'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/60/29638?source=see_link&amp;anchor=H12#H12\">",
"       \"Physiologic response to hypoglycemia in normal subjects and patients with diabetes mellitus\", section on 'Hypoglycemia-associated autonomic failure'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Measuring symptomatic and counterregulatory hormone response to hypoglycemia, although accurate in determining the risk of severe hypoglycemia, is too cumbersome for routine use. A simpler and more practical approach during intensive insulin therapy is to evaluate the frequency and severity of low blood glucose readings from blood glucose monitoring records kept by the patient or from continuous glucose monitoring (CGM). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/60/29641?source=see_link\">",
"       \"Blood glucose self-monitoring in management of adults with diabetes mellitus\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Hypothyroidism and adrenal insufficiency are also causes, albeit rarely, of recurrent severe hypoglycemia; they can be treated easily once the condition is recognized [",
"      <a class=\"abstract\" href=\"UTD.htm?17/45/18135/abstract/17\">",
"       17",
"      </a>",
"      ]. Thus, thyroid function tests (TSH, free thyroxine) and an",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/20/24902?source=see_link\">",
"       ACTH stimulation test",
"      </a>",
"      should be performed if the clinical history is suggestive of hypothyroidism or glucocorticoid deficiency. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/7/26744?source=see_link\">",
"       \"Diagnosis of and screening for hypothyroidism\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?43/46/44777?source=see_link\">",
"       \"Diagnosis of adrenal insufficiency in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Insulin autoimmune hypoglycemia occurs in patients who have antibodies directed to endogenous insulin or to the insulin receptor. Symptoms can occur postprandially, fasting, or in both states. In patients with insulin autoantibodies, insulin secreted in response to a meal binds to the antibody and then disassociates in an unregulated fashion causing hyperinsulinemia and hypoglycemia. In patients with antibodies to the insulin receptor, hypoglycemia occurs as a result of antibody activation of the receptor. Measurement of insulin and insulin receptor antibodies is necessary to confirm the diagnosis [",
"      <a class=\"abstract\" href=\"UTD.htm?17/45/18135/abstract/3\">",
"       3",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/39/24184?source=see_link&amp;anchor=H18#H18\">",
"       \"Hypoglycemia in adults without diabetes mellitus: Diagnostic approach\", section on 'Determining the cause of hypoglycemia'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For patients with recurrent episodes of ketoacidosis, a possible chronic cryptic infection (such as sinusitis, osteomyelitis, renal or perinephric abscess, lung abscess) should be excluded. These problems are more likely in a patient using intravenous drugs. Thus, a urinary drug screen for opiates and amphetamines may be helpful if drug use is suspected.",
"   </p>",
"   <p>",
"    For all patients, a diabetic educational assessment is useful to evaluate whether the patient knows how to manage diabetes, and whether the current insulin regimen is reasonable.",
"   </p>",
"   <p>",
"    If deliberate mismanagement (factitious brittle diabetes) by a patient is suspected, in-hospital assessment and management of blood sugars are necessary [",
"    <a class=\"abstract\" href=\"UTD.htm?17/45/18135/abstract/15\">",
"     15",
"    </a>",
"    ]. During the initial period, the patient has to stay on the treatment unit at all times, where he or she can be closely monitored and observed, with all blood glucose testing, food, and insulin being administered by the staff. Subsequently, the patient may be allowed to become involved in his or her management, provided blood glucose control and behavior remain reasonable. Many patients with so-called &ldquo;brittle&rdquo; diabetes will have relatively easy to control diabetes in this setting, clearly suggesting that behavioral or regimen-based problems underlie their brittle state as an outpatient.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2934997\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The approach to management will obviously vary depending on the specific etiology in each case. However, regardless of the cause, brittle diabetes is difficult to treat.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H857118\">",
"    <span class=\"h2\">",
"     General principles",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diabetes education is important for the patient who is struggling with insulin dosing and dietary prescriptions. Patients need to be instructed on how to match the insulin dose to the amount of carbohydrates ingested at each meal. In addition, insulin regimens must be individually tailored to reduce the risk of hypoglycemia, while maintaining or improving glycemic control. Health care professionals who treat patients with insulin dependent diabetes should have expertise in the principles of insulin management. Patient education and empowerment, frequent self-monitoring of blood glucose (SMBG), flexible and rational insulin (and other drug) regimens, individualized glycemic goals, and ongoing professional guidance and support are required to meet these goals. Carbohydrate counting, insulin therapy (multiple daily injections or continuous subcutaneous insulin infusion [insulin pump]), and strategies to prevent hypoglycemia are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/2/25641?source=see_link&amp;anchor=H3#H3\">",
"     \"Nutritional considerations in type 1 diabetes mellitus\", section on 'Carbohydrate consistency'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/20/24906?source=see_link&amp;anchor=H5#H5\">",
"     \"Insulin therapy in adults with type 1 diabetes mellitus\", section on 'Choice of insulin regimen'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/63/27641?source=see_link&amp;anchor=H18#H18\">",
"     \"Management of hypoglycemia during treatment of diabetes mellitus\", section on 'Strategies to prevent hypoglycemia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Regular SMBG is critical to the glycemic management of type 1 and intensively treated",
"    <span class=\"nowrap\">",
"     (basal/bolus",
"    </span>",
"    insulin) type 2 diabetes. Continuous glucose monitoring may further facilitate glycemic control or at least a more clear understanding of the time periods when glucose control is problematic. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/60/29641?source=see_link&amp;anchor=H13#H13\">",
"     \"Blood glucose self-monitoring in management of adults with diabetes mellitus\", section on 'Continuous glucose monitoring'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Continuous subcutaneous insulin (insulin pump) has also been used in conjunction with a continuous glucose monitoring (CGM) device to give the patient more information about their blood glucose levels and allow them to make better informed decisions about insulin dosing. This approach, known as sensor-augmented insulin pump therapy, may improve glycemic control without an increase in the rate of severe hypoglycemia. Studies are currently evaluating the efficacy of a fully automated closed loop system of insulin delivery based upon continuous glucose sensing. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/20/24906?source=see_link&amp;anchor=H12#H12\">",
"     \"Insulin therapy in adults with type 1 diabetes mellitus\", section on 'Continuous subcutaneous insulin infusion (insulin pump)'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If there is a history of hypoglycemia unawareness, a two- to three-week period of scrupulous avoidance of hypoglycemia is advisable since that often restores awareness. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/63/27641?source=see_link&amp;anchor=H22#H22\">",
"     \"Management of hypoglycemia during treatment of diabetes mellitus\", section on 'Hypoglycemia unawareness'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Pancreas transplantation is an option for the small minority of patients with a history of severe and frequent metabolic complications (hypoglycemia, ketoacidosis) and a consistent failure of insulin-based management to prevent these complications [",
"    <a class=\"abstract\" href=\"UTD.htm?17/45/18135/abstract/3\">",
"     3",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/63/7162?source=see_link&amp;anchor=H867495#H867495\">",
"     \"Pancreas and islet transplantation in diabetes mellitus\", section on 'Indications for transplantation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H857125\">",
"    <span class=\"h2\">",
"     Gastroparesis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although gastroparesis can lead to a severe mismatch between food absorption and insulin absorption, causing unexplained hypoglycemia, there are no conclusive data showing that treatment of gastric stasis improves long-term diabetic control or prevents complications. In a randomized controlled trial of eight patients with poorly controlled type 1 diabetes and delayed gastric emptying, cisapride 20 mg twice daily improved gastric emptying time significantly but had no beneficial effects on day-to-day glucose variability, A1C or frequency of hypoglycemia [",
"    <a class=\"abstract\" href=\"UTD.htm?17/45/18135/abstract/18\">",
"     18",
"    </a>",
"    ]. In addition, cisapride has been associated with a number of drug interactions and fatal cardiac arrhythmias, prompting the manufacturer to severely restrict its availability in the United States, although it remains available in several other countries. Thus, while cisapride may help relieve the symptoms of gastroparesis, it does not appear to help with metabolic control. Given these findings and the drug's restricted status, we do not recommend cisapride for the management of unexplained hypoglycemia due to gastroparesis. Gastroparesis is reviewed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/25/24985?source=see_link&amp;anchor=H4#H4\">",
"     \"Diabetic autonomic neuropathy of the gastrointestinal tract\", section on 'Gastroparesis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/50/33576?source=see_link\">",
"     \"Treatment of delayed gastric emptying\"",
"    </a>",
"    .)",
"    <br/>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H857132\">",
"    <span class=\"h2\">",
"     Psychosocial",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with a clear psychosocial component to diabetes instability, a psychological evaluation is warranted, since psychotherapy has been shown to be effective in selected patients [",
"    <a class=\"abstract\" href=\"UTD.htm?17/45/18135/abstract/19\">",
"     19",
"    </a>",
"    ]. Nevertheless, many patients will continue to be admitted with recurrent problems until their general life situation improves. Referral to a specialty center may be indicated in severe cases. This is particularly important if there is a possibility that the clinician (or another team member) is becoming so involved with the patient's case that they may lose objectivity or be manipulated by the patient. Patients who are using their brittleness to escape from an unhappy situation in the outside world may use the hospital as a sanctuary, become very familiar with all the staff, bend the rules for their own convenience, and interfere with their management in bizarre ways to ensure that they need to remain hospitalized.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?0/43/692?source=see_link\">",
"       \"Patient information: Type 1 diabetes (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?27/58/28579?source=see_link\">",
"       \"Patient information: Using insulin (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?35/26/36259?source=see_link\">",
"       \"Patient information: Diabetes mellitus type 1: Overview (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?38/43/39603?source=see_link\">",
"       \"Patient information: Self-blood glucose monitoring in diabetes mellitus (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?34/31/35317?source=see_link\">",
"       \"Patient information: Diabetes mellitus type 1: Insulin treatment (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4990875\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Most experts define brittle diabetes as severe instability of blood glucose levels with frequent and unpredictable episodes of hypoglycemia",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      ketoacidosis that disrupt quality of life. The unpredictable episodes of hypoglycemia",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      ketoacidosis are due to an absolute insulin dependency (undetectable C-peptide levels). Thus, brittle diabetic patients virtually always have type 1 diabetes. (See",
"      <a class=\"local\" href=\"#H2935179\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Three clinical presentations have been described: (1) predominant hyperglycemia with recurrent ketoacidosis, (2) predominant hypoglycemia, and (3) mixed hyper- and hypoglycemia. Patients with brittle diabetes have wide swings in their blood sugar levels and report differing blood sugar responses to the same dose and type of insulin. Glycated hemoglobin (A1C) levels are typically elevated (10 to 14 percent). Although some patients are able to control their blood sugars with time, the overall mortality rate for patients with brittle diabetes is high. (See",
"      <a class=\"local\" href=\"#H2935179\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of brittle diabetes is established when a patient with absolute insulin deficiency (type 1 or long-standing type 2 diabetes mellitus) has frequent episodes of severe hyper",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      hypoglycemia, requiring frequent hospitalizations and preventing a normal lifestyle. (See",
"      <a class=\"local\" href=\"#H4990844\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The major cause of brittle diabetes is patient or clinician errors in management, particularly non-physiologic matching of",
"      <span class=\"nowrap\">",
"       meals/exercise",
"      </span>",
"      and insulin administration. Other potential causes of brittle diabetes include psychosocial problems, malabsorption, delayed gastric emptying due to autonomic neuropathy, impairment of behavioral and counterregulatory responses to falling plasma glucose concentrations, use of certain drugs (alcohol, antipsychotics), systemic insulin resistance, and abnormal insulin absorption or degradation, or a combination of the above. (See",
"      <a class=\"local\" href=\"#H2935579\">",
"       'Etiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A careful evaluation should be performed in patients with brittle diabetes to differentiate among the various causes. It is important to take a detailed history to include several specific points, such as the duration of diabetes, a description of all episodes of ketoacidosis and severe hypoglycemia, prescribed insulin regimens, and the presence of diabetes complications (particularly autonomic neuropathy, which may be indicative of gastroparesis). Because psychosocial factors are important contributor to disease instability, psychosocial assessment is an important component of the evaluation. (See",
"      <a class=\"local\" href=\"#H2935572\">",
"       'Evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The treatment of brittle diabetes includes diabetes education, intensive insulin therapy (multiple daily injections or insulin pump) with frequent or continuous glucose monitoring, and frequent interaction between patient and clinician. Health care professionals who treat patients with insulin dependent diabetes should have expertise in the principles of insulin management. For the small minority of patients who comply with intensive insulin therapy and educational programs but have persistent, recurrent, and disabling hypoglycemia",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      ketoacidosis, pancreas or islet cell transplantation may be effective. In patients with a clear psychosocial component to diabetes instability, a psychological evaluation is warranted, since psychotherapy has been shown to be effective in selected patients. (See",
"      <a class=\"local\" href=\"#H2934997\">",
"       'Management'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/45/18135/abstract/1\">",
"      Tattersall R, Gregory R, Selby C, et al. Course of brittle diabetes: 12 year follow up. BMJ 1991; 302:1240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/45/18135/abstract/2\">",
"      Cartwright A, Wallymahmed M, Macfarlane IA, et al. The outcome of brittle type 1 diabetes--a 20 year study. QJM 2011; 104:575.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/45/18135/abstract/3\">",
"      Bertuzzi F, Verzaro R, Provenzano V, Ricordi C. Brittle type 1 diabetes mellitus. Curr Med Chem 2007; 14:1739.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/45/18135/abstract/4\">",
"      Vantyghem MC, Press M. Management strategies for brittle diabetes. Ann Endocrinol (Paris) 2006; 67:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/45/18135/abstract/5\">",
"      Schade DS, Drumm DA, Duckworth WC, Eaton RP. The etiology of incapacitating, brittle diabetes. Diabetes Care 1985; 8:12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/45/18135/abstract/6\">",
"      Benbow SJ, Walsh A, Gill GV. Brittle diabetes in the elderly. J R Soc Med 2001; 94:578.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/45/18135/abstract/7\">",
"      Schade DS, Burge MR. Brittle diabetes: etiology and treatment. Adv Endocrinol Metab 1995; 6:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/45/18135/abstract/8\">",
"      Kent LA, Gill GV, Williams G. Mortality and outcome of patients with brittle diabetes and recurrent ketoacidosis. Lancet 1994; 344:778.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/45/18135/abstract/9\">",
"      Pickup J, Williams G, Johns P, Keen H. Clinical features of brittle diabetic patients unresponsive to optimized subcutaneous insulin therapy (continuous subcutaneous insulin infusion). Diabetes Care 1983; 6:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/45/18135/abstract/10\">",
"      Service FJ. Normalization of plasma glucose of unstable diabetes: studies under ambulatory, fed conditions with pumped intravenous insulin. J Lab Clin Med 1978; 91:480.",
"     </a>",
"    </li>",
"    <li>",
"     Schade DS, Eaton RP. Intraperitoneal insulin administration in brittle diabetes. In: Brittle Diabetes, Pichup JC (Ed), Blackwell, Oxford 1985. p.275.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/45/18135/abstract/12\">",
"      Gill GV, Husband DJ, Wright PD, et al. The management of severe brittle diabetes with \"Infusaid\" implantable pumps. Diabetes Res 1986; 3:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/45/18135/abstract/13\">",
"      Connor H, Atkin G, Attwood E. Short-term control of brittle diabetes using a Biostator. Br Med J (Clin Res Ed) 1982; 285:1316.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/45/18135/abstract/14\">",
"      Gill GV, Lucas S, Kent LA. Prevalence and characteristics of brittle diabetes in Britain. QJM 1996; 89:839.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/45/18135/abstract/15\">",
"      Schade DS, Drumm DA, Eaton RP, Sterling WA. Factitious brittle diabetes mellitus. Am J Med 1985; 78:777.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/45/18135/abstract/16\">",
"      Schade DS, Eaton RP, Drumm DA, Duckworth WC. A clinical algorithm to determine the etiology of brittle diabetes. Diabetes Care 1985; 8:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/45/18135/abstract/17\">",
"      Hardy KJ, Burge MR, Boyle PJ, Scarpello JH. A treatable cause of recurrent severe hypoglycemia. Diabetes Care 1994; 17:722.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/45/18135/abstract/18\">",
"      Lehmann R, Honegger RA, Feinle C, et al. Glucose control is not improved by accelerating gastric emptying in patients with type 1 diabetes mellitus and gastroparesis. a pilot study with cisapride as a model drug. Exp Clin Endocrinol Diabetes 2003; 111:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/45/18135/abstract/19\">",
"      Moran G, Fonagy P, Kurtz A, et al. A controlled study of psychoanalytic treatment of brittle diabetes. J Am Acad Child Adolesc Psychiatry 1991; 30:926.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1803 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-118.97.94.19-A2277D8E11-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_45_18135=[""].join("\n");
var outline_f17_45_18135=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H4990875\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2935179\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4990844\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2935579\">",
"      ETIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2935572\">",
"      EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2934997\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H857118\">",
"      General principles",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H857125\">",
"      Gastroparesis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H857132\">",
"      Psychosocial",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4990875\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/60/29641?source=related_link\">",
"      Blood glucose self-monitoring in management of adults with diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/25/24985?source=related_link\">",
"      Diabetic autonomic neuropathy of the gastrointestinal tract",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/46/44777?source=related_link\">",
"      Diagnosis of adrenal insufficiency in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/7/26744?source=related_link\">",
"      Diagnosis of and screening for hypothyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/2/14377?source=related_link\">",
"      Diagnosis of celiac disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/55/15225?source=related_link\">",
"      General principles of insulin therapy in diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/39/24184?source=related_link\">",
"      Hypoglycemia in adults without diabetes mellitus: Diagnostic approach",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/20/24906?source=related_link\">",
"      Insulin therapy in adults with type 1 diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/24/30089?source=related_link\">",
"      Insulin therapy in type 2 diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/63/27641?source=related_link\">",
"      Management of hypoglycemia during treatment of diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/2/25641?source=related_link\">",
"      Nutritional considerations in type 1 diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/63/7162?source=related_link\">",
"      Pancreas and islet transplantation in diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/44/40650?source=related_link\">",
"      Pathogenesis, epidemiology, and clinical manifestations of celiac disease in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?34/31/35317?source=related_link\">",
"      Patient information: Diabetes mellitus type 1: Insulin treatment (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?35/26/36259?source=related_link\">",
"      Patient information: Diabetes mellitus type 1: Overview (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?38/43/39603?source=related_link\">",
"      Patient information: Self-blood glucose monitoring in diabetes mellitus (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?0/43/692?source=related_link\">",
"      Patient information: Type 1 diabetes (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?27/58/28579?source=related_link\">",
"      Patient information: Using insulin (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/60/29638?source=related_link\">",
"      Physiologic response to hypoglycemia in normal subjects and patients with diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/50/33576?source=related_link\">",
"      Treatment of delayed gastric emptying",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f17_45_18136="Extrapulmonary manifestations of alpha-1 antitrypsin deficiency";
var content_f17_45_18136=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Extrapulmonary manifestations of alpha-1 antitrypsin deficiency",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/45/18136/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/45/18136/contributors\">",
"     James K Stoller, MS, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/45/18136/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/45/18136/contributors\">",
"     Peter J Barnes, DM, DSc, FRCP, FRS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/45/18136/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/45/18136/contributors\">",
"     Helen Hollingsworth, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?17/45/18136/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 19, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Alpha-1 antitrypsin (AAT) is a serine protease inhibitor (PI) that is produced in hepatocytes. AAT deficiency is characterized by autosomal co-dominant inheritance of mutations in the alpha 1 antitrypsin gene (MIM 107400) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/45/18136/abstract/1\">",
"     1",
"    </a>",
"    ]. AAT deficiency is associated with lung, liver, and skin disease.",
"   </p>",
"   <p>",
"    The extrapulmonary manifestations of AAT deficiency will be reviewed here. The pulmonary manifestations and treatment of AAT deficiency are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/8/6281?source=see_link\">",
"     \"Clinical manifestations, diagnosis, and natural history of alpha-1 antitrypsin deficiency\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/62/16361?source=see_link\">",
"     \"Treatment of alpha-1 antitrypsin deficiency\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The American Thoracic Society (ATS) and European Respiratory Society (ERS) statement on the diagnosis and management of AAT deficiency, as well as other ATS guidelines, can be accessed through the ATS web site at",
"    <a class=\"external\" href=\"file://www.thoracic.org/statements\">",
"     www.thoracic.org/statements",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     HEPATIC DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Liver disorders, such as neonatal hepatitis, cirrhosis both in children and adults, and hepatocellular carcinoma are associated with some AAT-deficient phenotypes [",
"    <a class=\"abstract\" href=\"UTD.htm?17/45/18136/abstract/2-7\">",
"     2-7",
"    </a>",
"    ]. Approximately 10 to 15 percent of newborns are at risk for developing some form of hepatic disease, and approximately 10 to 15 percent of adults develop hepatic disease [",
"    <a class=\"abstract\" href=\"UTD.htm?17/45/18136/abstract/8\">",
"     8",
"    </a>",
"    ]. Among never smokers, the prevalence of liver disease at death is higher (28 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/45/18136/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The two alleles that are best described to confer risk for liver disease, Z and M (malton), are associated with accumulation of AAT protein in the hepatocyte. Other rare alleles, M (duarte), M (nichinan), S, and S (iiyama), are also known to cause intrahepatocytic accumulation [",
"    <a class=\"abstract\" href=\"UTD.htm?17/45/18136/abstract/8,10-12\">",
"     8,10-12",
"    </a>",
"    ]. Liver disease has not yet been described in these latter disorders, but too few individuals have been identified to reach a conclusion [",
"    <a class=\"abstract\" href=\"UTD.htm?17/45/18136/abstract/11,13\">",
"     11,13",
"    </a>",
"    ]. The PI Null (Hong Kong) is a variant in which no serum AAT is detected, but truncated protein can be found in the endoplasmic reticulum in the hepatocyte in vitro. Whether clinical liver disease can accompany this variant is unclear based on sparse clinical experience [",
"    <a class=\"abstract\" href=\"UTD.htm?17/45/18136/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Pathogenesis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pathogenesis of the liver injury in AAT deficiency differs from that of the pulmonary disease. The latter is primarily due to destruction of elastin by elastase, the activity of which is increased because of deficiency of the elastase inhibitor AAT. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/8/6281?source=see_link\">",
"     \"Clinical manifestations, diagnosis, and natural history of alpha-1 antitrypsin deficiency\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In contrast, liver disease is caused by pathologic polymerization of the variant AAT, resulting in intrahepatocyte accumulation of AAT molecules, rather than a proteolytic mechanism [",
"    <a class=\"abstract\" href=\"UTD.htm?17/45/18136/abstract/15-17\">",
"     15-17",
"    </a>",
"    ]. Pathologically, the accumulated AAT appears as inclusions within hepatocytes that stain positively with periodic acid-Schiff (PAS) reagent but resist digestion by diastase (",
"    <a class=\"graphic graphic_picture graphicRef71334 \" href=\"UTD.htm?12/20/12616\">",
"     picture 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    This mechanism of liver disease is supported by two main observations [",
"    <a class=\"abstract\" href=\"UTD.htm?17/45/18136/abstract/13\">",
"     13",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Liver disease has only been observed in individuals with alleles causing intrahepatocyte accumulation, Z and M (malton).",
"     </li>",
"     <li>",
"      Liver disease has not been observed among PI*Null-Null individuals. These patients have no circulating AAT, which predicts the greatest proteolytic risk. However, the liver is not affected because there is no accumulation within the hepatocyte.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Intrahepatocyte accumulation of Z-type molecules occurs within the rough endoplasmic reticulum and results from abnormal folding and aggregation of variant AAT molecules in a mechanism called loop-sheet polymerization [",
"    <a class=\"abstract\" href=\"UTD.htm?17/45/18136/abstract/6,18-20\">",
"     6,18-20",
"    </a>",
"    ]. Factors promoting loop-sheet polymerization include increased temperature and increased concentration of Z-type protein [",
"    <a class=\"abstract\" href=\"UTD.htm?17/45/18136/abstract/18\">",
"     18",
"    </a>",
"    ]. Polypeptides that inhibit loop-sheet polymerization of variant Z-type molecules are being developed [",
"    <a class=\"abstract\" href=\"UTD.htm?17/45/18136/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, abnormal folding does not explain why only some PI*ZZ individuals develop liver disease. It appears that a second defect is also required: decreased degradation of the Z-type molecules within the endoplasmic reticulum, possibly through defects in the proteasomal or autophagic degradation pathways [",
"    <a class=\"abstract\" href=\"UTD.htm?17/45/18136/abstract/22\">",
"     22",
"    </a>",
"    ], which further promotes the intrahepatocyte accumulation of AAT [",
"    <a class=\"abstract\" href=\"UTD.htm?17/45/18136/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It is unclear how the accumulation of Z-type protein within the rough endoplasmic reticulum causes liver cell injury. Possible mechanisms include simple cell engorgement related to mass build-up, and release of lysosomal enzymes caused by cell engorgement, with resultant cell damage. Some investigators have also suggested that the PI*ZZ phenotype predisposes to hepatitis and that the liver damage is mediated by viral infection [",
"    <a class=\"abstract\" href=\"UTD.htm?17/45/18136/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Risk and natural history",
"    </span>",
"    &nbsp;&mdash;&nbsp;Available data about the risk and natural history of liver disease in AAT-deficient individuals are based primarily on studies of PI*Z homozygotes identified by screening at birth. One study of 200,000 Swedish newborns, for example, found 127 PI*Z homozygotes (prevalence",
"    <span class=\"nowrap\">",
"     1/1575)",
"    </span>",
"    who were then followed into adolescence [",
"    <a class=\"abstract\" href=\"UTD.htm?17/45/18136/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Liver damage occurred in 14 of these neonates (11 percent), most commonly presenting as neonatal hepatitis with cholestasis beginning between four days and four months after birth and persisting for up to 12 months.",
"     </li>",
"     <li>",
"      Other clinical presentations among newborns included hepatomegaly with elevated aminotransferase levels (but without hyperbilirubinemia), ascites, and bleeding (often umbilical, superficial, or intracranial [5 percent of affected newborns]).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Follow-up of PI*Z homozygotes identified at birth shows a variable natural history of AAT deficiency-associated liver disease [",
"    <a class=\"abstract\" href=\"UTD.htm?17/45/18136/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Three of 14 children (21 percent) with neonatal hepatitis developed cirrhosis by age seven, two of whom died of complications of cirrhosis.",
"     </li>",
"     <li>",
"      By age eight, the remaining 11 children were clinically well but frequently had elevated aminotransferase levels. A few children (14 percent) developed newly elevated values of gamma glutamyl transferase without antecedent neonatal hepatitis.",
"     </li>",
"     <li>",
"      Later follow-up at age 12 showed elevated aminotransferase levels in 20 percent of those with icteric neonatal hepatitis and in 14 percent with anicteric hepatitis. However, none of these adolescents had clinically evident liver disease.",
"     </li>",
"     <li>",
"      By age 18, only 12 percent had elevations in serum alanine aminotransferase or gamma glutamyl transferase [",
"      <a class=\"abstract\" href=\"UTD.htm?17/45/18136/abstract/5\">",
"       5",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Others have summarized the natural history of liver dysfunction in children with the PI*ZZ phenotype [",
"    <a class=\"abstract\" href=\"UTD.htm?17/45/18136/abstract/25\">",
"     25",
"    </a>",
"    ]. Of the 10 to 15 percent of newborns with neonatal hepatitis, 5 percent remained jaundiced and developed progressive cirrhosis with death from complications of cirrhosis within the first year of life. In the remaining children, four clinical patterns of liver evolution were apparent, each occurring in approximately 25 percent of cases:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Resolution of hepatitis by ages 3 to 10 years without hepatomegaly or splenomegaly",
"     </li>",
"     <li>",
"      Development of cirrhosis between age six months and 17 years, often causing death from complications of end-stage liver disease",
"     </li>",
"     <li>",
"      Histologic evidence of cirrhosis but with survival through the first decade with few sequelae",
"     </li>",
"     <li>",
"      Persistent elevation of liver function tests without cirrhosis",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Liver disease in adults",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adults with at-risk alleles (eg, Z and M) may develop adult-onset chronic hepatitis, cirrhosis, or hepatocellular carcinoma, the former often occurring without antecedent childhood liver disease [",
"    <a class=\"abstract\" href=\"UTD.htm?17/45/18136/abstract/9,26-28\">",
"     9,26-28",
"    </a>",
"    ]. Approximately 40 percent of adults with PI*ZZ have histologically significant liver injury and cirrhosis [",
"    <a class=\"abstract\" href=\"UTD.htm?17/45/18136/abstract/28\">",
"     28",
"    </a>",
"    ]. Male gender and obesity may be risk factors for progression to advanced liver disease in adulthood among patients with severe AAT deficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?17/45/18136/abstract/29,30\">",
"     29,30",
"    </a>",
"    ]. In contrast, alcohol use and viral hepatitis do not appear to increase the risk of progressive hepatic failure [",
"    <a class=\"abstract\" href=\"UTD.htm?17/45/18136/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The American Thoracic Society (ATS) guidelines suggest routine assessment of liver function tests in patients with known AAT deficiency and pulmonary symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?17/45/18136/abstract/8\">",
"     8",
"    </a>",
"    ]. However, in a cross sectional study of 647 adults with AAT deficiency, the prevalence of an elevated alanine aminotransferase level was 8 percent, which did not differ from normal controls [",
"    <a class=\"abstract\" href=\"UTD.htm?17/45/18136/abstract/30\">",
"     30",
"    </a>",
"    ]. In this study, the sensitivity of an elevated ALT level for identifying self-reported liver disease was 12 percent. Thus, additional studies are needed to determine the optimal protocol for screening for liver disease. Until there is greater clarity on the ideal testing protocol, our practice is to assess serum aminotransferases (eg, alanine aminotransferase, aspartate aminotransferase) annually [",
"    <a class=\"abstract\" href=\"UTD.htm?17/45/18136/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    No specific treatment for AAT-associated liver disease in adults has been identified, as the mechanism of liver injury is the accumulation of mutant Z protein in hepatocytes rather than protease deficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?17/45/18136/abstract/28\">",
"     28",
"    </a>",
"    ]. Management focuses on supportive measures to prevent or reduce the complications of chronic liver disease. For adults with end-stage liver disease due to AAT, liver transplantation has resulted in a five year survival of 83 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?17/45/18136/abstract/31\">",
"     31",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/59/17337?source=see_link\">",
"     \"Overview of the complications, prognosis, and management of cirrhosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/61/25559?source=see_link\">",
"     \"Patient selection for liver transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The risk for hepatocellular carcinoma is greater in men (odds ratio 12 compared to controls) than women (odds ratio 8), and hepatocellular carcinoma can occur in the absence of accompanying cirrhosis. In patients with AAT deficiency and established cirrhosis, targeted testing for hepatocellular carcinoma has been recommended with ultrasound examination of the liver every six months [",
"    <a class=\"abstract\" href=\"UTD.htm?17/45/18136/abstract/32\">",
"     32",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/38/25194?source=see_link\">",
"     \"Epidemiology and etiologic associations of hepatocellular carcinoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/6/28778?source=see_link&amp;anchor=H61645279#H61645279\">",
"     \"Prevention of hepatocellular carcinoma and recommendations for surveillance in adults with chronic liver disease\", section on 'Surveillance methods'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     SKIN DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The major dermatologic manifestation of AAT deficiency, although rare, is necrotizing panniculitis. Other possible dermatologic associations with AAT deficiency include systemic vasculitis, psoriasis, urticaria, and angioedema [",
"    <a class=\"abstract\" href=\"UTD.htm?17/45/18136/abstract/8\">",
"     8",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'ANCA-positive vasculitis'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H176414\">",
"    <span class=\"h2\">",
"     Clinical features",
"    </span>",
"    &nbsp;&mdash;&nbsp;Necrotizing panniculitis is characterized by inflammatory lesions of the skin and subcutaneous tissue. [",
"    <a class=\"abstract\" href=\"UTD.htm?17/45/18136/abstract/33-36\">",
"     33-36",
"    </a>",
"    ]. The mean age of onset is 40 years old [",
"    <a class=\"abstract\" href=\"UTD.htm?17/45/18136/abstract/8\">",
"     8",
"    </a>",
"    ]. Patients present with one or more hot, painful, red nodules or plaques on the thigh or buttocks [",
"    <a class=\"abstract\" href=\"UTD.htm?17/45/18136/abstract/37\">",
"     37",
"    </a>",
"    ]. These lesions can be difficult to distinguish from panniculitis due to other causes, but may be more inflammatory with an oily yellow discharge and more pronounced histologic evidence of acute inflammation (",
"    <a class=\"graphic graphic_table graphicRef65180 \" href=\"UTD.htm?8/62/9196\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/45/17112?source=see_link&amp;anchor=H2492460#H2492460\">",
"     \"Panniculitis: Recognition and diagnosis\", section on 'Enzymatic destruction'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Panniculitis is the least common of the well-recognized complications of AAT deficiency, with fewer than 50 cases reported in the English literature [",
"    <a class=\"abstract\" href=\"UTD.htm?17/45/18136/abstract/33,36-40\">",
"     33,36-40",
"    </a>",
"    ]. The prevalence among AAT-deficient subjects is probably less than one case per thousand.",
"   </p>",
"   <p>",
"    The American Thoracic Society (ATS) and European Respiratory Society (ERS) statement on the diagnosis and management of AAT deficiency, as well as other ATS guidelines, can be accessed through the ATS web site at",
"    <a class=\"external\" href=\"file://www.thoracic.org/statements\">",
"     www.thoracic.org/statements",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Pathogenesis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Panniculitis has been reported to occur in a variety of phenotypes, including PI*ZZ, PI*MZ, PI*SS, and PI*MS [",
"    <a class=\"abstract\" href=\"UTD.htm?17/45/18136/abstract/37\">",
"     37",
"    </a>",
"    ]. Seventy percent of reported cased have occurred in patients with PI*ZZ phenotype and severe AAT deficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?17/45/18136/abstract/37\">",
"     37",
"    </a>",
"    ]. Similar to the pathophysiology of emphysema in such individuals, the panniculitis is thought to result from unopposed proteolysis in the skin. In a case report, skin biopsy revealed Z type AAT polymers in affected areas, raising the possibility that AAT polymers in the skin contribute to the observed inflammation [",
"    <a class=\"abstract\" href=\"UTD.htm?17/45/18136/abstract/41\">",
"     41",
"    </a>",
"    ]. Further study is needed before this pathogenetic mechanism is established.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H176869\">",
"    <span class=\"h2\">",
"     Diagnosis and therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;As necrotizing panniculitis is a rare manifestation of AAT deficiency, a deep excisional biopsy is usually obtained to establish the diagnosis. Characteristic histologic findings on skin biopsy include lobular fat necrosis of the lower reticular dermis and abundant neutrophil influx interspersed with normal-appearing fat and necrotic panniculus [",
"    <a class=\"abstract\" href=\"UTD.htm?17/45/18136/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Based upon the presumed pathophysiologic mechanism of unopposed proteolysis, treatment of panniculitis in AAT-deficient subjects has focused on restoring antiprotease activity. Intravenous infusion of purified AAT has ameliorated the panniculitis in some patients [",
"    <a class=\"abstract\" href=\"UTD.htm?17/45/18136/abstract/34,36,37\">",
"     34,36,37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other treatments have included",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/59/32688?source=see_link\">",
"     dapsone",
"    </a>",
"    (100",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    for several weeks) and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    (200",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    for as long as several months) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/45/18136/abstract/34,37,39,42\">",
"     34,37,39,42",
"    </a>",
"    ]. However, evidence in support of these therapies is limited. Doxycycline is believed to act by scavenging reactive oxygen species produced by neutrophils",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    by slowing the breakdown of matrix proteins by elastase. Topical and systemic glucocorticoids have not been helpful [",
"    <a class=\"abstract\" href=\"UTD.htm?17/45/18136/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     OTHER ASSOCIATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Associations between AAT and vascular disease, inflammatory bowel disease, glomerulonephritis, and vasculitis have been proposed but not definitively established.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Vascular disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vascular complications are a less well-established consequence of the PI*ZZ phenotype [",
"    <a class=\"abstract\" href=\"UTD.htm?17/45/18136/abstract/43,44\">",
"     43,44",
"    </a>",
"    ]. A number of vascular abnormalities have been suggested, including abdominal and intracranial aneurysms and arterial fibromuscular dysplasia, all based on the principle that unopposed proteolytic activity damages vessel walls in severely deficient individuals [",
"    <a class=\"abstract\" href=\"UTD.htm?17/45/18136/abstract/8,37\">",
"     8,37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition, one allele (so-called AAT Pittsburgh) is characterized by substitution of an arginine for a methionine at position 358, causing the protein to mimic the hemorrhagic effects of antithrombin III [",
"    <a class=\"abstract\" href=\"UTD.htm?17/45/18136/abstract/45\">",
"     45",
"    </a>",
"    ]. Two individuals with AAT Pittsburgh have thus far been identified, one of whom died of massive bleeding when the acute phase reactant properties of the AAT protein caused levels of the Pittsburgh variant to rise after a viral infection [",
"    <a class=\"abstract\" href=\"UTD.htm?17/45/18136/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Inflammatory bowel disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;It has been hypothesized that decreased antiprotease activity in the bowel may promote local injury and progression to inflammatory bowel disease, although data have been conflicting regarding an association between AAT and inflammatory bowel disease [",
"    <a class=\"abstract\" href=\"UTD.htm?17/45/18136/abstract/46\">",
"     46",
"    </a>",
"    ]. One case control study from Sweden found that significantly more patients with ulcerative colitis were PI*MZ than in the general population (8.5 versus 4.7 percent), and that PI*MZ individuals tended to have more severe colitis [",
"    <a class=\"abstract\" href=\"UTD.htm?17/45/18136/abstract/47\">",
"     47",
"    </a>",
"    ]. However, a second study from Germany comparing 135 patients with either Crohn's disease or ulcerative colitis with controls found no such associations [",
"    <a class=\"abstract\" href=\"UTD.htm?17/45/18136/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Glomerulonephritis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Glomerular disease is an uncommon finding in AAT. Two different types have been described, one related to AAT and the other to the development of liver failure:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A proliferative glomerulonephritis, most often of the membranoproliferative type, rarely occurs in association with the PI*ZZ phenotype [",
"      <a class=\"abstract\" href=\"UTD.htm?17/45/18136/abstract/49-52\">",
"       49-52",
"      </a>",
"      ]. Why this might occur is not clear. Virtually all reported patients have had cirrhosis, suggesting that serious liver disease plays an important role in the development of this immune complex disorder. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/51/43833?source=see_link\">",
"       \"Clinical presentation, classification, and causes of membranoproliferative glomerulonephritis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      IgA nephropathy occurring in association with hepatic cirrhosis [",
"      <a class=\"abstract\" href=\"UTD.htm?17/45/18136/abstract/53\">",
"       53",
"      </a>",
"      ]. Glomerular IgA deposition is a common finding in hepatic cirrhosis of any cause, occurring in up to one-third of patients [",
"      <a class=\"abstract\" href=\"UTD.htm?17/45/18136/abstract/54\">",
"       54",
"      </a>",
"      ]. Impaired removal of IgA-containing complexes (such as those directed against alimentary antigens) by the Kupffer cells in the liver is thought to predispose to IgA deposition in the kidney. One study evaluated 18 children with end-stage liver disease due mostly to AAT deficiency or biliary atresia in whom renal biopsy was performed at the time of hepatic transplantation [",
"      <a class=\"abstract\" href=\"UTD.htm?17/45/18136/abstract/53\">",
"       53",
"      </a>",
"      ]. Pathologic evidence of either a mesangial proliferative or membranoproliferative glomerulonephritis was seen in all; most patients had IgA nephropathy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     ANCA-positive vasculitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;A putative association between vasculitis and AAT deficiency is based on reports from many countries that AAT variants, both homozygous ZZ and heterozygous Z, occur in higher than expected frequency among individuals with multisystem vasculitides (",
"    <a class=\"graphic graphic_table graphicRef59808 \" href=\"UTD.htm?10/41/10908\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/45/18136/abstract/55,56\">",
"     55,56",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/62/17386?source=see_link\">",
"     \"Clinical manifestations and diagnosis of granulomatosis with polyangiitis (Wegener's) and microscopic polyangiitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The association between AAT deficiency and C-ANCA positive vasculitis is strengthened by plausible pathogenetic mechanisms. For example, in the extravascular fluid, AAT plays an important role as an inhibitor of proteinase-3, a neutrophil elastase-like serine protease located in the primary granules of the neutrophil. Unchecked, proteinase-3 exerts potent tissue-destructive capacity, so a deficiency of AAT could conceivably trigger an auto-immune response by allowing increased extracellular exposure to proteinase-3 [",
"    <a class=\"abstract\" href=\"UTD.htm?17/45/18136/abstract/57\">",
"     57",
"    </a>",
"    ]. Alternatively, linkage disequilibrium might promote inheritance of important autoimmunity genes along with abnormal AAT phenotypes [",
"    <a class=\"abstract\" href=\"UTD.htm?17/45/18136/abstract/58\">",
"     58",
"    </a>",
"    ]. Finally, though unproven, it is conceivable that circulating Z or S polymers could prompt a vasculitic response. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/20/33097?source=see_link\">",
"     \"Pathogenesis of granulomatosis with polyangiitis (Wegener&rsquo;s) and related vasculitides\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    These findings have prompted a suggestion from the joint American Thoracic",
"    <span class=\"nowrap\">",
"     Society/European",
"    </span>",
"    Respiratory Society in favor of genetic testing for AAT deficiency in individuals with C-ANCA positive vasculitis [",
"    <a class=\"abstract\" href=\"UTD.htm?17/45/18136/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The American Thoracic Society (ATS) and European Respiratory Society (ERS) statement on the diagnosis and management of AAT deficiency, as well as other ATS guidelines, can be accessed through the ATS web site at",
"    <a class=\"external\" href=\"file://www.thoracic.org/statements\">",
"     www.thoracic.org/statements",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H176990\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Depending on the specific mutation in the alpha 1 antitrypsin (AAT) gene (OMIM 107400), a variety of extrapulmonary manifestations may occur in AAT deficient individuals.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The types of liver disease associated with AAT deficiency include neonatal hepatitis, hepatomegaly with elevated aminotransferase levels, ascites, cirrhosis, and hepatocellular carcinoma. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Hepatic disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The two AAT alleles most commonly associated with liver disease are Z and M (malton). The pathogenesis of liver disease in AAT deficient individuals is via accumulation of abnormal AAT protein within hepatocytes. The rare alleles, M (duarte), M (nichinan), S, and PI S (iiyama), are also known to cause intrahepatocytic accumulation, but it is not known whether they cause clinically significant liver disease. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Hepatic disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Among children with neonatal hepatitis, a quarter will have resolution of hepatitis by age 3 to 10 years without hepatomegaly or splenomegaly; a quarter will develop cirrhosis between age six months and 17 years; often causing end-stage liver disease; a quarter will have histologic evidence of cirrhosis but with few sequelae; and a quarter will have persistent elevation of liver function tests without cirrhosis. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Risk and natural history'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Adults with the at risk alleles Z and M(malton) may develop cirrhosis or hepatocellular carcinoma without antecedent childhood liver disease. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Liver disease in adults'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/41/23194?source=see_link&amp;anchor=H12#H12\">",
"       \"Diagnostic approach to the patient with cirrhosis\", section on 'Determining the cause of cirrhosis'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/10/34986?source=see_link&amp;anchor=H11#H11\">",
"       \"Clinical features and diagnosis of primary hepatocellular carcinoma\", section on 'Diagnosis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Necrotizing panniculitis, which presents with one or more hot, painful, red nodules or plaques on the thigh or buttocks, is a rare manifestation of AAT deficiency. It occurs in patients with more severe AAT deficiency and those with the PI*ZZ, PI*MZ, PI*SS, and PI*MS genotypes. (See",
"      <a class=\"local\" href=\"#H176414\">",
"       'Clinical features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Treatments for panniculitis include intravenous AAT augmentation therapy,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/59/32688?source=see_link\">",
"       dapsone",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"       doxycycline",
"      </a>",
"      . (See",
"      <a class=\"local\" href=\"#H176869\">",
"       'Diagnosis and therapy'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/62/16361?source=see_link&amp;anchor=H2#H2\">",
"       \"Treatment of alpha-1 antitrypsin deficiency\", section on 'Intravenous augmentation therapy'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Associations between AAT and several other disease processes (eg, vascular disease, inflammatory bowel disease, glomerulonephritis, and systemic vasculitis) have been proposed, but not definitively established. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Other associations'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     file://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=107400 (Accessed on July 07, 2009).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/45/18136/abstract/2\">",
"      Sveger T. Liver disease in alpha1-antitrypsin deficiency detected by screening of 200,000 infants. N Engl J Med 1976; 294:1316.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/45/18136/abstract/3\">",
"      Larsson C. Natural history and life expectancy in severe alpha1-antitrypsin deficiency, Pi Z. Acta Med Scand 1978; 204:345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/45/18136/abstract/4\">",
"      Eriksson S, Carlson J, Velez R. Risk of cirrhosis and primary liver cancer in alpha 1-antitrypsin deficiency. N Engl J Med 1986; 314:736.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/45/18136/abstract/5\">",
"      Sharp HL, Bridges RA, Krivit W, Freier EF. Cirrhosis associated with alpha-1-antitrypsin deficiency: a previously unrecognized inherited disorder. J Lab Clin Med 1969; 73:934.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/45/18136/abstract/6\">",
"      Mahadeva R, Chang WS, Dafforn TR, et al. Heteropolymerization of S, I, and Z alpha1-antitrypsin and liver cirrhosis. J Clin Invest 1999; 103:999.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/45/18136/abstract/7\">",
"      Fairbanks KD, Tavill AS. Liver disease in alpha 1-antitrypsin deficiency: a review. Am J Gastroenterol 2008; 103:2136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/45/18136/abstract/8\">",
"      American Thoracic Society, European Respiratory Society. American Thoracic Society/European Respiratory Society statement: standards for the diagnosis and management of individuals with alpha-1 antitrypsin deficiency. Am J Respir Crit Care Med 2003; 168:818.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/45/18136/abstract/9\">",
"      Tanash HA, Nilsson PM, Nilsson JA, Piitulainen E. Clinical course and prognosis of never-smokers with severe alpha-1-antitrypsin deficiency (PiZZ). Thorax 2008; 63:1091.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/45/18136/abstract/10\">",
"      Salahuddin P. Genetic variants of alpha1-antitrypsin. Curr Protein Pept Sci 2010; 11:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/45/18136/abstract/11\">",
"      Seyama K, Nukiwa T, Takabe K, et al. Siiyama (serine 53 (TCC) to phenylalanine 53 (TTC)). A new alpha 1-antitrypsin-deficient variant with mutation on a predicted conserved residue of the serpin backbone. J Biol Chem 1991; 266:12627.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/45/18136/abstract/12\">",
"      Janciauskiene S, Eriksson S, Callea F, et al. Differential detection of PAS-positive inclusions formed by the Z, Siiyama, and Mmalton variants of alpha1-antitrypsin. Hepatology 2004; 40:1203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/45/18136/abstract/13\">",
"      Birrer P, McElvaney NG, Chang-Stroman LM, Crystal RG. Alpha 1-antitrypsin deficiency and liver disease. J Inherit Metab Dis 1991; 14:512.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/45/18136/abstract/14\">",
"      Frazier GC, Siewertsen MA, Hofker MH, et al. A null deficiency allele of alpha 1-antitrypsin, QOludwigshafen, with altered tertiary structure. J Clin Invest 1990; 86:1878.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/45/18136/abstract/15\">",
"      Lomas DA, Parfrey H. Alpha1-antitrypsin deficiency. 4: Molecular pathophysiology. Thorax 2004; 59:529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/45/18136/abstract/16\">",
"      Teckman JH, Qu D, Perlmutter DH. Molecular pathogenesis of liver disease in alpha1-antitrypsin deficiency. Hepatology 1996; 24:1504.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/45/18136/abstract/17\">",
"      Wu Y, Whitman I, Molmenti E, et al. A lag in intracellular degradation of mutant alpha 1-antitrypsin correlates with the liver disease phenotype in homozygous PiZZ alpha 1-antitrypsin deficiency. Proc Natl Acad Sci U S A 1994; 91:9014.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/45/18136/abstract/18\">",
"      Lomas DA, Finch JT, Seyama K, et al. Alpha 1-antitrypsin Siiyama (Ser53--&gt;Phe). Further evidence for intracellular loop-sheet polymerization. J Biol Chem 1993; 268:15333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/45/18136/abstract/19\">",
"      Lomas DA, Evans DL, Finch JT, Carrell RW. The mechanism of Z alpha 1-antitrypsin accumulation in the liver. Nature 1992; 357:605.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/45/18136/abstract/20\">",
"      Sivasothy P, Dafforn TR, Gettins PG, Lomas DA. Pathogenic alpha 1-antitrypsin polymers are formed by reactive loop-beta-sheet A linkage. J Biol Chem 2000; 275:33663.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/45/18136/abstract/21\">",
"      Parfrey H, Dafforn TR, Belorgey D, et al. Inhibiting polymerization: new therapeutic strategies for Z alpha1-antitrypsin-related emphysema. Am J Respir Cell Mol Biol 2004; 31:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/45/18136/abstract/22\">",
"      Perlmutter DH, Brodsky JL, Balistreri WF, Trapnell BC. Molecular pathogenesis of alpha-1-antitrypsin deficiency-associated liver disease: a meeting review. Hepatology 2007; 45:1313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/45/18136/abstract/23\">",
"      Propst T, Propst A, Dietze O, et al. High prevalence of viral infection in adults with homozygous and heterozygous alpha 1-antitrypsin deficiency and chronic liver disease. Ann Intern Med 1992; 117:641.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/45/18136/abstract/24\">",
"      Sveger T. The natural history of liver disease in alpha 1-antitrypsin deficient children. Acta Paediatr Scand 1988; 77:847.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/45/18136/abstract/25\">",
"      Hussain M, Mieli-Vergani G, Mowat AP. Alpha 1-antitrypsin deficiency and liver disease: clinical presentation, diagnosis and treatment. J Inherit Metab Dis 1991; 14:497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/45/18136/abstract/26\">",
"      Zhou H, Ortiz-Pallard&oacute; ME, Ko Y, Fischer HP. Is heterozygous alpha-1-antitrypsin deficiency type PIZ a risk factor for primary liver carcinoma? Cancer 2000; 88:2668.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/45/18136/abstract/27\">",
"      Fischer HP, Ortiz-Pallard&oacute; ME, Ko Y, et al. Chronic liver disease in heterozygous alpha1-antitrypsin deficiency PiZ. J Hepatol 2000; 33:883.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/45/18136/abstract/28\">",
"      Bals R. Alpha-1-antitrypsin deficiency. Best Pract Res Clin Gastroenterol 2010; 24:629.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/45/18136/abstract/29\">",
"      Bowlus CL, Willner I, Zern MA, et al. Factors associated with advanced liver disease in adults with alpha1-antitrypsin deficiency. Clin Gastroenterol Hepatol 2005; 3:390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/45/18136/abstract/30\">",
"      Clark VC, Dhanasekaran R, Brantly M, et al. Liver test results do not identify liver disease in adults with &alpha;(1)-antitrypsin deficiency. Clin Gastroenterol Hepatol 2012; 10:1278.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/45/18136/abstract/31\">",
"      Kemmer N, Kaiser T, Zacharias V, Neff GW. Alpha-1-antitrypsin deficiency: outcomes after liver transplantation. Transplant Proc 2008; 40:1492.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/45/18136/abstract/32\">",
"      Nelson DR, Teckman J, Di Bisceglie AM, Brenner DA. Diagnosis and management of patients with &alpha;1-antitrypsin (A1AT) deficiency. Clin Gastroenterol Hepatol 2012; 10:575.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/45/18136/abstract/33\">",
"      Stoller JK, Aboussouan LS. Alpha1-antitrypsin deficiency. Lancet 2005; 365:2225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/45/18136/abstract/34\">",
"      Pittelkow MR, Smith KC, Su WP. Alpha-1-antitrypsin deficiency and panniculitis. Perspectives on disease relationship and replacement therapy. Am J Med 1988; 84:80.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/45/18136/abstract/35\">",
"      Edmonds BK, Hodge JA, Rietschel RL. Alpha 1-antitrypsin deficiency-associated panniculitis: case report and review of the literature. Pediatr Dermatol 1991; 8:296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/45/18136/abstract/36\">",
"      Stoller, JK, Piliang, M. Panniculitis in alpha-1 antitrypsin deficiency. Clin Pulm Med 2008; 15:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/45/18136/abstract/37\">",
"      Geraminejad P, DeBloom JR 2nd, Walling HW, et al. Alpha-1-antitrypsin associated panniculitis: the MS variant. J Am Acad Dermatol 2004; 51:645.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/45/18136/abstract/38\">",
"      Irvine C, Neild V, Stephens C, Black M. Alpha-1-antitrypsin deficiency panniculitis. J R Soc Med 1990; 83:743.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/45/18136/abstract/39\">",
"      Sorsa T, Lindy O, Konttinen YT, et al. Doxycycline in the protection of serum alpha-1-antitrypsin from human neutrophil collagenase and gelatinase. Antimicrob Agents Chemother 1993; 37:592.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/45/18136/abstract/40\">",
"      O'Riordan K, Blei A, Rao MS, Abecassis M. alpha 1-antitrypsin deficiency-associated panniculitis: resolution with intravenous alpha 1-antitrypsin administration and liver transplantation. Transplantation 1997; 63:480.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/45/18136/abstract/41\">",
"      Gross B, Grebe M, Wencker M, et al. New Findings in PiZZ alpha1-antitrypsin deficiency-related panniculitis. Demonstration of skin polymers and high dosing requirements of intravenous augmentation therapy. Dermatology 2009; 218:370.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/45/18136/abstract/42\">",
"      Chng WJ, Henderson CA. Suppurative panniculitis associated with alpha 1-antitrypsin deficiency (PiSZ phenotype) treated with doxycycline. Br J Dermatol 2001; 144:1282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/45/18136/abstract/43\">",
"      Schievink WI, Bj&ouml;rnsson J, Parisi JE, Prakash UB. Arterial fibromuscular dysplasia associated with severe alpha 1-antitrypsin deficiency. Mayo Clin Proc 1994; 69:1040.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/45/18136/abstract/44\">",
"      Cox DW. Alpha 1-antitrypsin: a guardian of vascular tissue. Mayo Clin Proc 1994; 69:1123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/45/18136/abstract/45\">",
"      Owen MC, Brennan SO, Lewis JH, Carrell RW. Mutation of antitrypsin to antithrombin. alpha 1-antitrypsin Pittsburgh (358 Met leads to Arg), a fatal bleeding disorder. N Engl J Med 1983; 309:694.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/45/18136/abstract/46\">",
"      Yang P, Tremaine WJ, Meyer RL, Prakash UB. Alpha1-antitrypsin deficiency and inflammatory bowel diseases. Mayo Clin Proc 2000; 75:450.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/45/18136/abstract/47\">",
"      Elzouki AN, Eriksson S, L&ouml;fberg R, et al. The prevalence and clinical significance of alpha 1-antitrypsin deficiency (PiZ) and ANCA specificities (proteinase 3, BPI) in patients with ulcerative colitis. Inflamm Bowel Dis 1999; 5:246.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/45/18136/abstract/48\">",
"      Folwaczny C, Urban S, Schr&ouml;der M, et al. Alpha1-antitrypsin alleles and phenotypes in patients with inflammatory bowel disease. Scand J Gastroenterol 1998; 33:78.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/45/18136/abstract/49\">",
"      Davis ID, Burke B, Freese D, et al. The pathologic spectrum of the nephropathy associated with alpha 1-antitrypsin deficiency. Hum Pathol 1992; 23:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/45/18136/abstract/50\">",
"      Strife CF, Hug G, Chuck G, et al. Membranoproliferative glomerulonephritis and alpha 1-antitrypsin deficiency in children. Pediatrics 1983; 71:88.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/45/18136/abstract/51\">",
"      Moroz SP, Cutz E, Balfe JW, Sass-Kortsak A. Membranoproliferative glomerulonephritis in childhood cirrhosis associated with alpha1-antitrypsin deficiency. Pediatrics 1976; 57:232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/45/18136/abstract/52\">",
"      Roy LP, Webster HL. alpha 1-Antitrypsin and membranoproliferative glomerulonephritis. Pediatrics 1977; 60:784.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/45/18136/abstract/53\">",
"      Noble-Jamieson G, Thiru S, Johnston P, et al. Glomerulonephritis with end-stage liver disease in childhood. Lancet 1992; 339:706.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/45/18136/abstract/54\">",
"      Newell GC. Cirrhotic glomerulonephritis: incidence, morphology, clinical features, and pathogenesis. Am J Kidney Dis 1987; 9:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/45/18136/abstract/55\">",
"      Esnault VL, Testa A, Audrain M, et al. Alpha 1-antitrypsin genetic polymorphism in ANCA-positive systemic vasculitis. Kidney Int 1993; 43:1329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/45/18136/abstract/56\">",
"      O'Donoghue DJ, Guickian M, Blundell G, Winney RJ. Alpha-1-proteinase inhibitor and pulmonary haemorrhage in systemic vasculitis. Adv Exp Med Biol 1993; 336:331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/45/18136/abstract/57\">",
"      Esnault VL, Audrain MA, Sesbo&uuml;&eacute; R. Alpha-1-antitrypsin phenotyping in ANCA-associated diseases: one of several arguments for protease/antiprotease imbalance in systemic vasculitis. Exp Clin Immunogenet 1997; 14:206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/45/18136/abstract/58\">",
"      Griffith ME, Lovegrove JU, Gaskin G, et al. C-antineutrophil cytoplasmic antibody positivity in vasculitis patients is associated with the Z allele of alpha-1-antitrypsin, and P-antineutrophil cytoplasmic antibody positivity with the S allele. Nephrol Dial Transplant 1996; 11:438.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1429 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-61.234.146.186-40244E071D-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_45_18136=[""].join("\n");
var outline_f17_45_18136=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H176990\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      HEPATIC DISEASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Risk and natural history",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Liver disease in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      SKIN DISEASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H176414\">",
"      Clinical features",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H176869\">",
"      Diagnosis and therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      OTHER ASSOCIATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Vascular disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Inflammatory bowel disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Glomerulonephritis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      ANCA-positive vasculitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H176990\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PULM/1429\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/1429|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?12/20/12616\" title=\"picture 1\">",
"      AAT deficiency liver Light",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/1429|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?8/62/9196\" title=\"table 1\">",
"      Classification of panniculitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?10/41/10908\" title=\"table 2\">",
"      AAT deficiency and ANCA",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/10/34986?source=related_link\">",
"      Clinical features and diagnosis of primary hepatocellular carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/62/17386?source=related_link\">",
"      Clinical manifestations and diagnosis of granulomatosis with polyangiitis (Wegener's) and microscopic polyangiitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/8/6281?source=related_link\">",
"      Clinical manifestations, diagnosis, and natural history of alpha-1 antitrypsin deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/51/43833?source=related_link\">",
"      Clinical presentation, classification, and causes of membranoproliferative glomerulonephritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/41/23194?source=related_link\">",
"      Diagnostic approach to the patient with cirrhosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/38/25194?source=related_link\">",
"      Epidemiology and etiologic associations of hepatocellular carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/59/17337?source=related_link\">",
"      Overview of the complications, prognosis, and management of cirrhosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/45/17112?source=related_link\">",
"      Panniculitis: Recognition and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/20/33097?source=related_link\">",
"      Pathogenesis of granulomatosis with polyangiitis (Wegener&rsquo;s) and related vasculitides",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/61/25559?source=related_link\">",
"      Patient selection for liver transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/6/28778?source=related_link\">",
"      Prevention of hepatocellular carcinoma and recommendations for surveillance in adults with chronic liver disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/62/16361?source=related_link\">",
"      Treatment of alpha-1 antitrypsin deficiency",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f17_45_18137="Short daily hemodialysis";
var content_f17_45_18137=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Short daily hemodialysis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/45/18137/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/45/18137/contributors\">",
"     Gihad E Nesrallah, MD, FRCPC, FACP",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/45/18137/contributors\">",
"     Robert M Lindsay, MD, FRCPC, FRCPE",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/45/18137/contributors\">",
"     Andreas Pierratos, MD, FRCPC",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/45/18137/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/45/18137/contributors\">",
"     Steve J Schwab, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/45/18137/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/45/18137/contributors\">",
"     Alice M Sheridan, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?17/45/18137/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 12, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The first successful use of short daily, or \"quotidian\" hemodialysis was first reported by DePalma in 1969 [",
"    <a class=\"abstract\" href=\"UTD.htm?17/45/18137/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. This approach was based upon the premise that improved patient outcomes, compared with conventional three times per week hemodialysis, would occur with a dialysis schedule that consisted of the same number of hours of dialysis per week but delivered over twice as many sessions. More specifically, this schedule consists of daily hemodialysis (five to seven days per week) provided for a duration of 1.5 to 3 or more hours per session.",
"   </p>",
"   <p>",
"    Initial attempts to popularize daily dialysis in the United States were thwarted by financial and logistical issues. This led to a decline in its use both in the home and in-center settings.",
"   </p>",
"   <p>",
"    Over the last decade, however, there has been a resurgence in the use of daily dialysis, with several studies emerging from the United States and Europe showing improvements in various intermediate outcomes. Most recently, in the wake of the HEMO study, attention has turned from increasing the per-session dialytic dose, to altering variables such as treatment frequency or duration to improve outcomes [",
"    <a class=\"abstract\" href=\"UTD.htm?17/45/18137/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. Daily dialysis has also been proposed as a rescue therapy and in the intensive care unit setting [",
"    <a class=\"abstract\" href=\"UTD.htm?17/45/18137/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/47/33530?source=see_link\">",
"     \"Sustained low efficiency or extended daily dialysis\"",
"    </a>",
"    .) Short daily hemofiltration and hemodiafiltration have also been introduced, being used both in center and at home [",
"    <a class=\"abstract\" href=\"UTD.htm?17/45/18137/abstract/7,8\">",
"     7,8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This topic review will discuss short daily hemodialysis. A review of long daily or nocturnal hemodialysis is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/16/264?source=see_link\">",
"     \"Technical aspects of nocturnal hemodialysis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     OVERVIEW OF RATIONALE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The rationale for short daily hemodialysis is based upon a strategy that is proposed to enhance both dialysis efficiency and hemodynamic stability.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Improved dialysis efficiency",
"    </span>",
"    &nbsp;&mdash;&nbsp;The exponential decrease in the serum concentration of small molecules, such as urea, during hemodialysis leads to dissipation of the blood-to-dialysate gradient and to reduced efficiency of small molecule removal over time [",
"    <a class=\"abstract\" href=\"UTD.htm?17/45/18137/abstract/9\">",
"     9",
"    </a>",
"    ]. With short daily dialysis, shortening the dialysis time while increasing the frequency of dialysis allows more time to be spent dialyzing against higher uremic solute concentration gradients. This enhances the efficiency of solute removal. Ultimately, a new steady state with lower peak but higher trough solute concentrations is achieved.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Improved hemodynamic stability",
"    </span>",
"    &nbsp;&mdash;&nbsp;More frequent dialysis allows for less interdialytic fluid accumulation. This is likely to improve hemodynamic stability during dialysis with increased potential for normalizing the extracellular fluid volume (ECFV).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     MEASURES OF ADEQUACY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Traditional urea kinetic modeling, as validated for conventional (three times weekly) hemodialysis, cannot be directly applied to the assessment of dialysis adequacy with frequent (short-daily or nocturnal) dialysis regimens. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/14/6378?source=see_link\">",
"     \"Kt/V and the adequacy of hemodialysis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/16/264?source=see_link\">",
"     \"Technical aspects of nocturnal hemodialysis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The need for a universal dose measure applicable to all modalities that may correlate with patient outcomes has therefore led to the following proposed measures of adequacy:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Equivalent renal urea clearance &mdash; The equivalent renal urea clearance (EKR) is equal to the amount of urea clearance provided by native renal function that is required to produce a serum urea concentration equal to the time averaged concentration (TAC) of urea achieved on dialysis [",
"      <a class=\"abstract\" href=\"UTD.htm?17/45/18137/abstract/10\">",
"       10",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Normalized",
"      <span class=\"nowrap\">",
"       Kt/V",
"      </span>",
"      &mdash; The normalized",
"      <span class=\"nowrap\">",
"       Kt/V",
"      </span>",
"      is based on a two-compartment model using a lower intercompartment mass transfer coefficient to simulate greater solute disequilibrium than would be found with urea [",
"      <a class=\"abstract\" href=\"UTD.htm?17/45/18137/abstract/11\">",
"       11",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Standard",
"      <span class=\"nowrap\">",
"       Kt/V",
"      </span>",
"      &mdash; The standard",
"      <span class=\"nowrap\">",
"       Kt/V",
"      </span>",
"      <span class=\"nowrap\">",
"       (stdKt/V),",
"      </span>",
"      which is more widely utilized than the other methods, is calculated based upon the midweek predialysis urea rather than the TAC [",
"      <a class=\"abstract\" href=\"UTD.htm?17/45/18137/abstract/12\">",
"       12",
"      </a>",
"      ]. The minimum recommended dialysis dose, which follows the current Dialysis Outcomes Quality Initiative (DOQI) guidelines, is a",
"      <span class=\"nowrap\">",
"       stdKt/V",
"      </span>",
"      value of about 2.0 per week for all dialysis methods. A weekly",
"      <span class=\"nowrap\">",
"       stdKt/V",
"      </span>",
"      of 2 is provided by a daily dose with an equilibrated",
"      <span class=\"nowrap\">",
"       Kt/V",
"      </span>",
"      <span class=\"nowrap\">",
"       (eKt/V)",
"      </span>",
"      of 0.38 (less than half of the required dose of 1.05 with conventional hemodialysis).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Compared with conventional dialysis, however, the same number of hours per week of daily dialysis results in lower predialysis urea values. Thus, current daily short hemodialysis provides a higher",
"    <span class=\"nowrap\">",
"     stdKt/V",
"    </span>",
"    of about 3.0 [",
"    <a class=\"abstract\" href=\"UTD.htm?17/45/18137/abstract/13,14\">",
"     13,14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    How well any of these measures correlate with clinical outcomes is currently unclear.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     PRACTICAL ASPECTS OF DAILY HEMODIALYSIS DELIVERY",
"    </span>",
"    &nbsp;&mdash;&nbsp;General features of and prerequisites for a home dialysis program are discussed in a separate topic review. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/44/25286?source=see_link\">",
"     \"Organization and elements of a home hemodialysis program\"",
"    </a>",
"    .) The following section elaborates on some of the technical and logistical details of daily dialysis delivery with a focus on the home setting.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Patient recruitment and selection",
"    </span>",
"    &nbsp;&mdash;&nbsp;To date, there are no evidence-based recommendations to guide patient selection for home daily dialysis. In practice environments where resources limit its use, daily dialysis should be prescribed on the basis of need, such as the management of refractory uremic complications, fluid overload, resistant hypertension, or intradialytic hypotension.",
"   </p>",
"   <p>",
"    Until large-scale comparative studies are available, the selection of nocturnal versus short daily dialysis should largely be dictated by availability and patient preference, although patients with particularly difficult to manage hyperphosphatemia clearly benefit more from the longer treatment time conferred by nocturnal therapy. Where resources are not limited and in the absence of contraindications, patient willingness remains the primary criterion for selection for daily dialysis. Significant barriers to home-based therapy include decreased compliance, cognitive ability, visual acuity,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    motor skills,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    a lack of an assistant.",
"   </p>",
"   <p>",
"    Center-based daily hemodialysis may be reserved for those in greatest medical need or for volunteers ardently seeking improved quality of life or functional status. Patients with high levels of comorbidity and those with hemodynamic instability or seizure disorders are better suited to the supervised in-center environment.",
"   </p>",
"   <p>",
"    For center-based therapy, patient proximity to the dialysis unit and availability of transportation may be important limiting factors. However, this does not mean that the use of daily dialysis as a form of \"rescue therapy\" for medical reasons cannot be considered in patients with geographic limitations (if even for shorter periods of time).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Training and education for a home daily hemodialysis patient",
"    </span>",
"    &nbsp;&mdash;&nbsp;Training usually requires a full-time six week commitment, although two weeks can be sufficient for a patient with self-care experience. Training focuses on the use of the dialysis machine, troubleshooting alarms, adjusting treatment parameters (including dialysate composition), dealing with emergencies (eg, air embolism, accidental disconnection from the blood circuit), and proper vascular access",
"    <span class=\"nowrap\">",
"     cannulation/connection",
"    </span>",
"    technique. It is also important to include machine and water treatment maintenance, supply management, medication self-administration, and laboratory sampling in the training schedule [",
"    <a class=\"abstract\" href=\"UTD.htm?17/45/18137/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patient training for daily hemodialysis was compared with those undergoing conventional hemodialysis in the London",
"    <span class=\"nowrap\">",
"     Daily/Nocturnal",
"    </span>",
"    hemodialysis study of 11, 12, and 22 patients undergoing short daily, nocturnal, and conventional hemodialysis, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?17/45/18137/abstract/15\">",
"     15",
"    </a>",
"    ]. The average patient training period was approximately 17 days, with patients using native arteriovenous fistulae, grafts, or central catheters.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Vascular access",
"    </span>",
"    &nbsp;&mdash;&nbsp;Native arteriovenous fistulae (AVF), synthetic grafts, and long-term central venous catheters (CVCs) are all acceptable for use in daily hemodialysis, with the same order of preference as for conventional dialysis. Similarly, needles suitable for conventional dialysis can be used for daily dialysis.",
"   </p>",
"   <p>",
"    Patient comfort and AVF longevity may be increased by using the buttonhole technique, which involves re-cannulation of the same two or three sites on a rotating basis [",
"    <a class=\"abstract\" href=\"UTD.htm?17/45/18137/abstract/16-18\">",
"     16-18",
"    </a>",
"    ]. Using this method, the",
"    <span class=\"nowrap\">",
"     needle/cannula",
"    </span>",
"    are inserted through exactly the same hole at the same angle and depth of penetration [",
"    <a class=\"abstract\" href=\"UTD.htm?17/45/18137/abstract/18-20\">",
"     18-20",
"    </a>",
"    ]. After 8 to 10 cannulations (or 12 to 14 in diabetic patients), an epithelialized track develops that allows the use of blunt needles [",
"    <a class=\"abstract\" href=\"UTD.htm?17/45/18137/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Buttonhole cannulation without the use of local",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/30/33252?source=see_link\">",
"     mupirocin",
"    </a>",
"    can be associated with staphylococcus aureus bacteremia often leading to life threatening metastatic infections. The risk of infection was examined in a randomized trial of 140 conventional hemodialysis patients assigned to either the buttonhole technique or to conventional &ldquo;rope ladder&rdquo; needling [",
"    <a class=\"abstract\" href=\"UTD.htm?17/45/18137/abstract/21\">",
"     21",
"    </a>",
"    ]. At eight weeks, the rate of localized infection was higher among patients assigned to the buttonhole technique compared with conventional needling (50 versus 22.4 per 1000, respectively). There was one episode of staphylococcus aureus bacteremia at eight weeks and two more episodes after the study ended, but within twelve months, in the group utilizing the buttonhole technique versus none in the conventional needling group. At twelve months, the number of needling site abscesses requiring intravenous antibiotics was higher in the buttonhole group versus the conventional needling group (9 versus 0, respectively). The degree to which these data from conventional hemodialysis patients may be extrapolated to nocturnal daily hemodialysis or self-cannulating patients is not clear [",
"    <a class=\"abstract\" href=\"UTD.htm?17/45/18137/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As a result of the increased risk of infection, avoidance of buttonhole cannulation has been advocated by some experts. We have not seen any case of staphylococcus aureus bacteremia in our center since the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/30/33252?source=see_link\">",
"     mupirocin",
"    </a>",
"    use started a number of years ago. Most centers do not practice the buttonhole technique for facility based dialysis.",
"   </p>",
"   <p>",
"    The buttonhole technique may be associated with fewer thrombotic complications. In the Frequent Hemodialysis Network (FHN) trial, in which 245 patients were randomly assigned to receive in-center six days per week hemodialysis or conventional three days per week hemodialysis, compared with the rope-ladder technique, the buttonhole technique was associated with longer intervals between access-related events (hazard ratio [HR] 0.44, 95% CI 0.20-0.97) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/45/18137/abstract/23\">",
"     23",
"    </a>",
"    ]. This benefit was driven mostly by a reduction in thrombotic episodes. Irrespective of technique (ie, buttonhole versus rope ladder), more frequent cannulation may lead to more frequent access-related complications. (See",
"    <a class=\"local\" href=\"#H26\">",
"     'Vascular access'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Equipment and technical aspects",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is important to establish standardized technical requirements that incorporate the assessment of the patient's home, the installation planning, home renovation, and equipment installation. Although the choice of hemodialysis equipment is wide, it is still based upon the designs of hemodialysis machines that are used in-center.",
"   </p>",
"   <p>",
"    The recent proliferation of home hemodialysis has led to the production of dialysis machines specifically designed for home use. In general, these machines should be simple to use, compact, and quiet, with easily accessible controls. A review of the different dialysis machines currently available for the home can be found elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/44/19144?source=see_link\">",
"     \"Home hemodialysis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Appropriate water treatment must be provided to the home. Prior to choosing the type, water samples for chemical content and bacteria are needed to determine water treatment requirements. These may be different for rural patients on well-water versus those in an urban area on municipal water.",
"   </p>",
"   <p>",
"    There are essentially two types of water treatment systems: reverse osmosis (RO) or deionization (DI) systems. The choice of either RO or DI water system should be determined by a program policy that factors in capital equipment costs, operating costs, water system support and service, patient training responsibility, and system safety and reliability. Most centers use RO water systems, as they are less costly to operate after the initial higher cost of purchase.",
"   </p>",
"   <p>",
"    A suitable RO system for home use must be small and quiet and must be compatible with the patient's dialysis machine. The configuration of the patient's home should be considered when choosing a purification system. For daily dialysis, the water treatment system can be located in the room adjacent to the dialysis machine as noise levels may not be so important (as compared with nocturnal dialysis, where sleep can be affected by noise).",
"   </p>",
"   <p>",
"    With respect to in-center dialysis, the ideal dialysis equipment should provide quick patient turnaround to help with scheduling, although any equipment can be used. Consideration of having more machines available than usual may have to be made.",
"   </p>",
"   <p>",
"    One program has reported its experience with 20 dialysis machine installations using a DI system composed of pretreatment, purification, and post-treatment components [",
"    <a class=\"abstract\" href=\"UTD.htm?17/45/18137/abstract/24\">",
"     24",
"    </a>",
"    ]. Using standard bacteriological testing, there were only four occurrences of failed endotoxin and bacterial tests, with all eventually being retested with satisfactory results.",
"   </p>",
"   <p>",
"    Additional details of the technical requirements of home hemodialysis programs with full references can be found elsewhere [",
"    <a class=\"abstract\" href=\"UTD.htm?17/45/18137/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Dialyzer selection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Membrane selection for daily hemodialysis is the same as for conventional hemodialysis, and synthetic, high-flux membranes are typically used. While reuse has been practiced in the past (more so with nocturnal hemodialysis) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/45/18137/abstract/25\">",
"     25",
"    </a>",
"    ], only a few programs currently reuse membranes. The effect of reuse on clinical outcomes in the daily dialysis setting has not been studied in detail.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Dialysis prescription and dose monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;As previously mentioned, the optimal method of prescribing and monitoring the dose of daily hemodialysis regimens is not established. Some method of dose quantification is necessary to guide individual patient prescriptions to monitor adequate dialysis delivery, and to allow patient outcome comparisons between the various dialysis regimens.",
"   </p>",
"   <p>",
"    Based upon mathematical modeling, a per-session",
"    <span class=\"nowrap\">",
"     eKt/V",
"    </span>",
"    of 0.37 (single pool",
"    <span class=\"nowrap\">",
"     Kt/V",
"    </span>",
"    <span class=\"nowrap\">",
"     [spKt/V]",
"    </span>",
"    of 0.53 to 0.56) delivered using a short-daily hemodialysis regimen is roughly equivalent to conventional hemodialysis with a per-session",
"    <span class=\"nowrap\">",
"     eKt/V",
"    </span>",
"    of 1.05 [",
"    <a class=\"abstract\" href=\"UTD.htm?17/45/18137/abstract/26\">",
"     26",
"    </a>",
"    ]. This should be considered a minimum acceptable dose when using short daily dialysis.",
"   </p>",
"   <p>",
"    In our opinion, however, a weekly",
"    <span class=\"nowrap\">",
"     stdKt/V",
"    </span>",
"    target of 3.0 should be sought, as was achieved in the London",
"    <span class=\"nowrap\">",
"     Daily/Nocturnal",
"    </span>",
"    Study [",
"    <a class=\"abstract\" href=\"UTD.htm?17/45/18137/abstract/13\">",
"     13",
"    </a>",
"    ]. This dose was associated with improvements in a number of physiological parameters (as noted in the next section) and allows for a margin of safety in case the prescribed dose is not fully delivered. This is equivalent to a weekly",
"    <span class=\"nowrap\">",
"     spKt/V",
"    </span>",
"    of 5.6, a per session",
"    <span class=\"nowrap\">",
"     spKt/V",
"    </span>",
"    of 0.93, or a sessional",
"    <span class=\"nowrap\">",
"     eKt/V",
"    </span>",
"    of 0.82.",
"   </p>",
"   <p>",
"    Modeling indicates that this target is likely to be achievable with a 2.5 hour, six day per week regimen in 95 percent of patients (F. Gotch, personal communication). In the London Study, the delivered dose was achieved using high flux, large surface area dialysers (eg, F80, Optiflux 160 or 200, manufactured by Fresenius Medical Care, North America [Lexington, MA]) with dialyser blood flow rates of 400 to 500",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    and a dialysate flow rate of 800",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?17/45/18137/abstract/13,27\">",
"     13,27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The value of urea clearance in daily hemodialysis has not been clearly established. Other markers, such as phosphorous clearance, may be important as well. In one study, treatment times of three hours per session were associated with improvements in phosphate levels and calcium-phosphorous product [",
"    <a class=\"abstract\" href=\"UTD.htm?17/45/18137/abstract/28\">",
"     28",
"    </a>",
"    ], which are not consistently seen with shorter treatment times [",
"    <a class=\"abstract\" href=\"UTD.htm?17/45/18137/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As more rigorous studies are conducted in this area, ideal clearance targets for daily hemodialysis will hopefully emerge.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Dialysate composition",
"    </span>",
"    &nbsp;&mdash;&nbsp;The dialysate composition used with daily hemodialysis in the manner described above is generally not different from that used with conventional hemodialysis. The composition of the dialysate is as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Sodium - 135 to 140",
"      <span class=\"nowrap\">",
"       mEq/L",
"      </span>",
"     </li>",
"     <li>",
"      Potassium - 2.0 to 3.0",
"      <span class=\"nowrap\">",
"       mEq/L",
"      </span>",
"     </li>",
"     <li>",
"      Bicarbonate - 35 to 40",
"      <span class=\"nowrap\">",
"       mEq/L",
"      </span>",
"     </li>",
"     <li>",
"      Calcium - 2.5 to 3.5",
"      <span class=\"nowrap\">",
"       mEq/L",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Patient monitoring and safety",
"    </span>",
"    &nbsp;&mdash;&nbsp;Unlike home nocturnal hemodialysis, daily hemodialysis does not require remote monitoring since treatments are generally carried out during the daytime and always with the patient awake. Security devices such as enuresis alarms and connector clamps are also generally not needed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     OUTCOMES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple observational studies and one randomized trial have shown that more frequent dialysis improves selected outcomes. A benefit on survival has not been shown.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9482545\">",
"    <span class=\"h2\">",
"     Frequent Hemodialysis Network (FHN) daily trial",
"    </span>",
"    &nbsp;&mdash;&nbsp;The FHN trial was a multicenter, randomized trial that included 245 patients assigned to either frequent hemodialysis (six times weekly) or conventional hemodialysis [",
"    <a class=\"abstract\" href=\"UTD.htm?17/45/18137/abstract/30\">",
"     30",
"    </a>",
"    ]. Two primary composite outcomes were determined at one year, including death or one-year change from baseline in left ventricular (LV) mass as assessed by cardiac resonance imaging, and death or one-year change in physical health as assessed by a RAND heath survey. Both composite outcomes showed significant benefit to the frequent-dialysis group compared with the conventional-dialysis group (with hazard ratios of 0.61, 95% CI, 0.46-0.82 for death or change in LV mass; and 0.70, 95% CI, 0.53-0.92, for death or change in physical health).",
"   </p>",
"   <p>",
"    This study also demonstrated benefits in pre-determined secondary outcomes to the frequent dialysis group such as a decrease in LV mass, improved blood pressure control and phosphate balance but not on cognitive performance, depression, serum albumin concentration, or use of erythropoiesis-stimulating agents.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9482552\">",
"    <span class=\"h2\">",
"     Observational data",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several hundred observational studies have evaluated the various potential benefits and risks of daily hemodialysis. Most have used patients as their own controls, using pre-post comparisons as opposed to parallel control groups. While these studies have been limited by the usual methodologic problems encountered in observational research, they have been instrumental in shaping the way daily hemodialysis is delivered, and have shown improvements in a number of important secondary outcomes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Clearances",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Urea",
"    </span>",
"    &nbsp;&mdash;&nbsp;A discussion of clearances of urea with short daily hemodialysis is presented above. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Dialysis prescription and dose monitoring'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H5\">",
"     'Measures of adequacy'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Middle molecules",
"    </span>",
"    &nbsp;&mdash;&nbsp;In general, middle molecule removal is determined by the dialyser permeability, the presence of convection, protein binding, and dialysis duration. Given that daily dialysis results in more frequent solute level equilibration with less rebound, this technique provides higher middle molecule removal than with conventional hemodialysis, although the reported increase varies by the method of calculation:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The increased clearance is quantitatively modest if the measurement is based on the TAC of the solute (as in the calculation of EKR) [",
"      <a class=\"abstract\" href=\"UTD.htm?17/45/18137/abstract/31\">",
"       31",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The increased clearance is significant when it is based upon the predialysis concentration of the solute (as in the case of",
"      <span class=\"nowrap\">",
"       stdKt/V)",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?17/45/18137/abstract/32\">",
"       32",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    By comparison, middle molecule removal increases significantly by daily nocturnal hemodialysis independent of the calculation method since both time and frequency increases [",
"    <a class=\"abstract\" href=\"UTD.htm?17/45/18137/abstract/31-33\">",
"     31-33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The serum levels of advanced glycosylation end products also decrease upon conversion from conventional to short (and long nocturnal) hemodialysis [",
"    <a class=\"abstract\" href=\"UTD.htm?17/45/18137/abstract/34,35\">",
"     34,35",
"    </a>",
"    ]. However, middle molecule clearance is better with daily hemofiltration than with daily short hemodialysis [",
"    <a class=\"abstract\" href=\"UTD.htm?17/45/18137/abstract/36\">",
"     36",
"    </a>",
"    ]. A discussion of middle molecules can be found elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/24/37258?source=see_link\">",
"     \"Uremic toxins\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Protein bound molecules",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although protein bound molecules are not easily removed by dialysis, they appear to be cleared more efficiently (eg, indole-3-acetic, acid indoxyl sulfate) with daily as compared with conventional hemodialysis [",
"    <a class=\"abstract\" href=\"UTD.htm?17/45/18137/abstract/34\">",
"     34",
"    </a>",
"    ]. The serum levels of homocysteine also decrease with short daily hemodialysis [",
"    <a class=\"abstract\" href=\"UTD.htm?17/45/18137/abstract/34,35\">",
"     34,35",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/24/37258?source=see_link\">",
"     \"Uremic toxins\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Phosphate",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several studies have shown that short daily hemodialysis improves phosphate balance [",
"    <a class=\"abstract\" href=\"UTD.htm?17/45/18137/abstract/28,30,37\">",
"     28,30,37",
"    </a>",
"    ]. In the FHN daily trial, at one year, compared with the conventional-dialysis group, the frequent-dialysis group had a lower predialysis serum phosphorus (5.24 versus 5.65, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/45/18137/abstract/30\">",
"     30",
"    </a>",
"    ] and a 1.35",
"    <span class=\"nowrap\">",
"     g/day",
"    </span>",
"    reduction in the required equivalent phosphate binder dose [",
"    <a class=\"abstract\" href=\"UTD.htm?17/45/18137/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Quality of life",
"    </span>",
"    &nbsp;&mdash;&nbsp;Health-related quality of life has been studied using a number of validated instruments. Studies in this area have been mostly positive, with multiple studies showing increases in SF-36 physical or mental component scores [",
"    <a class=\"abstract\" href=\"UTD.htm?17/45/18137/abstract/39-45\">",
"     39-45",
"    </a>",
"    ]. One study, for example, demonstrated a significant improvement in utility score (from 0.34 to 0.84) as measured using the time trade-off method, after converting from conventional hemodialysis to daily hemodialysis [",
"    <a class=\"abstract\" href=\"UTD.htm?17/45/18137/abstract/40\">",
"     40",
"    </a>",
"    ]. However, no difference in utility was observed when the Health Utilities Index was used.",
"   </p>",
"   <p>",
"    A variety of other instruments have shown improvements in or disappearance of uremia and dialysis-related symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?17/45/18137/abstract/39,40,43,46-49\">",
"     39,40,43,46-49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a prospective cohort study (FREEDOM study), among 154 participants (90 percent of whom converted from in-center hemodialysis) who completed an SF-36 health survey at enrollment and at 12 months, there was a sustained improvement in the physical- and mental- component summary scores as well as in individual domains of the survey [",
"    <a class=\"abstract\" href=\"UTD.htm?17/45/18137/abstract/45\">",
"     45",
"    </a>",
"    ]. The number of individuals who achieved a physical-component score comparable to the general population more than doubled.",
"   </p>",
"   <p>",
"    Among 94 patients with disturbed sleep",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    restless leg syndrome who were included in the FREEDOM study, short daily hemodialysis resulted in a sustained improvement in restless legs symptoms as assessed by the International Restless Leg Syndrome (IRLS) Study Group rating scale [",
"    <a class=\"abstract\" href=\"UTD.htm?17/45/18137/abstract/50\">",
"     50",
"    </a>",
"    ]. However the percentage of patients prescribed medication for restless leg syndrome did not decrease.",
"    <br/>",
"    <br/>",
"    After adjusting for restless legs syndrome and the use of related medications, daily hemodialysis was also associated with an improvement in sleep adequacy and disturbances.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Cardiovascular",
"    </span>",
"    &nbsp;&mdash;&nbsp;Improvements in blood pressure control have been observed with short daily hemodialysis [",
"    <a class=\"abstract\" href=\"UTD.htm?17/45/18137/abstract/5,39,46,49,51-54\">",
"     5,39,46,49,51-54",
"    </a>",
"    ]. These include decreases in systolic, diastolic,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    mean predialysis arterial pressures, with concomitant reductions in blood pressure medication doses [",
"    <a class=\"abstract\" href=\"UTD.htm?17/45/18137/abstract/5,30,46,55,56\">",
"     5,30,46,55,56",
"    </a>",
"    ]. In the FHN daily trial, the frequent-dialysis group had a lower average predialysis systolic blood pressure compared with the conventional-dialysis group at one year (137 versus 147 mmHg, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/45/18137/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Improvements in blood pressure control also correlate with reductions in left ventricular (LV) mass. This was first illustrated in a randomized crossover study of 12 patients in which LV mass fell after six months with daily short hemodialysis (148.7 &plusmn; 59.7",
"    <span class=\"nowrap\">",
"     g/m2",
"    </span>",
"    during conventional hemodialysis to 120.1 &plusmn; 60.4",
"    <span class=\"nowrap\">",
"     g/m2)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?17/45/18137/abstract/52\">",
"     52",
"    </a>",
"    ]. A reduction in LV mass was also shown in the FHN trial; the mean LV mass decreased by 16.4 g in frequent dialysis patients over one year compared with 2.6 g in the controls [",
"    <a class=\"abstract\" href=\"UTD.htm?17/45/18137/abstract/30\">",
"     30",
"    </a>",
"    ]. Regression of cardiac hypertrophy [",
"    <a class=\"abstract\" href=\"UTD.htm?17/45/18137/abstract/37\">",
"     37",
"    </a>",
"    ], a decrease in the markers of inflammation (CRP) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/45/18137/abstract/37\">",
"     37",
"    </a>",
"    ], and a reduction in regional wall motion abnormalities [",
"    <a class=\"abstract\" href=\"UTD.htm?17/45/18137/abstract/57\">",
"     57",
"    </a>",
"    ] have all been associated with more frequent hemodialysis.",
"   </p>",
"   <p>",
"    A concomitant significant reduction in extracellular fluid volume (as measured by bioimpedance spectroscopy) from 52.7 &plusmn; 11.4 percent of total body water to 47.6 &plusmn; 7.5 percent was also observed. Similarly, the London",
"    <span class=\"nowrap\">",
"     Daily/Nocturnal",
"    </span>",
"    Hemodialysis Study found that extracellular fluid volume was lower in daily hemodialysis patients than in matched cohorts receiving conventional hemodialysis [",
"    <a class=\"abstract\" href=\"UTD.htm?17/45/18137/abstract/54\">",
"     54",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    All of these studies also demonstrated improved blood pressure control [",
"    <a class=\"abstract\" href=\"UTD.htm?17/45/18137/abstract/52,54\">",
"     52,54",
"    </a>",
"    ]. This suggests that some of the beneficial antihypertensive effect of daily hemodialysis is related to improved extracellular fluid volume control [",
"    <a class=\"abstract\" href=\"UTD.htm?17/45/18137/abstract/58\">",
"     58",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Despite these encouraging findings, the effect of daily hemodialysis on cardiovascular morbidity and mortality has not yet been described in an adequately powered study.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Anemia and erythropoietin dosing",
"    </span>",
"    &nbsp;&mdash;&nbsp;The effect of daily hemodialysis others have found little change [",
"    <a class=\"abstract\" href=\"UTD.htm?17/45/18137/abstract/5,39,52,59\">",
"     5,39,52,59",
"    </a>",
"    ]. The accurate interpretation of these findings is complicated by the potential for increased surveillance by home dialysis programs, with more aggressive treatment with erythropoiesis-stimulating agents (ESA) and iron in this setting.",
"   </p>",
"   <p>",
"    At least three cohorts have required significantly less use of ESAs after converting to daily hemodialysis [",
"    <a class=\"abstract\" href=\"UTD.htm?17/45/18137/abstract/5,39,48\">",
"     5,39,48",
"    </a>",
"    ]. However, most studies have failed to show any significant change in ESA utilization [",
"    <a class=\"abstract\" href=\"UTD.htm?17/45/18137/abstract/30\">",
"     30",
"    </a>",
"    ]. Increased blood loss through the dialysis circuit resulting in iron deficiency may theoretically mask the potential pro-erythropoietic effects of daily dialysis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Nutritional effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Daily dialysis may impact on a number of nutritional indices. Daily in-center hemodialysis has been used as a rescue therapy for patients with severe malnutrition complicating uremia [",
"    <a class=\"abstract\" href=\"UTD.htm?17/45/18137/abstract/5,60\">",
"     5,60",
"    </a>",
"    ], with patients generally reporting increased appetite after switching from conventional to daily hemodialysis. One study, for example, showed an increase in protein intake by 25 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?17/45/18137/abstract/60\">",
"     60",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The effects on serum albumin, nPNA and dry body weight have been variable with many studies showing improvements in these parameters, and others showing no significant change. Statistical power may have been an issue in some of these negative studies. A secondary analysis of data from the FHN trial cited above showed no difference between patients undergoing frequent versus conventional hemodialysis in serum albumin, protein catabolic rate, or lean body mass [",
"    <a class=\"abstract\" href=\"UTD.htm?17/45/18137/abstract/61\">",
"     61",
"    </a>",
"    ]. Frequent dialysis was associated with an increase in body weight that was probably due to increased fat.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Hospitalizations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some studies have found a reduction in hospital admissions with daily hemodialysis [",
"    <a class=\"abstract\" href=\"UTD.htm?17/45/18137/abstract/5,62\">",
"     5,62",
"    </a>",
"    ]. In one study of 42 patients with a high burden of comorbidity, there was a significant reduction in hospital days from 12.2",
"    <span class=\"nowrap\">",
"     patient/year",
"    </span>",
"    on conventional hemodialysis to 8.0",
"    <span class=\"nowrap\">",
"     patient/year",
"    </span>",
"    on daily hemodialysis [",
"    <a class=\"abstract\" href=\"UTD.htm?17/45/18137/abstract/5\">",
"     5",
"    </a>",
"    ]. This was associated with a 40 percent reduction in hospital admissions per patient per year.",
"   </p>",
"   <p>",
"    However, no study has yet demonstrated significant differences in hospitalization rates with daily hemodialysis using a parallel control group on conventional hemodialysis, nor in a daily hemodialysis cohort with a level of comorbidity that is representative of the general hemodialysis patient population. In addition, most studies have lacked adequate statistical power to study the effect of daily hemodialysis on hospitalization rates. As a result, while current data are encouraging, larger studies with longer periods of follow-up are needed to study this important outcome.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Vascular access",
"    </span>",
"    &nbsp;&mdash;&nbsp;More frequent vascular access cannulation required for daily hemodialysis may result in decreased access survival. This issue was addressed in the FHN daily trial, in which the primary vascular outcome was time to first access event (including repair, loss of access or access-related hospitalization), and the secondary vascular outcome was the time to all repairs and time to all losses [",
"    <a class=\"abstract\" href=\"UTD.htm?17/45/18137/abstract/30\">",
"     30",
"    </a>",
"    ]. Among all participants (including 198 with a fistula or graft and 47 with a tunneled catheter), the risk for a first access event was higher in the daily group compared with the conventional group (33 repairs and 15 losses versus 17 repairs and 11 losses and 1 hospitalization, respectively, HR 1.76, 95% CI 1.11&ndash;2.79). The increase in risk of a first access event associated with daily dialysis was even greater when patients with a tunneled catheter were excluded from the analysis (HR 1.90, 95% CI 1.1-3.25). Overall, daily dialysis was associated with more access repairs and 55 percent of all repairs involved thrombectomy [",
"    <a class=\"abstract\" href=\"UTD.htm?17/45/18137/abstract/23\">",
"     23",
"    </a>",
"    ]. The risk of permanent access loss and of infection did not differ between the groups. These outcomes should be considered when patients are weighing dialysis options [",
"    <a class=\"abstract\" href=\"UTD.htm?17/45/18137/abstract/63\">",
"     63",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other studies have reported access survival comparable to that seen with conventional hemodialysis [",
"    <a class=\"abstract\" href=\"UTD.htm?17/45/18137/abstract/62,64\">",
"     62,64",
"    </a>",
"    ]. It is possible that more uniform use of the buttonhole method of cannulating AV fistulas may reduce the number of thrombotic complications associated with daily hemodialysis [",
"    <a class=\"abstract\" href=\"UTD.htm?17/45/18137/abstract/65\">",
"     65",
"    </a>",
"    ], although infectious complications may be more frequent with this technique [",
"    <a class=\"abstract\" href=\"UTD.htm?17/45/18137/abstract/21\">",
"     21",
"    </a>",
"    ]. This issue is discussed above (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Vascular access'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Cost",
"    </span>",
"    &nbsp;&mdash;&nbsp;The few analyses of the economic costs associated with more frequent hemodialysis treatment have demonstrated that overall simulated annual direct healthcare costs are likely to be lower for daily dialysis protocols compared with conventional hemodialysis [",
"    <a class=\"abstract\" href=\"UTD.htm?17/45/18137/abstract/66,67\">",
"     66,67",
"    </a>",
"    ]. As an example, higher costs for dialysis consumables are offset by lower costs for hospitalizations and medications. In addition, should the patient receive the therapy at home, an advantage is realized with reduced labor costs that more than offset the capital cost of equipment and renovations provided that the patient remains at home for at least 24 months [",
"    <a class=\"abstract\" href=\"UTD.htm?17/45/18137/abstract/68\">",
"     68",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    While daily dialysis regimens may be economically attractive from the societal perspective, it may not be appealing from the prospective of the dialysis facility as the expected cost savings are often realized at other levels of the healthcare system. Thus, the economics of daily dialysis within current funding mechanisms represents a barrier to widespread adoption of these modalities.",
"   </p>",
"   <p>",
"    Larger and better controlled studies are needed to provide additional proof that more frequent hemodialysis can improve clinical parameters and at the same time reduce total healthcare costs in the long run. A detailed review of the published information regarding to the economics of daily hemodialysis can be found elsewhere [",
"    <a class=\"abstract\" href=\"UTD.htm?17/45/18137/abstract/69,70\">",
"     69,70",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Survival",
"    </span>",
"    &nbsp;&mdash;&nbsp;No randomized controlled trials have directly studied the effect of daily hemodialysis on survival. There are conflicting data from retrospective and observational studies although most suggest a benefit [",
"    <a class=\"abstract\" href=\"UTD.htm?17/45/18137/abstract/71-73\">",
"     71-73",
"    </a>",
"    ]. In the largest observational study, 1873 home hemodialysis patients were compared with 9365 matched in-center patients selected from the United States Renal Data System (USRDS) database [",
"    <a class=\"abstract\" href=\"UTD.htm?17/45/18137/abstract/74\">",
"     74",
"    </a>",
"    ]. The incidence of death was lower among home hemodialysis patients (19.2 versus 21.7 percent among in-center patients, hazard ratio 0.87, 95% CI 0.78-0.97).",
"   </p>",
"   <p>",
"    In another retrospective study, 338 patients who were receiving intensive home hemodialysis (mean of 4.8 sessions per week with a mean treatment time of 7.4 hours per session) were compared with 1338 propensity-matched patients on conventional hemodialysis (mean of 3 sessions per week with a mean treatment time of 7.4 hours per session) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/45/18137/abstract/73\">",
"     73",
"    </a>",
"    ]. Mortality was lower among patients on intensive hemodialysis (13 percent versus 21 percent for control patients on conventional hemodialysis).",
"   </p>",
"   <p>",
"    While both studies used rigorous statistical methods and adjusted for most prognostic variables, unmeasured confounders may have contributed to the differences in outcomes. Thus the association between more frequent hemodialysis and survival requires confirmation in larger clinical trials.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h1\">",
"     ONGOING STUDIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Short daily hemodialysis is an emerging and promising therapy that may prove not only to improve patient outcomes, but to provide a cost-effective alternative to conventional in-center hemodialysis. Future studies in this area that compare daily with three-times weekly in-center hemodialysis and an international registry [",
"    <a class=\"abstract\" href=\"UTD.htm?17/45/18137/abstract/75\">",
"     75",
"    </a>",
"    ] to compare frequent hemodialysis regimens with other forms or renal replacement will hopefully help establish a role for daily hemodialysis in the next decade. Further information is available at",
"    <a class=\"external\" href=\"mailto:info@quotidiandialysis.org\">",
"     info@quotidiandialysis.org",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Short daily or \"quotidian\" hemodialysis consists of daily hemodialysis (five to seven days per week) provided for a duration of 1.5 to 2.5 hours per session. The rationale for this strategy is based upon the premise that improved patient outcomes, compared with conventional three times per week hemodialysis may occur due to improved dialysis efficiency and hemodynamic stability. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H2\">",
"       'Overview of rationale'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In practice environments where resources limit its use, daily hemodialysis should be prescribed on the basis of need, such as the management of refractory uremic complications, fluid overload, or intractable hypertension. Until large-scale comparative studies are available, the selection of nocturnal versus short daily hemodialysis should largely be dictated by availability and patient preference. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Patient recruitment and selection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Training a home daily hemodialysis patient usually requires a full-time six week commitment, although two weeks can be sufficient for a patient with self-care experience. Newer dialysis machines may require shorter training times. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Training and education for a home daily hemodialysis patient'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Native arteriovenous fistulae, synthetic grafts, and long-term central venous catheters are all acceptable for use in daily hemodialysis. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Vascular access'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Although the choice of hemodialysis equipment is wide, it is still based upon the designs of hemodialysis machines that are used in-center. Appropriate water treatment must be provided to the home. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Equipment and technical aspects'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A weekly",
"      <span class=\"nowrap\">",
"       stdKt/V",
"      </span>",
"      target of 3.0 should be sought, which is associated with improvements in a number of physiological parameters. Modeling indicates that this target is likely to be achievable with a 2.5 hour, six day per week regimen, using high flux, large surface area dialysers with dialyser blood flow rates of 400 to 500",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      and a dialysate flow rate of 800",
"      <span class=\"nowrap\">",
"       mL/min.",
"      </span>",
"      (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Dialysis prescription and dose monitoring'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The dialysate composition used with daily hemodialysis is generally not different from that used with conventional hemodialysis. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Dialysate composition'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Daily hemodialysis does not require remote monitoring, and security devices such as enuresis alarms and connector clamps are also generally not needed. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Patient monitoring and safety'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Compared with conventional hemodialysis, short daily hemodialysis is associated with increased clearances of urea (based upon",
"      <span class=\"nowrap\">",
"       stdKt/V),",
"      </span>",
"      middle molecules, and protein bound molecules. It may also be associated with a better quality of life, blood pressure control, improved appetite, and decreased rate of hospitalizations. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Clearances'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The effect of daily hemodialysis on erythropoiesis is uncertain, with increases in hemoglobin levels being inconsistent. (See",
"      <a class=\"local\" href=\"#H23\">",
"       'Anemia and erythropoietin dosing'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Overall simulated annual direct healthcare costs are likely to be lower for daily hemodialysis protocols compared with conventional hemodialysis. (See",
"      <a class=\"local\" href=\"#H27\">",
"       'Cost'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/45/18137/abstract/1\">",
"      DePalma, JR, Pecker, EA, Maxwell, MH. A new automatic coil dialyser system for 'daily' dialysis. Proc EDTA 1969; 6:26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/45/18137/abstract/2\">",
"      DePalma, JR, Pecker, EA, Maxwell, MH. A new automatic coil dialyser system for 'daily' dialysis. Semin Dial 1999; 12:410.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/45/18137/abstract/3\">",
"      Uldall, PR, Francoeur, R, Ouwendyk, M. Simplified nocturnal home hemodialysis (SNHHD). A new approach to renal replacement therapy. J Am Soc Nephrol 1994; 5:428.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/45/18137/abstract/4\">",
"      Pierratos A, Ouwendyk M, Francoeur R, et al. Nocturnal hemodialysis: three-year experience. J Am Soc Nephrol 1998; 9:859.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/45/18137/abstract/5\">",
"      Ting GO, Kjellstrand C, Freitas T, et al. Long-term study of high-comorbidity ESRD patients converted from conventional to short daily hemodialysis. Am J Kidney Dis 2003; 42:1020.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/45/18137/abstract/6\">",
"      Schiffl H, Lang SM, Fischer R. Daily hemodialysis and the outcome of acute renal failure. N Engl J Med 2002; 346:305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/45/18137/abstract/7\">",
"      Maduell F, del Pozo C, Garcia H, et al. Change from conventional haemodiafiltration to on-line haemodiafiltration. Nephrol Dial Transplant 1999; 14:1202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/45/18137/abstract/8\">",
"      Jaber BL, Zimmerman DL, Teehan GS, et al. Daily hemofiltration for end-stage renal disease: a feasibility and efficacy trial. Blood Purif 2004; 22:481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/45/18137/abstract/9\">",
"      Henderson LW, Leypoldt JK, Lysaght MJ, Cheung AK. Death on dialysis and the time/flux trade-off. Blood Purif 1997; 15:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/45/18137/abstract/10\">",
"      Casino FG, Lopez T. The equivalent renal urea clearance: a new parameter to assess dialysis dose. Nephrol Dial Transplant 1996; 11:1574.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/45/18137/abstract/11\">",
"      Depner TA. Daily hemodialysis efficiency: an analysis of solute kinetics. Adv Ren Replace Ther 2001; 8:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/45/18137/abstract/12\">",
"      Gotch FA. The current place of urea kinetic modelling with respect to different dialysis modalities. Nephrol Dial Transplant 1998; 13 Suppl 6:10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/45/18137/abstract/13\">",
"      Suri R, Depner TA, Blake PG, et al. Adequacy of quotidian hemodialysis. Am J Kidney Dis 2003; 42:42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/45/18137/abstract/14\">",
"      Williams AW, Chebrolu SB, Ing TS, et al. Early clinical, quality-of-life, and biochemical changes of \"daily hemodialysis\" (6 dialyses per week). Am J Kidney Dis 2004; 43:90.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/45/18137/abstract/15\">",
"      Leitch R, Ouwendyk M, Ferguson E, et al. Nursing issues related to patient selection, vascular access, and education in quotidian hemodialysis. Am J Kidney Dis 2003; 42:56.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/45/18137/abstract/16\">",
"      Twardowski, ZJ. Constant site (buttonhole) method of needle insertion for hemodialysis. Dial Transplant 1995; 24:559.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/45/18137/abstract/17\">",
"      van Loon MM, Goovaerts T, Kessels AG, et al. Buttonhole needling of haemodialysis arteriovenous fistulae results in less complications and interventions compared to the rope-ladder technique. Nephrol Dial Transplant 2010; 25:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/45/18137/abstract/18\">",
"      Hashmi A, Cheema MQ, Moss AH. Hemodialysis patients' experience with and attitudes toward the buttonhole technique for arteriovenous fistula cannulation. Clin Nephrol 2010; 74:346.",
"     </a>",
"    </li>",
"    <li>",
"     Twardowski, ZJ, Harper, G. Buttonhole method of needle insertion into arteriovenous fistulas. 1997.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/45/18137/abstract/20\">",
"      Twardowski, Z, Kubara, H. Different sites versus constant sites of needle insertion into arteriovenous fistulas for treatment by repeated dialysis. Dial Transpl 1979; 8:978.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/45/18137/abstract/21\">",
"      MacRae JM, Ahmed SB, Atkar R, Hemmelgarn BR. A randomized trial comparing buttonhole with rope ladder needling in conventional hemodialysis patients. Clin J Am Soc Nephrol 2012; 7:1632.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/45/18137/abstract/22\">",
"      Zimmerman D, Lok CE. Accessing the access. Clin J Am Soc Nephrol 2012; 7:1548.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/45/18137/abstract/23\">",
"      Suri RS, Larive B, Sherer S, et al. Risk of vascular access complications with frequent hemodialysis. J Am Soc Nephrol 2013; 24:498.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/45/18137/abstract/24\">",
"      Mehrabian S, Morgan D, Schlaeper C, et al. Equipment and water treatment considerations for the provision of quotidian home hemodialysis. Am J Kidney Dis 2003; 42:66.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/45/18137/abstract/25\">",
"      Pierratos, A, Francoeur, R, Ouwendyk, M. Delayed dialyzer reproducing for home hemodialysis. Home hemodial 2000; 4:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/45/18137/abstract/26\">",
"      Daugirdas JT. Dialysis adequacy and kinetics. Curr Opin Nephrol Hypertens 2000; 9:599.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/45/18137/abstract/27\">",
"      Suri RS, Depner T, Lindsay RM. Dialysis prescription and dose monitoring in frequent hemodialysis. Contrib Nephrol 2004; 145:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/45/18137/abstract/28\">",
"      Ayus JC, Achinger SG, Mizani MR, et al. Phosphorus balance and mineral metabolism with 3 h daily hemodialysis. Kidney Int 2007; 71:336.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/45/18137/abstract/29\">",
"      Suri RS, Nesrallah GE, Mainra R, et al. Daily hemodialysis: a systematic review. Clin J Am Soc Nephrol 2006; 1:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/45/18137/abstract/30\">",
"      FHN Trial Group, Chertow GM, Levin NW, et al. In-center hemodialysis six times per week versus three times per week. N Engl J Med 2010; 363:2287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/45/18137/abstract/31\">",
"      Clark WR, Leypoldt JK, Henderson LW, et al. Quantifying the effect of changes in the hemodialysis prescription on effective solute removal with a mathematical model. J Am Soc Nephrol 1999; 10:601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/45/18137/abstract/32\">",
"      Goldfarb-Rumyantzev AS, Cheung AK, Leypoldt JK. Computer simulation of small-solute and middle-molecule removal during short daily and long thrice-weekly hemodialysis. Am J Kidney Dis 2002; 40:1211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/45/18137/abstract/33\">",
"      Pierratos A. Effect of therapy time and frequency on effective solute removal. Semin Dial 2001; 14:284.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/45/18137/abstract/34\">",
"      Floridi A, Antolini F, Galli F, et al. Daily haemodialysis improves indices of protein glycation. Nephrol Dial Transplant 2002; 17:871.",
"     </a>",
"    </li>",
"    <li>",
"     Cacho, C, Erhard, P, Priester, A, et al. Nocturnal Dialysis Reduces SErum Pentosidine in Patients with ESRD. Perit Dial Int 2001; 21(Suppl 1):S61 [Abstract].",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/45/18137/abstract/36\">",
"      Leypoldt JK. Solute fluxes in different treatment modalities. Nephrol Dial Transplant 2000; 15 Suppl 1:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/45/18137/abstract/37\">",
"      Ayus JC, Mizani MR, Achinger SG, et al. Effects of short daily versus conventional hemodialysis on left ventricular hypertrophy and inflammatory markers: a prospective, controlled study. J Am Soc Nephrol 2005; 16:2778.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/45/18137/abstract/38\">",
"      Daugirdas JT, Chertow GM, Larive B, et al. Effects of frequent hemodialysis on measures of CKD mineral and bone disorder. J Am Soc Nephrol 2012; 23:727.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/45/18137/abstract/39\">",
"      Traeger, J, Galland, R, Delawari, E, et al. Six years' experience with short daily hemodialysis: Do the early improvements persist in the mid and long term? Hemodialysis International 2004; 8:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/45/18137/abstract/40\">",
"      Heidenheim AP, Muirhead N, Moist L, Lindsay RM. Patient quality of life on quotidian hemodialysis. Am J Kidney Dis 2003; 42:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/45/18137/abstract/41\">",
"      Pinciaroli, AR. Results of daily hemodialysis in Catanzaro: a 12-year experience with 22 patients treated for more than 1 year. Home Hemodial Int 1998; 2:12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/45/18137/abstract/42\">",
"      Vos PF, Zilch O, Jennekens-Schinkel A, et al. Effect of short daily home haemodialysis on quality of life, cognitive functioning and the electroencephalogram. Nephrol Dial Transplant 2006; 21:2529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/45/18137/abstract/43\">",
"      Jaber BL, Lee Y, Collins AJ, et al. Effect of daily hemodialysis on depressive symptoms and postdialysis recovery time: interim report from the FREEDOM (Following Rehabilitation, Economics and Everyday-Dialysis Outcome Measurements) Study. Am J Kidney Dis 2010; 56:531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/45/18137/abstract/44\">",
"      Hall YN, Larive B, Painter P, et al. Effects of six versus three times per week hemodialysis on physical performance, health, and functioning: Frequent Hemodialysis Network (FHN) randomized trials. Clin J Am Soc Nephrol 2012; 7:782.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/45/18137/abstract/45\">",
"      Finkelstein FO, Schiller B, Daoui R, et al. At-home short daily hemodialysis improves the long-term health-related quality of life. Kidney Int 2012; 82:561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/45/18137/abstract/46\">",
"      Woods JD, Port FK, Orzol S, et al. Clinical and biochemical correlates of starting \"daily\" hemodialysis. Kidney Int 1999; 55:2467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/45/18137/abstract/47\">",
"      Andr&eacute; MB, Rembold SM, Pereira CM, Lugon JR. Prospective evaluation of an in-center daily hemodialysis program: results of two years of treatment. Am J Nephrol 2002; 22:473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/45/18137/abstract/48\">",
"      Koshikawa S, Akizawa T, Saito A, Kurokawa K. Clinical effect of short daily in-center hemodialysis. Nephron Clin Pract 2003; 95:c23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/45/18137/abstract/49\">",
"      Goldfarb-Rumyantzev AS, Leypoldt JK, Nelson N, et al. A crossover study of short daily haemodialysis. Nephrol Dial Transplant 2006; 21:166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/45/18137/abstract/50\">",
"      Jaber BL, Schiller B, Burkart JM, et al. Impact of short daily hemodialysis on restless legs symptoms and sleep disturbances. Clin J Am Soc Nephrol 2011; 6:1049.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/45/18137/abstract/51\">",
"      Fagugli RM, Buoncristiani U, Ciao G. Anemia and blood pressure correction obtained by daily hemodialysis induce a reduction of left ventricular hypertrophy in dialysed patients. Int J Artif Organs 1998; 21:429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/45/18137/abstract/52\">",
"      Fagugli RM, Reboldi G, Quintaliani G, et al. Short daily hemodialysis: blood pressure control and left ventricular mass reduction in hypertensive hemodialysis patients. Am J Kidney Dis 2001; 38:371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/45/18137/abstract/53\">",
"      Piccoli GB, Bermond F, Mezza E, et al. Vascular access survival and morbidity on daily dialysis: a comparative analysis of home and limited care haemodialysis. Nephrol Dial Transplant 2004; 19:2084.",
"     </a>",
"    </li>",
"    <li>",
"     Nesrallah, G, Bergman, A, Heidenheim, AP, et al. Short-Hours Daily and Slow Nocturnal Hemodialysis Improve Blood Pressure Control: Are the Mechanisms the Same? J Am Soc Nephrol 2001; 12:273 [Abstract].",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/45/18137/abstract/55\">",
"      Al-Hejaili F, Kortas C, Leitch R, et al. Nocturnal but not short hours quotidian hemodialysis requires an elevated dialysate calcium concentration. J Am Soc Nephrol 2003; 14:2322.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/45/18137/abstract/56\">",
"      Kooistra MP, Vos J, Koomans HA, Vos PF. Daily home haemodialysis in The Netherlands: effects on metabolic control, haemodynamics, and quality of life. Nephrol Dial Transplant 1998; 13:2853.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/45/18137/abstract/57\">",
"      Jefferies HJ, Virk B, Schiller B, et al. Frequent hemodialysis schedules are associated with reduced levels of dialysis-induced cardiac injury (myocardial stunning). Clin J Am Soc Nephrol 2011; 6:1326.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/45/18137/abstract/58\">",
"      Zilch O, Vos PF, Oey PL, et al. Sympathetic hyperactivity in haemodialysis patients is reduced by short daily haemodialysis. J Hypertens 2007; 25:1285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/45/18137/abstract/59\">",
"      Rao M, Muirhead N, Klarenbach S, et al. Management of anemia with quotidian hemodialysis. Am J Kidney Dis 2003; 42:18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/45/18137/abstract/60\">",
"      Galland R, Traeger J, Arkouche W, et al. Short daily hemodialysis and nutritional status. Am J Kidney Dis 2001; 37:S95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/45/18137/abstract/61\">",
"      Kaysen GA, Greene T, Larive B, et al. The effect of frequent hemodialysis on nutrition and body composition: frequent Hemodialysis Network Trial. Kidney Int 2012; 82:90.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/45/18137/abstract/62\">",
"      Martins Castro MC, Luders C, Elias RM, et al. High-efficiency short daily haemodialysis--morbidity and mortality rate in a long-term study. Nephrol Dial Transplant 2006; 21:2232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/45/18137/abstract/63\">",
"      Berns JS, Dember LM. Can frequent hemodialysis be too frequent? J Am Soc Nephrol 2013; 24:334.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/45/18137/abstract/64\">",
"      Quintaliani G, Buoncristiani U, Fagugli R, et al. Survival of vascular access during daily and three times a week hemodialysis. Clin Nephrol 2000; 53:372.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/45/18137/abstract/65\">",
"      Twardowski ZJ, Misra M. \"Daily\" dialysis--lessons from a randomized, controlled trial. N Engl J Med 2010; 363:2363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/45/18137/abstract/66\">",
"      Mohr PE, Neumann PJ, Franco SJ, et al. The case for daily dialysis: its impact on costs and quality of life. Am J Kidney Dis 2001; 37:777.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/45/18137/abstract/67\">",
"      McFarlane PA, Pierratos A, Redelmeier DA. Cost savings of home nocturnal versus conventional in-center hemodialysis. Kidney Int 2002; 62:2216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/45/18137/abstract/68\">",
"      Ting, G, Carrie, B, Freitas, T, Zarghamee, S. Global ESRD costs associated with a short daily hemodialysis program in the United States. Home Hemodial Int 1999; 3:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/45/18137/abstract/69\">",
"      Kroeker, A, Clark, WF, Heidenheim, AP, et al. Costs of Quotidian Home Hemodialysis. Hemo Int 2003; 7:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/45/18137/abstract/70\">",
"      Kroeker A, Clark WF, Heidenheim AP, et al. An operating cost comparison between conventional and home quotidian hemodialysis. Am J Kidney Dis 2003; 42:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/45/18137/abstract/71\">",
"      Kjellstrand CM, Buoncristiani U, Ting G, et al. Short daily haemodialysis: survival in 415 patients treated for 1006 patient-years. Nephrol Dial Transplant 2008; 23:3283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/45/18137/abstract/72\">",
"      Johansen KL, Zhang R, Huang Y, et al. Survival and hospitalization among patients using nocturnal and short daily compared to conventional hemodialysis: a USRDS study. Kidney Int 2009; 76:984.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/45/18137/abstract/73\">",
"      Nesrallah GE, Lindsay RM, Cuerden MS, et al. Intensive hemodialysis associates with improved survival compared with conventional hemodialysis. J Am Soc Nephrol 2012; 23:696.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/45/18137/abstract/74\">",
"      Weinhandl ED, Liu J, Gilbertson DT, et al. Survival in daily home hemodialysis and matched thrice-weekly in-center hemodialysis patients. J Am Soc Nephrol 2012; 23:895.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/45/18137/abstract/75\">",
"      Nesrallah GE, Moist LM, Awaraji C, Lindsay RM. An international registry to compare quotidian dialysis regimens with conventional thrice-weekly hemodialysis: why, how, and potential pitfalls. Semin Dial 2004; 17:131.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1898 Version 15.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1102-222.190.118.195-812927D4EA-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_45_18137=[""].join("\n");
var outline_f17_45_18137=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H30\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      OVERVIEW OF RATIONALE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Improved dialysis efficiency",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Improved hemodynamic stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      MEASURES OF ADEQUACY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      PRACTICAL ASPECTS OF DAILY HEMODIALYSIS DELIVERY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Patient recruitment and selection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Training and education for a home daily hemodialysis patient",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Vascular access",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Equipment and technical aspects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Dialyzer selection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Dialysis prescription and dose monitoring",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Dialysate composition",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Patient monitoring and safety",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      OUTCOMES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9482545\">",
"      Frequent Hemodialysis Network (FHN) daily trial",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9482552\">",
"      Observational data",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Clearances",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Urea",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Middle molecules",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Protein bound molecules",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Phosphate",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Quality of life",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Cardiovascular",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Anemia and erythropoietin dosing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Nutritional effects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Hospitalizations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Vascular access",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Cost",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Survival",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      ONGOING STUDIES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/44/19144?source=related_link\">",
"      Home hemodialysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/14/6378?source=related_link\">",
"      Kt/V and the adequacy of hemodialysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/44/25286?source=related_link\">",
"      Organization and elements of a home hemodialysis program",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/47/33530?source=related_link\">",
"      Sustained low efficiency or extended daily dialysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/16/264?source=related_link\">",
"      Technical aspects of nocturnal hemodialysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/24/37258?source=related_link\">",
"      Uremic toxins",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f17_45_18138="Lipoprotein classification; metabolism; and role in atherosclerosis";
var content_f17_45_18138=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Lipoprotein classification; metabolism; and role in atherosclerosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/45/18138/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/45/18138/contributors\">",
"     Robert S Rosenson, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/45/18138/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/45/18138/contributors\">",
"     Mason W Freeman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/45/18138/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/45/18138/contributors\">",
"     Gordon M Saperia, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?17/45/18138/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 22, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lipids, such as cholesterol and triglycerides, are insoluble in plasma and circulating lipid is carried in lipoproteins that transport the lipid to various tissues for energy utilization, lipid deposition, steroid hormone production, and bile acid formation. The lipoprotein consists of esterified and unesterified cholesterol, triglycerides, and phospholipids, and protein. The protein components of the lipoprotein are known as apolipoproteins (apo) or apoproteins. The different apolipoproteins serve as cofactors for enzymes and ligands for receptors.",
"   </p>",
"   <p>",
"    The classification of lipoproteins, the function of the different apolipoproteins that they contain, the pathways of lipid metabolism, and how lipoprotein disorders can promote the development of atherosclerosis will be reviewed here.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CLASSIFICATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are five major lipoproteins, each of which has a different function. The clinical measurement of lipoprotein levels is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/31/31222?source=see_link\">",
"     \"Measurement of serum lipids and lipoproteins\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Chylomicrons",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chylomicrons are very large particles that carry dietary lipid. They are associated with a variety of apolipoproteins, including A-I, A-II, A-IV, B-48, C-I, C-II, C-III, and E.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Very low density lipoprotein",
"    </span>",
"    &nbsp;&mdash;&nbsp;Very low density lipoprotein (VLDL) carries endogenous triglycerides and to a lesser degree cholesterol. The major apolipoproteins associated with VLDL are B-100, C-I, C-II, C-III, and E.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Intermediate density lipoprotein",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intermediate density lipoprotein (IDL) carries cholesterol esters and triglycerides. It is associated with apolipoproteins B-100, C-III, and E.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Low density lipoprotein",
"    </span>",
"    &nbsp;&mdash;&nbsp;Low density lipoprotein (LDL) carries cholesterol esters and is associated with apolipoproteins B-100 and C-III.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     High density lipoprotein",
"    </span>",
"    &nbsp;&mdash;&nbsp;High density lipoprotein (HDL) also carries cholesterol esters. It is associated with apolipoproteins A-I, A-II, C-I, C-II, C-III, D, and E.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Apolipoproteins",
"    </span>",
"    &nbsp;&mdash;&nbsp;Understanding the major functions of the different apolipoproteins is important clinically, because defects in apolipoprotein metabolism lead to abnormalities in lipid handling [",
"    <a class=\"abstract\" href=\"UTD.htm?17/45/18138/abstract/1\">",
"     1",
"    </a>",
"    ]. (See appropriate topic reviews on disorders of LDL-cholesterol, HDL-cholesterol, triglyceride, and Lp(a) metabolism).",
"   </p>",
"   <p>",
"    The assembly and secretion of apolipoprotein B containing lipoproteins in the liver and intestines is dependent upon microsomal triglyceride transfer protein which transfers lipids to apolipoprotein B. In one study, apolipoprotein B and microsomal transfer protein genes were expressed in the human heart, strongly suggesting that the heart synthesizes and secretes apolipoprotein B containing lipoproteins [",
"    <a class=\"abstract\" href=\"UTD.htm?17/45/18138/abstract/2\">",
"     2",
"    </a>",
"    ]. This may represent a pathway of \"reverse triglyceride transport\" by which the cardiac myocytes can unload surplus fatty acids not required for fuel.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A-I &mdash; Structural protein for HDL; activator of lecithin-cholesterol acyltransferase (LCAT).",
"     </li>",
"     <li>",
"      A-II &mdash; Structural protein for HDL; activator of hepatic lipase.",
"     </li>",
"     <li>",
"      A-IV &mdash; Activator of lipoprotein lipase (LPL) and LCAT.",
"     </li>",
"     <li>",
"      B-100 &mdash; Structural protein for VLDL, IDL, LDL, and Lp(a); ligand for the LDL receptor; required for assembly and secretion of VLDL.",
"     </li>",
"     <li>",
"      B-48 &mdash; Contains 48 percent of B-100; required for assembly and secretion of chylomicrons; does not bind to LDL receptor.",
"     </li>",
"     <li>",
"      C-I &mdash; Activator of LCAT.",
"     </li>",
"     <li>",
"      C-II &mdash; Essential cofactor for LPL.",
"     </li>",
"     <li>",
"      C-III &mdash; Interferes with apo-E mediated clearance of triglyceride-enriched lipoproteins by cellular receptors, particularly in the liver [",
"      <a class=\"abstract\" href=\"UTD.htm?17/45/18138/abstract/3\">",
"       3",
"      </a>",
"      ]; inhibits triglyceride hydrolysis by lipoprotein lipase and hepatic lipase [",
"      <a class=\"abstract\" href=\"UTD.htm?17/45/18138/abstract/4\">",
"       4",
"      </a>",
"      ]; has multiple proatherogenic effects on the arterial wall, including interfering with normal endothelial function [",
"      <a class=\"abstract\" href=\"UTD.htm?17/45/18138/abstract/5,6\">",
"       5,6",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      D &mdash; May be a cofactor for cholesteryl ester transfer protein (CETP).",
"     </li>",
"     <li>",
"      E &mdash; Ligand for hepatic chylomicron and VLDL remnant receptor, leading to clearance of these lipoproteins from the circulation; ligand for LDL receptor. There are three different apo E alleles in humans: E2, which has cysteine residues at positions 112 and 158; E3, which occurs in 60 to 80 percent of Caucasians and has cysteine at position 112 and arginine at position 158; and E4, which has arginine residues at positions 112 and 158 [",
"      <a class=\"abstract\" href=\"UTD.htm?17/45/18138/abstract/7\">",
"       7",
"      </a>",
"      ]. These alleles encode for a combination of apo E isoforms that are inherited in a codominant fashion. Compared to apo E3, apo E2 has reduced affinity and apo E4 has enhanced affinity for the LDL (apo",
"      <span class=\"nowrap\">",
"       B/E)",
"      </span>",
"      receptor. These isoforms are important clinically because apo E2 is associated with familial dysbetalipoproteinemia (due to less efficient clearance of VLDL and chylomicrons) and apo E4 is associated with an increased risk of hypercholesterolemia and coronary heart disease. (CHD) (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/25/37274?source=see_link&amp;anchor=H19#H19\">",
"       \"Inherited disorders of LDL-cholesterol metabolism\", section on 'Polygenic hypercholesterolemia'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/47/35578?source=see_link&amp;anchor=H13#H13\">",
"       \"Approach to the patient with hypertriglyceridemia\", section on 'Familial dysbetalipoproteinemia'",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Apo(a) &mdash; Structural protein for Lp(a); inhibitor of plasminogen activation on Lp(a).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     CLINICAL CLASSIFICATION OF DYSLIPIDEMIAS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The major classes of dyslipidemia are classified according to the Fredrickson phenotype [",
"    <a class=\"abstract\" href=\"UTD.htm?17/45/18138/abstract/8\">",
"     8",
"    </a>",
"    ]. A variety of defects, some of which are familial, can produce these disorders (",
"    <a class=\"graphic graphic_table graphicRef54329 \" href=\"UTD.htm?20/51/21307\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Fredrickson phenotype I &mdash; serum concentration of chylomicrons elevated; triglycerides concentrations are elevated to &gt;99th percentile",
"     </li>",
"     <li>",
"      Fredrickson phenotype IIa &mdash; serum concentration of LDL cholesterol elevated; the total cholesterol concentration is &gt;90th percentile. Concentrations of triglyceride",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      apolipoprotein B may also be &ge;90th percentile.",
"     </li>",
"     <li>",
"      Fredrickson phenotype IIb &mdash; serum concentrations of LDL and VLDL cholesterol elevated; total cholesterol",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      triglycerides may be &ge;90th percentile and apolipoprotein B &ge;90th percentile",
"     </li>",
"     <li>",
"      Fredrickson phenotype III &mdash; serum concentration of VLDL remnants and chylomicrons elevated; total cholesterol and triglycerides &gt;90th percentile",
"     </li>",
"     <li>",
"      Fredrickson phenotype IV &mdash; serum concentrations of VLDL elevated; total cholesterol may be &gt;90th percentile and may also see triglyceride concentrations &gt;90th percentile or low HDL",
"     </li>",
"     <li>",
"      Fredrickson phenotype V &mdash; elevated serum concentrations of chylomicrons and VLDL; triglycerides &gt;99th percentile",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     EXOGENOUS PATHWAY OF LIPID METABOLISM",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lipoprotein metabolism can be divided into exogenous and endogenous pathways. The exogenous pathway starts with the intestinal absorption of dietary cholesterol and fatty acids (",
"    <a class=\"graphic graphic_figure graphicRef67905 \" href=\"UTD.htm?40/9/41104\">",
"     figure 1",
"    </a>",
"    ). The mechanisms regulating the amount of dietary cholesterol that is absorbed are unknown. Sitosterolemia is a rare autosomal recessive disorder associated with hyperabsorption of cholesterol and plant sterols from the intestine [",
"    <a class=\"abstract\" href=\"UTD.htm?17/45/18138/abstract/9\">",
"     9",
"    </a>",
"    ]. These genes involved are expressed primarily in the liver and intestine and are upregulated by cholesterol feeding; they may normally cooperate to limit intestinal sterol absorption [",
"    <a class=\"abstract\" href=\"UTD.htm?17/45/18138/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Within the intestinal cell, free fatty acids combine with glycerol to form triglycerides, and cholesterol is esterified by acyl-coenzyme A:cholesterol acyltransferase (ACAT) to form cholesterol esters. The important role of ACAT was established in an animal model of ACAT deficiency, which found complete resistance to diet-induced hypercholesterolemia due to lack of cholesterol ester synthesis and reduced capacity to absorb cholesterol [",
"    <a class=\"abstract\" href=\"UTD.htm?17/45/18138/abstract/11\">",
"     11",
"    </a>",
"    ]. Despite this, clinical trials have found that ACAT inhibitors may worsen atherosclerosis [",
"    <a class=\"abstract\" href=\"UTD.htm?17/45/18138/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. Triglycerides and cholesterol are assembled intracellularly as chylomicrons. The main apolipoprotein is B-48, but C-II and E are acquired as the chylomicrons enter the circulation. Apo B-48 permits lipid binding to the chylomicron but not does not bind to the LDL receptor, thereby preventing premature clearance of chylomicrons from the circulation before they are acted upon by LPL.",
"   </p>",
"   <p>",
"    Apo C-II is a cofactor for LPL which makes the chylomicrons progressively smaller primarily by hydrolyzing the core triglycerides and releasing free fatty acids. The free fatty acids are then used as an energy source, converted to triglyceride, or stored in adipose tissue. The end-products of chylomicron metabolism are chylomicron remnants that are cleared from the circulation by hepatic chylomicron remnant receptors for which apo E is a high-affinity ligand. The chylomicron remnants contain a smaller core of lipids that is enveloped by excess surface components. These surface constituents are transferred from the chylomicron remnant for the formation of HDL.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     ENDOGENOUS PATHWAY OF LIPID METABOLISM",
"    </span>",
"    &nbsp;&mdash;&nbsp;The endogenous pathway of lipid metabolism begins with the synthesis of VLDL by the liver (",
"    <a class=\"graphic graphic_figure graphicRef51771 \" href=\"UTD.htm?8/29/8657\">",
"     figure 2",
"    </a>",
"    ). VLDL particles contain a core of triglycerides (60 percent by mass) and cholesterol esters (20 percent by mass). Microsomal triglyceride transfer protein (MTP) is an intracellular lipid-transfer protein found in the endoplasmic reticulum. It is essential for the transfer of the lipid molecules (principally triglycerides) onto apolipoprotein (apo) B 100 in the liver [",
"    <a class=\"abstract\" href=\"UTD.htm?17/45/18138/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. The surface apolipoproteins for VLDL are noted above. They include apo C-II which acts as a cofactor for LPL, apo C-III which inhibits this enzyme, and apo B-100 and E which serve as ligands for the apolipoprotein",
"    <span class=\"nowrap\">",
"     B/E",
"    </span>",
"    (LDL) receptor [",
"    <a class=\"abstract\" href=\"UTD.htm?17/45/18138/abstract/1\">",
"     1",
"    </a>",
"    ]. In the absence of functional MTP, VLDL is not secreted into the circulation. Abetalipoproteinemia is a rare genetic disorder in which MTP is absent. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/25/37274?source=see_link&amp;anchor=H180677128#H180677128\">",
"     \"Inherited disorders of LDL-cholesterol metabolism\", section on 'Abetalipoproteinemia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The triglyceride core of nascent VLDL particles is hydrolyzed by lipoprotein lipase. During lipolysis, the core of the VLDL particle is reduced, generating VLDL remnant particles (also called IDL) that are depleted of triglycerides via a process similar to the generation of chylomicron remnants. Some of the excess surface components in the remnant particle, including phospholipid, unesterified cholesterol, and apolipoproteins A, C and E, are transferred to HDL.",
"   </p>",
"   <p>",
"    VLDL remnants can either be cleared from the circulation by the apo",
"    <span class=\"nowrap\">",
"     B/E",
"    </span>",
"    (LDL) or the remnant receptors or remodeled by hepatic lipase to form LDL particles. There are four common sequence polymorphisms in the hepatic lipase gene promoter; the most frequent is a C to T substitution [",
"    <a class=\"abstract\" href=\"UTD.htm?17/45/18138/abstract/16\">",
"     16",
"    </a>",
"    ]. The presence of a C allele is associated with higher hepatic lipase activity; smaller, denser, and more atherogenic LDL particles, and inversely with lower levels of HDL cholesterol [",
"    <a class=\"abstract\" href=\"UTD.htm?17/45/18138/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Low density lipoprotein",
"    </span>",
"    &nbsp;&mdash;&nbsp;LDL particles contain a core of cholesterol esters, lesser amounts of triglyceride, and are enriched in apolipoprotein B-100, which is the ligand for binding to the apo",
"    <span class=\"nowrap\">",
"     B/E",
"    </span>",
"    (LDL) receptor. LDL can be internalized by hepatic and nonhepatic tissues. Hepatic LDL cholesterol can be converted to bile acids and secreted into the intestinal lumen. LDL cholesterol internalized by nonhepatic tissues can be used for hormone production, cell membrane synthesis, or stored in the esterified form.",
"   </p>",
"   <p>",
"    The internalization of LDL is regulated by cellular cholesterol requirements via negative feedback control of apo",
"    <span class=\"nowrap\">",
"     B/E",
"    </span>",
"    (LDL) receptor expression [",
"    <a class=\"abstract\" href=\"UTD.htm?17/45/18138/abstract/18\">",
"     18",
"    </a>",
"    ]. Cells in positive cholesterol balance, for example, suppress apo",
"    <span class=\"nowrap\">",
"     B/E",
"    </span>",
"    (LDL) receptor expression. On the other hand, decreased activity of HMG CoA reductase, the enzyme that controls the rate of de novo cholesterol synthesis by the cell, leads sequentially to a fall in cell cholesterol, increased expression of apo",
"    <span class=\"nowrap\">",
"     B/E",
"    </span>",
"    (LDL) receptors, enhanced uptake of cholesterol from the circulation, and a reduction in the plasma cholesterol concentration.",
"   </p>",
"   <p>",
"    Circulating LDL can also enter macrophages and some other tissues through the unregulated scavenger receptor. This pathway can result in excess accumulation of intracellular cholesterol and the formation of foam cells which contribute to the formation of atheromatous plaques (see",
"    <a class=\"local\" href=\"#H15\">",
"     'Lipoproteins and atherosclerosis'",
"    </a>",
"    below).",
"   </p>",
"   <p>",
"    The importance of the LDL receptor in the regulation of cholesterol metabolism has been demonstrated in both experimental animals and humans. Knockout of the LDL receptor in transgenic mice leads to a substantial elevation in total cholesterol levels, a defect that can be reversed by restoring the LDL receptor gene [",
"    <a class=\"abstract\" href=\"UTD.htm?17/45/18138/abstract/19\">",
"     19",
"    </a>",
"    ]. In humans, familial hypercholesterolemia is often associated with a defect in the LDL receptor [",
"    <a class=\"abstract\" href=\"UTD.htm?17/45/18138/abstract/20\">",
"     20",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/25/37274?source=see_link\">",
"     \"Inherited disorders of LDL-cholesterol metabolism\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     High density lipoprotein",
"    </span>",
"    &nbsp;&mdash;&nbsp;The formation and metabolism of HDL involves the following steps (",
"    <a class=\"graphic graphic_figure graphicRef83853 \" href=\"UTD.htm?39/56/40839\">",
"     figure 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/45/18138/abstract/1,5,21\">",
"     1,5,21",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hepatic and intestinal synthesis of small nascent HDL particles composed of phospholipid and apolipoproteins.",
"     </li>",
"     <li>",
"      Procurement of surface components (phospholipids, cholesterol, and apolipoproteins) from triglyceride-depleted chylomicron and VLDL remnants.",
"     </li>",
"     <li>",
"      Acquisition of free cholesterol from tissue sites and other lipoproteins, as the initial HDL particles contain relatively little cholesterol. Apolipoprotein A-I on the surface of HDL plays a central role in this process. It serves as a signal transduction protein to mobilize cholesterol esters from intracellular pools. After diffusion of free (unesterified) cholesterol onto HDL, the cholesterol is esterified to cholesterol esters by LCAT, a plasma enzyme that is activated primarily by apolipoprotein A-I. By a similar mechanism, HDL can act as an acceptor for cholesterol released during lipolysis of triglyceride-containing lipoproteins.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Cholesterol efflux regulatory protein also appears to play an important role in the uptake of cellular cholesterol by HDL by promoting the transfer of intracellular cholesterol to the cell membrane [",
"    <a class=\"abstract\" href=\"UTD.htm?17/45/18138/abstract/22,23\">",
"     22,23",
"    </a>",
"    ]. Mutations in the gene encoding for this protein, ABC1, are associated with low serum HDL concentrations in familial HDL deficiency and Tangier disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/2/39978?source=see_link&amp;anchor=H13#H13\">",
"     \"HDL metabolism and approach to the patient with abnormal HDL-cholesterol levels\", section on 'Familial HDL deficiency and Tangier disease'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Lipid transfer proteins, such as CETP, facilitate movement of these newly synthesized cholesterol esters to apolipoprotein B-containing lipoproteins (VLDL, IDL, and LDL). The cholesterol can then be delivered to the tissues for steroid synthesis or storage.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The net effect of the last two steps is the removal of excess cholesterol from cells, which constitutes most of the anti-atherogenic effect of HDL (see below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Lipoprotein(a)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lipoprotein(a) or Lp(a) is a specialized form of LDL that is assembled extracellularly from apolipoprotein (a) and LDL [",
"    <a class=\"abstract\" href=\"UTD.htm?17/45/18138/abstract/24\">",
"     24",
"    </a>",
"    ]. Apo(a) linked to apolipoprotein B-100 on the surface of LDL by disulfide bridges. The formation of apo(a):apo B complexes requires an LDL particle of a certain morphology and composition. The structural integrity of LDL, and therefore Lp(a) formation, are modulated by LCAT [",
"    <a class=\"abstract\" href=\"UTD.htm?17/45/18138/abstract/24\">",
"     24",
"    </a>",
"    ]. The apo(a) chain contains five domains known as kringles [",
"    <a class=\"abstract\" href=\"UTD.htm?17/45/18138/abstract/10\">",
"     10",
"    </a>",
"    ]. The fourth kringle contains regions that are homologous with the fibrin-binding domains of plasminogen. Through this structural similarity to plasminogen, Lp(a) interferes with fibrinolysis by competing with plasminogen binding to plasminogen receptors, fibrinogen, and fibrin.",
"   </p>",
"   <p>",
"    The net effect is impaired plasminogen activation and plasmin generation at the thrombus surface, leading to decreased thrombolysis [",
"    <a class=\"abstract\" href=\"UTD.htm?17/45/18138/abstract/25,26\">",
"     25,26",
"    </a>",
"    ]. Lp(a) can also bind to macrophages via a high-affinity receptor, possibly promoting foam cell formation and localization of Lp(a) at atherosclerotic plaques [",
"    <a class=\"abstract\" href=\"UTD.htm?17/45/18138/abstract/27\">",
"     27",
"    </a>",
"    ]. The full discussion of the potential role of Lp(a) in the development of atherosclerosis is found elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/19/40248?source=see_link\">",
"     \"Lipoprotein(a) and cardiovascular disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     LIPOPROTEINS AND ATHEROSCLEROSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Abnormal lipoprotein metabolism is a major predisposing factor to atherosclerosis.",
"   </p>",
"   <p>",
"    It is estimated, for example, that a dyslipidemia is present in over 70 percent of patients with premature CHD (",
"    <a class=\"graphic graphic_figure graphicRef59944 \" href=\"UTD.htm?15/40/16014\">",
"     figure 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/45/18138/abstract/28\">",
"     28",
"    </a>",
"    ]. Although the individual disorders are discussed elsewhere, it is useful to review briefly how high levels of LDL-cholesterol, Lp(a), or triglycerides or low levels of HDL-cholesterol might promote atheroma formation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Low density lipoprotein",
"    </span>",
"    &nbsp;&mdash;&nbsp;Low-density lipoprotein (LDL) particles contain cholesterol, triglycerides, phospholipids, and apolipoproteins B-100 and C-III. All LDL particles contain one copy of apolipoproteins B-100 (Apo B-100), whereas 10 to 20 percent of LDL particles contain apolipoprotein C-III (Apo C-III). Thus, there is a direct relationship between apolipoprotein B-100 and LDL levels.",
"   </p>",
"   <p>",
"    Elevated plasma concentrations of apo B-100 containing lipoproteins can induce the development of atherosclerosis even in the absence of other risk factors. It has been proposed that the initiating event in atherogenesis is the subendothelial retention of apo B-100 containing lipoproteins via a charge-mediated interaction with proteoglycans in the extracellular matrix. Consistent with this hypothesis is the observation that mice expressing LDL with defective proteoglycan binding develop significantly less atherosclerosis than mice expressing wild-type LDL [",
"    <a class=\"abstract\" href=\"UTD.htm?17/45/18138/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Small LDL particles penetrate the endothelial barrier 1.7-fold more than large LDL particles; these electronegative small LDL particles interact with positively charged intimal proteoglycans [",
"    <a class=\"abstract\" href=\"UTD.htm?17/45/18138/abstract/30,31\">",
"     30,31",
"    </a>",
"    ]. The increased retention of small LDL particles in the vessel wall allows a longer time for reactive oxygen species modification of surface phospholipids and unesterified cholesterol. In addition, the small LDL phenotype is associated with a clustering of other risk factors, including elevated levels of triglycerides, VLDL, and IDL, reduced concentrations of HDL and HDL2, and insulin resistance [",
"    <a class=\"abstract\" href=\"UTD.htm?17/45/18138/abstract/32\">",
"     32",
"    </a>",
"    ]. The discussion of the clinical use of the measurement of LDL particle size is found elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/31/31222?source=see_link&amp;anchor=H24360864#H24360864\">",
"     \"Measurement of serum lipids and lipoproteins\", section on 'LDL-cholesterol'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Circulating LDL also accumulates in the foam cells, but not the lipid core, of atherosclerotic plaques [",
"    <a class=\"abstract\" href=\"UTD.htm?17/45/18138/abstract/33\">",
"     33",
"    </a>",
"    ]. As noted above, circulating LDL that is not taken up by the apo",
"    <span class=\"nowrap\">",
"     B/E",
"    </span>",
"    (LDL) receptors can also enter macrophages through unregulated scavenger receptors [",
"    <a class=\"abstract\" href=\"UTD.htm?17/45/18138/abstract/18,34,35\">",
"     18,34,35",
"    </a>",
"    ]. The most important of these receptors appears to be CD36 (also called scavenger receptor B) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/45/18138/abstract/36-38\">",
"     36-38",
"    </a>",
"    ]. Uptake by these receptors requires chemical modification of the LDL particle by enzymatic, nonoxidative alteration [",
"    <a class=\"abstract\" href=\"UTD.htm?17/45/18138/abstract/39\">",
"     39",
"    </a>",
"    ]; oxidation, which accelerates the accumulation of cholesterol [",
"    <a class=\"abstract\" href=\"UTD.htm?17/45/18138/abstract/40\">",
"     40",
"    </a>",
"    ]; glycosylation; or glycoxidation. The oxidation process modifies a lysine amino acid on the apolipoprotein B. Oxidation of LDL can occur in any of the cells within the artery, including the endothelial cells, macrophages, smooth muscle cells, and T lymphocytes. Vitamin E can reduce the uptake of oxidized LDL by reducing expression of the CD36 receptor [",
"    <a class=\"abstract\" href=\"UTD.htm?17/45/18138/abstract/41\">",
"     41",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/53/26456?source=see_link\">",
"     \"Nutritional antioxidants in coronary heart disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The oxidation of LDL results in the formation of isoprostanes which are chemically stable, free radical catalyzed products of arachidonic acid that are structural isomers of conventional prostaglandins. They reflect lipid peroxidation and are markers of oxidant stress in hypercholesterolemia and atherosclerosis. Levels of isoprostanes are increased in atherosclerotic lesions and localize to foam cells and the extracellular matrix [",
"    <a class=\"abstract\" href=\"UTD.htm?17/45/18138/abstract/42\">",
"     42",
"    </a>",
"    ]. Asymptomatic patients with hypercholesterolemia may have increased urinary excretion of F2 isoprostanes compared to normal controls [",
"    <a class=\"abstract\" href=\"UTD.htm?17/45/18138/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Elevated plasma concentrations of oxidized LDL are associated with CHD [",
"    <a class=\"abstract\" href=\"UTD.htm?17/45/18138/abstract/44\">",
"     44",
"    </a>",
"    ], and patients with an acute coronary syndrome have higher levels of malondialdehyde (MDA)-modified LDL than patients with stable CHD [",
"    <a class=\"abstract\" href=\"UTD.htm?17/45/18138/abstract/45\">",
"     45",
"    </a>",
"    ]. MDA-modified LDL is a type of oxidatively modified LDL that may be produced when ischemic injury results in the release of aldehydes that substitute the lysine residues in apo B-100 [",
"    <a class=\"abstract\" href=\"UTD.htm?17/45/18138/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The prevention of oxidative modification of lipoproteins, as with paraoxonase, is associated with less severe coronary disease [",
"    <a class=\"abstract\" href=\"UTD.htm?17/45/18138/abstract/47-49\">",
"     47-49",
"    </a>",
"    ]. In addition, the cholesterol-enriched macrophages (called foam cells) can rupture, releasing oxidized LDL, intracellular enzymes, and oxygen free radicals that can further damage the vessel wall. One potential strategy for preventing the development of atherosclerosis is the recombinant adenovirus-mediated gene transfer of decoy macrophage scavenger receptors that can block foam cell formation [",
"    <a class=\"abstract\" href=\"UTD.htm?17/45/18138/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Oxidized LDL particles promote atherosclerosis via one or more of the following effects (",
"    <a class=\"graphic graphic_table graphicRef51940 \" href=\"UTD.htm?1/53/1883\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/45/18138/abstract/35,51\">",
"     35,51",
"    </a>",
"    ]; however, the inflammatory and immune response of the endothelial cell to oxidized LDL is genetically determined and can be seen in an inbred mouse strain that is susceptible to diet-induced atherosclerosis, but not in a resistant strain [",
"    <a class=\"abstract\" href=\"UTD.htm?17/45/18138/abstract/52\">",
"     52",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      They act as a chemoattractant for monocytes by increasing monocyte binding (via activation of monocyte &szlig;1 integrin) [",
"      <a class=\"abstract\" href=\"UTD.htm?17/45/18138/abstract/53\">",
"       53",
"      </a>",
"      ], which then develop into tissue macrophages. In addition, macrophage mobility may be reduced, thereby trapping the macrophages within the vessel wall. One study of patients with familial hypercholesterolemia undergoing selective LDL apheresis reported that hypercholesterolemia was associated with elevated levels of endothelial leukocyte adhesion molecule-1, vascular cell adhesion molecule-1, and intercellular adhesion molecule-1 which upregulate endothelial adhesiveness [",
"      <a class=\"abstract\" href=\"UTD.htm?17/45/18138/abstract/54\">",
"       54",
"      </a>",
"      ]. The levels of these adhesion molecules were reduced after apheresis.",
"     </li>",
"     <li>",
"      LDL particles can promote inflammatory and immune changes via cytokine release from macrophages and antibody production",
"     </li>",
"     <li>",
"      In any circumstance in which LDL-cholesterol levels are increased, due, for example, to an abnormality in the apo",
"      <span class=\"nowrap\">",
"       B/E",
"      </span>",
"      (LDL) receptor, unregulated uptake via the scavenger pathway leads to excess accumulation of modified LDL within macrophages [",
"      <a class=\"abstract\" href=\"UTD.htm?17/45/18138/abstract/18\">",
"       18",
"      </a>",
"      ]. These cholesterol-enriched cells (called foam cells) can rupture, releasing oxidized LDL, intracellular enzymes, and oxygen free radicals that can further damage the vessel wall. Oxidized LDL induces apoptosis of vascular smooth muscle [",
"      <a class=\"abstract\" href=\"UTD.htm?17/45/18138/abstract/55\">",
"       55",
"      </a>",
"      ] and human endothelial cells via activation of a CPP32-like protease, which suggests a mechanism for the response to injury hypothesis of atherosclerosis [",
"      <a class=\"abstract\" href=\"UTD.htm?17/45/18138/abstract/56\">",
"       56",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Oxidatively modified LDL can cause disruption of the endothelial cell surface [",
"      <a class=\"abstract\" href=\"UTD.htm?17/45/18138/abstract/57\">",
"       57",
"      </a>",
"      ] and impairs endothelial function, reducing the release of nitric oxide (NO), which is a major mediator of endothelium-dependent vasodilation [",
"      <a class=\"abstract\" href=\"UTD.htm?17/45/18138/abstract/58-60\">",
"       58-60",
"      </a>",
"      ]. High levels of cholesterol also increase endothelial production of oxygen free radicals, which may bind to and inactivate NO [",
"      <a class=\"abstract\" href=\"UTD.htm?17/45/18138/abstract/61,62\">",
"       61,62",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Treatment with lipid lowering drugs that reduce the susceptibility of LDL to oxidation may reverse some of these changes, resulting in an improved vasomotor response to acetylcholine [",
"    <a class=\"abstract\" href=\"UTD.htm?17/45/18138/abstract/51,59,63\">",
"     51,59,63",
"    </a>",
"    ]. Endothelial function can also be improved by the administration of the NO precursor L-arginine in hypercholesterolemic rabbits [",
"    <a class=\"abstract\" href=\"UTD.htm?17/45/18138/abstract/64\">",
"     64",
"    </a>",
"    ] and, in patients with hypercholesterolemia, vitamin C, folate, and 5-methyltetrahydrofolate, the active form of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/61/9174?source=see_link\">",
"     folic acid",
"    </a>",
"    ; improvement occurs without changes in plasma lipids [",
"    <a class=\"abstract\" href=\"UTD.htm?17/45/18138/abstract/65-67\">",
"     65-67",
"    </a>",
"    ]. Vitamin C and folate may prevent the degradation of NO.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Oxidized LDL causes an increase in platelet aggregation and thromboxane release, which contributes to vasoconstriction and intravascular thrombus formation [",
"      <a class=\"abstract\" href=\"UTD.htm?17/45/18138/abstract/68,69\">",
"       68,69",
"      </a>",
"      ]. LDL also inhibits NO synthase activity of platelets, which in turn, stimulates platelet activity and aggregation [",
"      <a class=\"abstract\" href=\"UTD.htm?17/45/18138/abstract/70,71\">",
"       70,71",
"      </a>",
"      ]. L-arginine supplementation attenuates platelet aggregation in humans, although the magnitude of the effect varies significantly among individual patients [",
"      <a class=\"abstract\" href=\"UTD.htm?17/45/18138/abstract/72\">",
"       72",
"      </a>",
"      ]. Oxidized LDL increases activation of redox-sensitive transcription factors nuclear factor &kappa;B (NF-&kappa;B) and activator protein 1 (AP-1), which in intern increase expression of a panoply of pro-inflammatory cytokines [",
"      <a class=\"abstract\" href=\"UTD.htm?17/45/18138/abstract/73,74\">",
"       73,74",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Oxidized LDL may also play a role in plaque instability [",
"      <a class=\"abstract\" href=\"UTD.htm?17/45/18138/abstract/75\">",
"       75",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Damage to the endothelium then promotes platelet adherence and the release of cytokines that stimulate smooth muscle proliferation. Thus, foam cell and platelet accumulation and smooth muscle proliferation all contribute to the formation of an atherosclerotic plaque [",
"    <a class=\"abstract\" href=\"UTD.htm?17/45/18138/abstract/76\">",
"     76",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Another potential mechanism by which LDL may promote atherosclerosis is by upregulation of the angiotensin II type I receptor [",
"    <a class=\"abstract\" href=\"UTD.htm?17/45/18138/abstract/77\">",
"     77",
"    </a>",
"    ]. This change may increase the functional response of vascular smooth muscle cells to angiotensin II stimulation [",
"    <a class=\"abstract\" href=\"UTD.htm?17/45/18138/abstract/78\">",
"     78",
"    </a>",
"    ]. In addition, the angiotensin II type I receptor regulates the induction of the lecithin-like oxidized LDL receptor-1 (LOX-1), an endothelial receptor for oxidized LDL that is distinct from the macrophage scavenger receptor pathway [",
"    <a class=\"abstract\" href=\"UTD.htm?17/45/18138/abstract/79\">",
"     79",
"    </a>",
"    ]. The LOX-1 receptor is important in the process of oxidized LDL-mediated monocyte adhesion to coronary artery endothelial cells [",
"    <a class=\"abstract\" href=\"UTD.htm?17/45/18138/abstract/80\">",
"     80",
"    </a>",
"    ]. Cholesterol lowering with a statin drug downregulates angiotensin II type I receptor density and reverses the elevated blood pressure response to angiotensin II [",
"    <a class=\"abstract\" href=\"UTD.htm?17/45/18138/abstract/78\">",
"     78",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/61/36825?source=see_link\">",
"     \"Actions of angiotensin II on the heart\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/2/32?source=see_link\">",
"     \"Mechanisms of benefit of lipid-lowering drugs in patients with coronary heart disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Intermediate density lipoprotein (remnant lipoproteins)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although LDL is accepted to be the major risk factor in the progression of atherosclerosis, the measurement of LDL also includes IDL. Several studies have shown that serum IDL concentrations are predictive of an increase incidence of CHD [",
"    <a class=\"abstract\" href=\"UTD.htm?17/45/18138/abstract/81\">",
"     81",
"    </a>",
"    ] and an increased incidence of coronary events in those with CHD, independently of other factors [",
"    <a class=\"abstract\" href=\"UTD.htm?17/45/18138/abstract/82,83\">",
"     82,83",
"    </a>",
"    ]. This relationship may be particularly strong in patients with normal total cholesterol levels and those with an elevated",
"    <span class=\"nowrap\">",
"     IDL/HDL",
"    </span>",
"    ratio [",
"    <a class=\"abstract\" href=\"UTD.htm?17/45/18138/abstract/84\">",
"     84",
"    </a>",
"    ]. The MARS study performed analytic ultracentrifugation to determine the lipoprotein subclasses: IDL, but not VLDL or LDL, was associated with the progression of carotid artery intima-media thickness [",
"    <a class=\"abstract\" href=\"UTD.htm?17/45/18138/abstract/85\">",
"     85",
"    </a>",
"    ]. In another study, normolipidemic men with CHD and subjects with dysbetalipoproteinemia had elevated levels of IDL when compared to controls; furthermore, the increased levels of IDL were not detected with conventional lipid screening [",
"    <a class=\"abstract\" href=\"UTD.htm?17/45/18138/abstract/86\">",
"     86",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Thus, IDL may be a major determinant of the atherogenic potential of LDL. Similar to LDL, IDL is taken up by macrophages and can cause foam cell formation and can impair endothelium-dependent vasomotor function in human coronary arteries [",
"    <a class=\"abstract\" href=\"UTD.htm?17/45/18138/abstract/87\">",
"     87",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Very low density lipoprotein",
"    </span>",
"    &nbsp;&mdash;&nbsp;The general contribution of hypertriglyceridemia to coronary risk remains uncertain [",
"    <a class=\"abstract\" href=\"UTD.htm?17/45/18138/abstract/88-90\">",
"     88-90",
"    </a>",
"    ]. Hypertriglyceridemia tends to be associated with low HDL levels; as a result, any apparent increase in CHD may be due to the reduction in HDL rather than the elevation in triglycerides [",
"    <a class=\"abstract\" href=\"UTD.htm?17/45/18138/abstract/89\">",
"     89",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Nevertheless, there may be some settings in which triglyceride-containing lipoproteins are atherogenic. As an example, VLDL particles from patients with hypertriglyceridemia are enriched in apo E. This can lead to a conformational change in the VLDL particle that facilitates binding to the macrophage scavenger receptor, resulting in unregulated uptake similar to that seen with oxidized LDL [",
"    <a class=\"abstract\" href=\"UTD.htm?17/45/18138/abstract/91\">",
"     91",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    LPL hydrolyzes triglycerides contained in the core of chylomicrons and VLDL. An Asn291Ser substitution in LPL causes impaired function of this enzyme and is associated with an increase in plasma triglycerides. Female, but not male, carriers of this mutation have a two-fold increase in the risk of CHD and nonfatal cerebrovascular disease [",
"    <a class=\"abstract\" href=\"UTD.htm?17/45/18138/abstract/92,93\">",
"     92,93",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A different mechanism occurs in patients with hypertriglyceridemia who overproduce apo B (as in combined hyperlipidemia). These patients have a subspecies of LDL that is smaller and more dense than LDL from patients with normal triglyceride levels [",
"    <a class=\"abstract\" href=\"UTD.htm?17/45/18138/abstract/94\">",
"     94",
"    </a>",
"    ]. Small, dense LDL particles bind less avidly to the LDL receptor. This prolongs their half-life in the circulation, making these particles more susceptible to oxidative modification and to subsequent uptake by the macrophage scavenger receptors [",
"    <a class=\"abstract\" href=\"UTD.htm?17/45/18138/abstract/95\">",
"     95",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Hypertriglyceridemia can also promote atherothrombosis by increasing coagulability and blood viscosity [",
"    <a class=\"abstract\" href=\"UTD.htm?17/45/18138/abstract/96\">",
"     96",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/47/35578?source=see_link\">",
"     \"Approach to the patient with hypertriglyceridemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Most patients with elevated levels of VLDL have excess amounts of both triglycerides and apolipoprotein CIII within these particles. Typically the LDL particles contain increased amounts of these to as well. The role of excess apo C-III in the genesis of atherosclerosis is discussed below. (See",
"    <a class=\"local\" href=\"#H20\">",
"     'Triglyceride rich lipoproteins and apo C-III'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     High density lipoprotein",
"    </span>",
"    &nbsp;&mdash;&nbsp;HDL, in contrast to LDL and VLDL, has antiatherogenic properties that include macrophage cholesterol efflux, antioxidation, protection against thrombosis, maintenance of endothelial function, and maintenance of low blood viscosity through a permissive action on red cell deformability [",
"    <a class=\"abstract\" href=\"UTD.htm?17/45/18138/abstract/5,96-100\">",
"     5,96-100",
"    </a>",
"    ]. The net effect is that there is an inverse relationship between plasma HDL-cholesterol levels and cardiovascular risk (",
"    <a class=\"graphic graphic_table graphicRef57480 \" href=\"UTD.htm?0/2/35\">",
"     table 3",
"    </a>",
"    ). Values above 75",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (1.9",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    are associated with a longevity syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?17/45/18138/abstract/101\">",
"     101",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/2/39978?source=see_link\">",
"     \"HDL metabolism and approach to the patient with abnormal HDL-cholesterol levels\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Macrophage cholesterol efflux is a process whereby excess cholesterol in cells and in atherosclerotic plaques is removed. How this occurs is described above as apo A-I plays an important role (",
"    <a class=\"graphic graphic_figure graphicRef83853 \" href=\"UTD.htm?39/56/40839\">",
"     figure 3",
"    </a>",
"    ). In a mouse model, the somatic gene transfer of human apo A-I can prevent the development of atherosclerosis or reverse preexisting atherosclerosis [",
"    <a class=\"abstract\" href=\"UTD.htm?17/45/18138/abstract/102,103\">",
"     102,103",
"    </a>",
"    ]. A similar benefit in animals can be seen with the oral administration of apo A-I mimetic peptides, independent of changes in serum total or HDL-cholesterol [",
"    <a class=\"abstract\" href=\"UTD.htm?17/45/18138/abstract/104\">",
"     104",
"    </a>",
"    ]. On the other hand, mutations in apo A-I can lead to lower plasma levels of apo A-I and HDL-cholesterol and can increase the risk of atherosclerosis [",
"    <a class=\"abstract\" href=\"UTD.htm?17/45/18138/abstract/105\">",
"     105",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The antioxidant properties of HDL particles may be important in humans. In a group of men with CHD who were atypical in that they had high HDL cholesterol levels (&ge;84",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [2.2",
"    <span class=\"nowrap\">",
"     mmol/L]),",
"    </span>",
"    the HDL particles were ineffective in mitigating oxidative stress and reducing ex vivo inflammatory responses compared to a control group with a similar lipid profile but without CHD [",
"    <a class=\"abstract\" href=\"UTD.htm?17/45/18138/abstract/106\">",
"     106",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The antioxidant properties of HDL may be due in part to the activity of HDL-associated enzymes such as paraoxonase. Paraoxonase inhibits oxidation of LDL in vitro and a genetic deletion of paraoxonase is associated with increased susceptibility of LDL to oxidation in vivo [",
"    <a class=\"abstract\" href=\"UTD.htm?17/45/18138/abstract/107\">",
"     107",
"    </a>",
"    ]. Two pieces of evidence support the antioxidant role of HDL-associated paraoxonase in humans:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Small HDL particles exhibit more antioxidant activity than large particles, due to stronger attachment of paraoxonase to these particles [",
"      <a class=\"abstract\" href=\"UTD.htm?17/45/18138/abstract/108\">",
"       108",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Higher paraoxonase activity measures were associated with both a lower prevalence of cardiovascular disease and a lower rate of future major adverse cardiac events in a prospective evaluation of 1399 patients [",
"      <a class=\"abstract\" href=\"UTD.htm?17/45/18138/abstract/107\">",
"       107",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    HDL and apo A-I also inhibit the generation of calcium-induced procoagulant activity on erythrocytes via stabilization of the cell membrane [",
"    <a class=\"abstract\" href=\"UTD.htm?17/45/18138/abstract/96\">",
"     96",
"    </a>",
"    ]. This membrane stabilizing action prevents the transbilayer diffusion of anionic lipids that is required for prothrombin activation, thereby minimizing thrombus formation.",
"   </p>",
"   <p>",
"    HDL improves endothelial function by increasing eNOS production [",
"    <a class=\"abstract\" href=\"UTD.htm?17/45/18138/abstract/109\">",
"     109",
"    </a>",
"    ] and inhibiting cellular adhesion molecule expression [",
"    <a class=\"abstract\" href=\"UTD.htm?17/45/18138/abstract/110\">",
"     110",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    HDL plays an important role in glucose homeostasis through its effect on increased pancreatic beta cell production of insulin [",
"    <a class=\"abstract\" href=\"UTD.htm?17/45/18138/abstract/111\">",
"     111",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Triglyceride rich lipoproteins and apo C-III",
"    </span>",
"    &nbsp;&mdash;&nbsp;Elevations in serum triglycerides are associated with an increased risk for atherosclerosis and some experts consider them to be an independent risk factor [",
"    <a class=\"abstract\" href=\"UTD.htm?17/45/18138/abstract/112\">",
"     112",
"    </a>",
"    ]. In addition, elevated levels of apo C-III are correlated with and may be causative for hypertriglyceridemia [",
"    <a class=\"abstract\" href=\"UTD.htm?17/45/18138/abstract/112\">",
"     112",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Apolipoproteins'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/47/35578?source=see_link\">",
"     \"Approach to the patient with hypertriglyceridemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Excessive apo C-III on the surface of triglyceride rich lipoproteins (VLDL or LDL) may contribute to the development of atherosclerosis by at least three mechanisms:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Delaying the lipolysis of VLDL and inhibiting its uptake and clearance from the plasma [",
"      <a class=\"abstract\" href=\"UTD.htm?17/45/18138/abstract/112,113\">",
"       112,113",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Augmenting arterial inflammation through effects on both peripheral monocytes and endothelial cells [",
"      <a class=\"abstract\" href=\"UTD.htm?17/45/18138/abstract/112\">",
"       112",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Interfering with normal nitric oxide function in endothelial cells, perhaps through interfering with insulin signaling, and thus causing endothelial dysfunction [",
"      <a class=\"abstract\" href=\"UTD.htm?17/45/18138/abstract/114\">",
"       114",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/23/6522?source=see_link\">",
"       \"Structure and function of the insulin receptor\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Lipoprotein(a)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lp(a), the specialized form of LDL, is a risk factor for the development of atherosclerotic events and evidence strongly suggests that it is causative. This issue is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/19/40248?source=see_link\">",
"     \"Lipoprotein(a) and cardiovascular disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?10/48/11011?source=see_link\">",
"       \"Patient information: High cholesterol (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topic (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?6/4/6212?source=see_link\">",
"       \"Patient information: High cholesterol and lipids (hyperlipidemia) (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H188693598\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Lipids, such as cholesterol and triglycerides, are insoluble in plasma and circulating lipid is carried in lipoproteins that transport the lipid to various tissues for energy utilization, lipid deposition, steroid hormone production, and bile acid formation. The lipoprotein consists of esterified and unesterified cholesterol, triglycerides, and phospholipids, and protein. The protein components of the lipoprotein are known as apolipoproteins (apo) or apoproteins. The different apolipoproteins serve as cofactors for enzymes and ligands for receptors. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Abnormal lipoprotein metabolism is a major predisposing factor to atherosclerosis. It is estimated that a dyslipidemia is present in over 70 percent of patients with premature coronary heart disease. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Lipoproteins and atherosclerosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Elevated plasma concentrations of apo B-100 containing lipoproteins (low density and very low density lipoprotein) can induce the development of atherosclerosis even in the absence of other risk factors. It has been proposed that the initiating event in atherogenesis is the subendothelial retention of apo B-100 containing lipoproteins. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Low density lipoprotein'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H18\">",
"       'Very low density lipoprotein'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The general contribution of hypertriglyceridemia to coronary risk remains uncertain. Hypertriglyceridemia tends to be associated with low HDL levels; as a result, any apparent increase in CHD may be due to the reduction in HDL rather than the elevation in triglycerides. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Triglyceride rich lipoproteins and apo C-III'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      HDL, in contrast to LDL and VLDL, has antiatherogenic properties that include macrophage cholesterol efflux, antioxidation, protection against thrombosis, maintenance of endothelial function, and maintenance of low blood viscosity through a permissive action on red cell deformability. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'High density lipoprotein'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Lp(a), the specialized form of LDL, is a risk factor for the development of atherosclerotic events and evidence strongly suggests that it is causative. This issue is discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/19/40248?source=see_link\">",
"       \"Lipoprotein(a) and cardiovascular disease\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/45/18138/abstract/1\">",
"      Rader DJ, Hoeg JM, Brewer HB Jr. Quantitation of plasma apolipoproteins in the primary and secondary prevention of coronary artery disease. Ann Intern Med 1994; 120:1012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/45/18138/abstract/2\">",
"      Nielsen LB, V&eacute;niant M, Bor&eacute;n J, et al. Genes for apolipoprotein B and microsomal triglyceride transfer protein are expressed in the heart: evidence that the heart has the capacity to synthesize and secrete lipoproteins. Circulation 1998; 98:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/45/18138/abstract/3\">",
"      de Silva HV, Lauer SJ, Wang J, et al. Overexpression of human apolipoprotein C-III in transgenic mice results in an accumulation of apolipoprotein B48 remnants that is corrected by excess apolipoprotein E. J Biol Chem 1994; 269:2324.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/45/18138/abstract/4\">",
"      Ginsberg HN, Le NA, Goldberg IJ, et al. Apolipoprotein B metabolism in subjects with deficiency of apolipoproteins CIII and AI. Evidence that apolipoprotein CIII inhibits catabolism of triglyceride-rich lipoproteins by lipoprotein lipase in vivo. J Clin Invest 1986; 78:1287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/45/18138/abstract/5\">",
"      Tall AR. Plasma high density lipoproteins. Metabolism and relationship to atherogenesis. J Clin Invest 1990; 86:379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/45/18138/abstract/6\">",
"      Mendivil CO, Rimm EB, Furtado J, et al. Low-density lipoproteins containing apolipoprotein C-III and the risk of coronary heart disease. Circulation 2011; 124:2065.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/45/18138/abstract/7\">",
"      Davignon J, Gregg RE, Sing CF. Apolipoprotein E polymorphism and atherosclerosis. Arteriosclerosis 1988; 8:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/45/18138/abstract/8\">",
"      Fredrickson DS. An international classification of hyperlipidemias and hyperlipoproteinemias. Ann Intern Med 1971; 75:471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/45/18138/abstract/9\">",
"      Patel SB, Salen G, Hidaka H, et al. Mapping a gene involved in regulating dietary cholesterol absorption. The sitosterolemia locus is found at chromosome 2p21. J Clin Invest 1998; 102:1041.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/45/18138/abstract/10\">",
"      Berge KE, Tian H, Graf GA, et al. Accumulation of dietary cholesterol in sitosterolemia caused by mutations in adjacent ABC transporters. Science 2000; 290:1771.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/45/18138/abstract/11\">",
"      Buhman KK, Accad M, Novak S, et al. Resistance to diet-induced hypercholesterolemia and gallstone formation in ACAT2-deficient mice. Nat Med 2000; 6:1341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/45/18138/abstract/12\">",
"      Nissen SE, Tuzcu EM, Brewer HB, et al. Effect of ACAT inhibition on the progression of coronary atherosclerosis. N Engl J Med 2006; 354:1253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/45/18138/abstract/13\">",
"      Fazio S, Linton M. Failure of ACAT inhibition to retard atherosclerosis. N Engl J Med 2006; 354:1307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/45/18138/abstract/14\">",
"      Raabe M, V&eacute;niant MM, Sullivan MA, et al. Analysis of the role of microsomal triglyceride transfer protein in the liver of tissue-specific knockout mice. J Clin Invest 1999; 103:1287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/45/18138/abstract/15\">",
"      Wetterau JR, Lin MC, Jamil H. Microsomal triglyceride transfer protein. Biochim Biophys Acta 1997; 1345:136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/45/18138/abstract/16\">",
"      Tahvanainen E, Syvanne M, Frick MH, et al. Association of variation in hepatic lipase activity with promoter variation in the hepatic lipase gene. The LOCAT Study Invsestigators. J Clin Invest 1998; 101:956.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/45/18138/abstract/17\">",
"      Zambon A, Deeb SS, Hokanson JE, et al. Common variants in the promoter of the hepatic lipase gene are associated with lower levels of hepatic lipase activity, buoyant LDL, and higher HDL2 cholesterol. Arterioscler Thromb Vasc Biol 1998; 18:1723.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/45/18138/abstract/18\">",
"      Brown MS, Goldstein JL. A receptor-mediated pathway for cholesterol homeostasis. Science 1986; 232:34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/45/18138/abstract/19\">",
"      Ishibashi S, Brown MS, Goldstein JL, et al. Hypercholesterolemia in low density lipoprotein receptor knockout mice and its reversal by adenovirus-mediated gene delivery. J Clin Invest 1993; 92:883.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/45/18138/abstract/20\">",
"      Hobbs HH, Russell DW, Brown MS, Goldstein JL. The LDL receptor locus in familial hypercholesterolemia: mutational analysis of a membrane protein. Annu Rev Genet 1990; 24:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/45/18138/abstract/21\">",
"      Rosenson RS, Brewer HB Jr, Davidson WS, et al. Cholesterol efflux and atheroprotection: advancing the concept of reverse cholesterol transport. Circulation 2012; 125:1905.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/45/18138/abstract/22\">",
"      Marcil M, Brooks-Wilson A, Clee SM, et al. Mutations in the ABC1 gene in familial HDL deficiency with defective cholesterol efflux. Lancet 1999; 354:1341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/45/18138/abstract/23\">",
"      Marcil M, Yu L, Krimbou L, et al. Cellular cholesterol transport and efflux in fibroblasts are abnormal in subjects with familial HDL deficiency. Arterioscler Thromb Vasc Biol 1999; 19:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/45/18138/abstract/24\">",
"      Steyrer E, Durovic S, Frank S, et al. The role of lecithin: cholesterol acyltransferase for lipoprotein (a) assembly. Structural integrity of low density lipoproteins is a prerequisite for Lp(a) formation in human plasma. J Clin Invest 1994; 94:2330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/45/18138/abstract/25\">",
"      Loscalzo J, Weinfeld M, Fless GM, Scanu AM. Lipoprotein(a), fibrin binding, and plasminogen activation. Arteriosclerosis 1990; 10:240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/45/18138/abstract/26\">",
"      Palabrica TM, Liu AC, Aronovitz MJ, et al. Antifibrinolytic activity of apolipoprotein(a) in vivo: human apolipoprotein(a) transgenic mice are resistant to tissue plasminogen activator-mediated thrombolysis. Nat Med 1995; 1:256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/45/18138/abstract/27\">",
"      Zioncheck TF, Powell LM, Rice GC, et al. Interaction of recombinant apolipoprotein(a) and lipoprotein(a) with macrophages. J Clin Invest 1991; 87:767.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/45/18138/abstract/28\">",
"      Genest JJ Jr, Martin-Munley SS, McNamara JR, et al. Familial lipoprotein disorders in patients with premature coronary artery disease. Circulation 1992; 85:2025.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/45/18138/abstract/29\">",
"      Sk&aring;l&eacute;n K, Gustafsson M, Rydberg EK, et al. Subendothelial retention of atherogenic lipoproteins in early atherosclerosis. Nature 2002; 417:750.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/45/18138/abstract/30\">",
"      de Graaf J, Hak-Lemmers HL, Hectors MP, et al. Enhanced susceptibility to in vitro oxidation of the dense low density lipoprotein subfraction in healthy subjects. Arterioscler Thromb 1991; 11:298.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/45/18138/abstract/31\">",
"      Hurt-Camejo E, Olsson U, Wiklund O, et al. Cellular consequences of the association of apoB lipoproteins with proteoglycans. Potential contribution to atherogenesis. Arterioscler Thromb Vasc Biol 1997; 17:1011.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/45/18138/abstract/32\">",
"      Austin MA, King MC, Vranizan KM, Krauss RM. Atherogenic lipoprotein phenotype. A proposed genetic marker for coronary heart disease risk. Circulation 1990; 82:495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/45/18138/abstract/33\">",
"      Iuliano L, Mauriello A, Sbarigia E, et al. Radiolabeled native low-density lipoprotein injected into patients with carotid stenosis accumulates in macrophages of atherosclerotic plaque : effect of vitamin E supplementation. Circulation 2000; 101:1249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/45/18138/abstract/34\">",
"      Hiltunen TP, Luoma JS, Nikkari T, Yl&auml;-Herttuala S. Expression of LDL receptor, VLDL receptor, LDL receptor-related protein, and scavenger receptor in rabbit atherosclerotic lesions: marked induction of scavenger receptor and VLDL receptor expression during lesion development. Circulation 1998; 97:1079.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/45/18138/abstract/35\">",
"      Steinberg D, Parthasarathy S, Carew TE, et al. Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity. N Engl J Med 1989; 320:915.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/45/18138/abstract/36\">",
"      Podrez EA, Febbraio M, Sheibani N, et al. Macrophage scavenger receptor CD36 is the major receptor for LDL modified by monocyte-generated reactive nitrogen species. J Clin Invest 2000; 105:1095.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/45/18138/abstract/37\">",
"      Febbraio M, Podrez EA, Smith JD, et al. Targeted disruption of the class B scavenger receptor CD36 protects against atherosclerotic lesion development in mice. J Clin Invest 2000; 105:1049.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/45/18138/abstract/38\">",
"      Febbraio M, Hajjar DP, Silverstein RL. CD36: a class B scavenger receptor involved in angiogenesis, atherosclerosis, inflammation, and lipid metabolism. J Clin Invest 2001; 108:785.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/45/18138/abstract/39\">",
"      Klouche M, Rose-John S, Schmiedt W, Bhakdi S. Enzymatically degraded, nonoxidized LDL induces human vascular smooth muscle cell activation, foam cell transformation, and proliferation. Circulation 2000; 101:1799.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/45/18138/abstract/40\">",
"      Witztum JL. The oxidation hypothesis of atherosclerosis. Lancet 1994; 344:793.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/45/18138/abstract/41\">",
"      Ricciarelli R, Zingg JM, Azzi A. Vitamin E reduces the uptake of oxidized LDL by inhibiting CD36 scavenger receptor expression in cultured aortic smooth muscle cells. Circulation 2000; 102:82.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/45/18138/abstract/42\">",
"      Pratic&ograve; D, Iuliano L, Mauriello A, et al. Localization of distinct F2-isoprostanes in human atherosclerotic lesions. J Clin Invest 1997; 100:2028.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/45/18138/abstract/43\">",
"      Reilly MP, Pratic&ograve; D, Delanty N, et al. Increased formation of distinct F2 isoprostanes in hypercholesterolemia. Circulation 1998; 98:2822.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/45/18138/abstract/44\">",
"      Tsimikas S, Brilakis ES, Miller ER, et al. Oxidized phospholipids, Lp(a) lipoprotein, and coronary artery disease. N Engl J Med 2005; 353:46.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/45/18138/abstract/45\">",
"      Holvoet P, Vanhaecke J, Janssens S, et al. Oxidized LDL and malondialdehyde-modified LDL in patients with acute coronary syndromes and stable coronary artery disease. Circulation 1998; 98:1487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/45/18138/abstract/46\">",
"      Holvoet P, Collen D, Van de Werf F. Malondialdehyde-modified LDL as a marker of acute coronary syndromes. JAMA 1999; 281:1718.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/45/18138/abstract/47\">",
"      James RW, Leviev I, Righetti A. Smoking is associated with reduced serum paraoxonase activity and concentration in patients with coronary artery disease. Circulation 2000; 101:2252.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/45/18138/abstract/48\">",
"      Aviram M, Hardak E, Vaya J, et al. Human serum paraoxonases (PON1) Q and R selectively decrease lipid peroxides in human coronary and carotid atherosclerotic lesions: PON1 esterase and peroxidase-like activities. Circulation 2000; 101:2510.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/45/18138/abstract/49\">",
"      Shih DM, Gu L, Xia YR, et al. Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis. Nature 1998; 394:284.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/45/18138/abstract/50\">",
"      Laukkanen J, Lehtolainen P, Gough PJ, et al. Adenovirus-mediated gene transfer of a secreted form of human macrophage scavenger receptor inhibits modified low-density lipoprotein degradation and foam-cell formation in macrophages. Circulation 2000; 101:1091.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/45/18138/abstract/51\">",
"      Rosenson RS. Current overview of statin-induced myopathy. Am J Med 2004; 116:408.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/45/18138/abstract/52\">",
"      Shi W, Haberland ME, Jien ML, et al. Endothelial responses to oxidized lipoproteins determine genetic susceptibility to atherosclerosis in mice. Circulation 2000; 102:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/45/18138/abstract/53\">",
"      Shih PT, Elices MJ, Fang ZT, et al. Minimally modified low-density lipoprotein induces monocyte adhesion to endothelial connecting segment-1 by activating beta1 integrin. J Clin Invest 1999; 103:613.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/45/18138/abstract/54\">",
"      Sampietro T, Tuoni M, Ferdeghini M, et al. Plasma cholesterol regulates soluble cell adhesion molecule expression in familial hypercholesterolemia. Circulation 1997; 96:1381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/45/18138/abstract/55\">",
"      Okura Y, Brink M, Itabe H, et al. Oxidized low-density lipoprotein is associated with apoptosis of vascular smooth muscle cells in human atherosclerotic plaques. Circulation 2000; 102:2680.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/45/18138/abstract/56\">",
"      Dimmeler S, Haendeler J, Galle J, Zeiher AM. Oxidized low-density lipoprotein induces apoptosis of human endothelial cells by activation of CPP32-like proteases. A mechanistic clue to the 'response to injury' hypothesis. Circulation 1997; 95:1760.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/45/18138/abstract/57\">",
"      Vink H, Constantinescu AA, Spaan JA. Oxidized lipoproteins degrade the endothelial surface layer : implications for platelet-endothelial cell adhesion. Circulation 2000; 101:1500.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/45/18138/abstract/58\">",
"      Chin JH, Azhar S, Hoffman BB. Inactivation of endothelial derived relaxing factor by oxidized lipoproteins. J Clin Invest 1992; 89:10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/45/18138/abstract/59\">",
"      Anderson TJ, Meredith IT, Charbonneau F, et al. Endothelium-dependent coronary vasomotion relates to the susceptibility of LDL to oxidation in humans. Circulation 1996; 93:1647.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/45/18138/abstract/60\">",
"      Mathew V, Cannan CR, Miller VM, et al. Enhanced endothelin-mediated coronary vasoconstriction and attenuated basal nitric oxide activity in experimental hypercholesterolemia. Circulation 1997; 96:1930.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/45/18138/abstract/61\">",
"      Andrews HE, Bruckdorfer KR, Dunn RC, Jacobs M. Low-density lipoproteins inhibit endothelium-dependent relaxation in rabbit aorta. Nature 1987; 327:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/45/18138/abstract/62\">",
"      Mangin EL Jr, Kugiyama K, Nguy JH, et al. Effects of lysolipids and oxidatively modified low density lipoprotein on endothelium-dependent relaxation of rabbit aorta. Circ Res 1993; 72:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/45/18138/abstract/63\">",
"      Anderson TJ, Meredith IT, Yeung AC, et al. The effect of cholesterol-lowering and antioxidant therapy on endothelium-dependent coronary vasomotion. N Engl J Med 1995; 332:488.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/45/18138/abstract/64\">",
"      Girerd XJ, Hirsch AT, Cooke JP, et al. L-arginine augments endothelium-dependent vasodilation in cholesterol-fed rabbits. Circ Res 1990; 67:1301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/45/18138/abstract/65\">",
"      Ting HH, Timimi FK, Haley EA, et al. Vitamin C improves endothelium-dependent vasodilation in forearm resistance vessels of humans with hypercholesterolemia. Circulation 1997; 95:2617.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/45/18138/abstract/66\">",
"      Verhaar MC, Wever RM, Kastelein JJ, et al. 5-methyltetrahydrofolate, the active form of folic acid, restores endothelial function in familial hypercholesterolemia. Circulation 1998; 97:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/45/18138/abstract/67\">",
"      Verhaar MC, Wever RM, Kastelein JJ, et al. Effects of oral folic acid supplementation on endothelial function in familial hypercholesterolemia. A randomized placebo-controlled trial. Circulation 1999; 100:335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/45/18138/abstract/68\">",
"      Hassall DG, Owen JS, Bruckdorfer KR. The aggregation of isolated human platelets in the presence of lipoproteins and prostacyclin. Biochem J 1983; 216:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/45/18138/abstract/69\">",
"      Griffin JH, Fern&aacute;ndez JA, Deguchi H. Plasma lipoproteins, hemostasis and thrombosis. Thromb Haemost 2001; 86:386.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/45/18138/abstract/70\">",
"      Pedre&ntilde;o J, de Castellarnau C, Cullar&eacute; C, et al. LDL binding sites on platelets differ from the \"classical\" receptor of nucleated cells. Arterioscler Thromb 1992; 12:1353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/45/18138/abstract/71\">",
"      Chen LY, Mehta P, Mehta JL. Oxidized LDL decreases L-arginine uptake and nitric oxide synthase protein expression in human platelets: relevance of the effect of oxidized LDL on platelet function. Circulation 1996; 93:1740.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/45/18138/abstract/72\">",
"      Wolf A, Zalpour C, Theilmeier G, et al. Dietary L-arginine supplementation normalizes platelet aggregation in hypercholesterolemic humans. J Am Coll Cardiol 1997; 29:479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/45/18138/abstract/73\">",
"      Levitan I, Volkov S, Subbaiah PV. Oxidized LDL: diversity, patterns of recognition, and pathophysiology. Antioxid Redox Signal 2010; 13:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/45/18138/abstract/74\">",
"      Rosenson RS. Statins in atherosclerosis: lipid-lowering agents with antioxidant capabilities. Atherosclerosis 2004; 173:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/45/18138/abstract/75\">",
"      Ehara S, Ueda M, Naruko T, et al. Elevated levels of oxidized low density lipoprotein show a positive relationship with the severity of acute coronary syndromes. Circulation 2001; 103:1955.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/45/18138/abstract/76\">",
"      Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 1993; 362:801.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/45/18138/abstract/77\">",
"      Nickenig G, Sachinidis A, Michaelsen F, et al. Upregulation of vascular angiotensin II receptor gene expression by low-density lipoprotein in vascular smooth muscle cells. Circulation 1997; 95:473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/45/18138/abstract/78\">",
"      Nickenig G, B&auml;umer AT, Temur Y, et al. Statin-sensitive dysregulated AT1 receptor function and density in hypercholesterolemic men. Circulation 1999; 100:2131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/45/18138/abstract/79\">",
"      Morawietz H, Rueckschloss U, Niemann B, et al. Angiotensin II induces LOX-1, the human endothelial receptor for oxidized low-density lipoprotein. Circulation 1999; 100:899.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/45/18138/abstract/80\">",
"      Li D, Mehta JL. Antisense to LOX-1 inhibits oxidized LDL-mediated upregulation of monocyte chemoattractant protein-1 and monocyte adhesion to human coronary artery endothelial cells. Circulation 2000; 101:2889.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/45/18138/abstract/81\">",
"      Krauss RM, Lindgren FT, Williams PT, et al. Intermediate-density lipoproteins and progression of coronary artery disease in hypercholesterolaemic men. Lancet 1987; 2:62.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/45/18138/abstract/82\">",
"      Kugiyama K, Doi H, Takazoe K, et al. Remnant lipoprotein levels in fasting serum predict coronary events in patients with coronary artery disease. Circulation 1999; 99:2858.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/45/18138/abstract/83\">",
"      Fukushima H, Kugiyama K, Sugiyama S, et al. Comparison of remnant-like lipoprotein particles in postmenopausal women with and without coronary artery disease and in men with coronary artery disease. Am J Cardiol 2001; 88:1370.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/45/18138/abstract/84\">",
"      Masuoka H, Kamei S, Wagayama H, et al. Association of remnant-like particle cholesterol with coronary artery disease in patients with normal total cholesterol levels. Am Heart J 2000; 139:305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/45/18138/abstract/85\">",
"      Hodis HN, Mack WJ, Dunn M, et al. Intermediate-density lipoproteins and progression of carotid arterial wall intima-media thickness. Circulation 1997; 95:2022.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/45/18138/abstract/86\">",
"      Devaraj S, Vega G, Lange R, et al. Remnant-like particle cholesterol levels in patients with dysbetalipoproteinemia or coronary artery disease. Am J Med 1998; 104:445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/45/18138/abstract/87\">",
"      Kugiyama K, Doi H, Motoyama T, et al. Association of remnant lipoprotein levels with impairment of endothelium-dependent vasomotor function in human coronary arteries. Circulation 1998; 97:2519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/45/18138/abstract/88\">",
"      Hypertriglyceridaemia and vascular risk. Report of a meeting of physicians and scientists, University College London Medical School. Lancet 1993; 342:781.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/45/18138/abstract/89\">",
"      Garber AM, Avins AL. Triglyceride concentration and coronary heart disease. BMJ 1994; 309:2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/45/18138/abstract/90\">",
"      Avins AL, Neuhaus JM. Do triglycerides provide meaningful information about heart disease risk? Arch Intern Med 2000; 160:1937.",
"     </a>",
"    </li>",
"    <li>",
"     Gianturco SH, Bradley WA. A cellular basis for the potential atherogenicity of triglyceride-rich lipoproteins. In: Pathobiology of the Human Atherosclerotic Plaque, Slagov S, Newman WP III, Schaffer SA (Eds), Springer-Verlag, New York 1990.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/45/18138/abstract/92\">",
"      Wittrup HH, Tybjaerg-Hansen A, Abildgaard S, et al. A common substitution (Asn291Ser) in lipoprotein lipase is associated with increased risk of ischemic heart disease. J Clin Invest 1997; 99:1606.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/45/18138/abstract/93\">",
"      Wittrup HH, Nordestgaard BG, Sillesen H, et al. A common mutation in lipoprotein lipase confers a 2-fold increase in risk of ischemic cerebrovascular disease in women but not in men. Circulation 2000; 101:2393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/45/18138/abstract/94\">",
"      Dejager S, Bruckert E, Chapman MJ. Dense low density lipoprotein subspecies with diminished oxidative resistance predominate in combined hyperlipidemia. J Lipid Res 1993; 34:295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/45/18138/abstract/95\">",
"      Nigon F, Lesnik P, Rouis M, Chapman MJ. Discrete subspecies of human low density lipoproteins are heterogeneous in their interaction with the cellular LDL receptor. J Lipid Res 1991; 32:1741.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/45/18138/abstract/96\">",
"      Rosenson RS, Shott S, Tangney CC. Hypertriglyceridemia is associated with an elevated blood viscosity Rosenson: triglycerides and blood viscosity. Atherosclerosis 2002; 161:433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/45/18138/abstract/97\">",
"      Stamos TD, Rosenson RS. Low high density lipoprotein levels are associated with an elevated blood viscosity. Atherosclerosis 1999; 146:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/45/18138/abstract/98\">",
"      Duverger N, Kruth H, Emmanuel F, et al. Inhibition of atherosclerosis development in cholesterol-fed human apolipoprotein A-I-transgenic rabbits. Circulation 1996; 94:713.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/45/18138/abstract/99\">",
"      Shah PK, Kaul S, Nilsson J, Cercek B. Exploiting the vascular protective effects of high-density lipoprotein and its apolipoproteins: an idea whose time for testing is coming, part I. Circulation 2001; 104:2376.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/45/18138/abstract/100\">",
"      Rosenson RS, Brewer HB Jr, Chapman MJ, et al. HDL measures, particle heterogeneity, proposed nomenclature, and relation to atherosclerotic cardiovascular events. Clin Chem 2011; 57:392.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/45/18138/abstract/101\">",
"      Castelli WP. Cardiovascular disease and multifactorial risk: challenge of the 1980s. Am Heart J 1983; 106:1191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/45/18138/abstract/102\">",
"      Benoit P, Emmanuel F, Caillaud JM, et al. Somatic gene transfer of human ApoA-I inhibits atherosclerosis progression in mouse models. Circulation 1999; 99:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/45/18138/abstract/103\">",
"      Tangirala RK, Tsukamoto K, Chun SH, et al. Regression of atherosclerosis induced by liver-directed gene transfer of apolipoprotein A-I in mice. Circulation 1999; 100:1816.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/45/18138/abstract/104\">",
"      Navab M, Anantharamaiah GM, Hama S, et al. Oral administration of an Apo A-I mimetic Peptide synthesized from D-amino acids dramatically reduces atherosclerosis in mice independent of plasma cholesterol. Circulation 2002; 105:290.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/45/18138/abstract/105\">",
"      Hovingh GK, Brownlie A, Bisoendial RJ, et al. A novel apoA-I mutation (L178P) leads to endothelial dysfunction, increased arterial wall thickness, and premature coronary artery disease. J Am Coll Cardiol 2004; 44:1429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/45/18138/abstract/106\">",
"      Ansell BJ, Navab M, Hama S, et al. Inflammatory/antiinflammatory properties of high-density lipoprotein distinguish patients from control subjects better than high-density lipoprotein cholesterol levels and are favorably affected by simvastatin treatment. Circulation 2003; 108:2751.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/45/18138/abstract/107\">",
"      Bhattacharyya T, Nicholls SJ, Topol EJ, et al. Relationship of paraoxonase 1 (PON1) gene polymorphisms and functional activity with systemic oxidative stress and cardiovascular risk. JAMA 2008; 299:1265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/45/18138/abstract/108\">",
"      Kontush A, Chantepie S, Chapman MJ. Small, dense HDL particles exert potent protection of atherogenic LDL against oxidative stress. Arterioscler Thromb Vasc Biol 2003; 23:1881.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/45/18138/abstract/109\">",
"      Bisoendial RJ, Hovingh GK, Levels JH, et al. Restoration of endothelial function by increasing high-density lipoprotein in subjects with isolated low high-density lipoprotein. Circulation 2003; 107:2944.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/45/18138/abstract/110\">",
"      McGrath KC, Li XH, Puranik R, et al. Role of 3beta-hydroxysteroid-delta 24 reductase in mediating antiinflammatory effects of high-density lipoproteins in endothelial cells. Arterioscler Thromb Vasc Biol 2009; 29:877.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/45/18138/abstract/111\">",
"      Fryirs MA, Barter PJ, Appavoo M, et al. Effects of high-density lipoproteins on pancreatic beta-cell insulin secretion. Arterioscler Thromb Vasc Biol 2010; 30:1642.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/45/18138/abstract/112\">",
"      Bobik A. Apolipoprotein CIII and atherosclerosis: beyond effects on lipid metabolism. Circulation 2008; 118:702.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/45/18138/abstract/113\">",
"      Sacks FM, Alaupovic P, Moye LA, et al. VLDL, apolipoproteins B, CIII, and E, and risk of recurrent coronary events in the Cholesterol and Recurrent Events (CARE) trial. Circulation 2000; 102:1886.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/45/18138/abstract/114\">",
"      Kawakami A, Osaka M, Tani M, et al. Apolipoprotein CIII links hyperlipidemia with vascular endothelial cell dysfunction. Circulation 2008; 118:731.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4565 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-122.72.76.133-1FB45B5B38-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_45_18138=[""].join("\n");
var outline_f17_45_18138=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H188693598\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CLASSIFICATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Chylomicrons",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Very low density lipoprotein",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Intermediate density lipoprotein",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Low density lipoprotein",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      High density lipoprotein",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Apolipoproteins",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      CLINICAL CLASSIFICATION OF DYSLIPIDEMIAS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      EXOGENOUS PATHWAY OF LIPID METABOLISM",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      ENDOGENOUS PATHWAY OF LIPID METABOLISM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Low density lipoprotein",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      High density lipoprotein",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Lipoprotein(a)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      LIPOPROTEINS AND ATHEROSCLEROSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Low density lipoprotein",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Intermediate density lipoprotein (remnant lipoproteins)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Very low density lipoprotein",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      High density lipoprotein",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Triglyceride rich lipoproteins and apo C-III",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Lipoprotein(a)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H188693598\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/4565\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/4565|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?40/9/41104\" title=\"figure 1\">",
"      Chylomicron metabolism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?8/29/8657\" title=\"figure 2\">",
"      VLDL metabolism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?39/56/40839\" title=\"figure 3\">",
"      Metabolic pathways that regulate high-density lipoprotein",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?15/40/16014\" title=\"figure 4\">",
"      Lipids and premature CHD",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/4565|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?20/51/21307\" title=\"table 1\">",
"      Fredrickson classification",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?1/53/1883\" title=\"table 2\">",
"      Oxidized LDL in atherosclerosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?0/2/35\" title=\"table 3\">",
"      HDL-C and cardiovascular risk",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/61/36825?source=related_link\">",
"      Actions of angiotensin II on the heart",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/47/35578?source=related_link\">",
"      Approach to the patient with hypertriglyceridemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/2/39978?source=related_link\">",
"      HDL metabolism and approach to the patient with abnormal HDL-cholesterol levels",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/25/37274?source=related_link\">",
"      Inherited disorders of LDL-cholesterol metabolism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/19/40248?source=related_link\">",
"      Lipoprotein(a) and cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/31/31222?source=related_link\">",
"      Measurement of serum lipids and lipoproteins",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/2/32?source=related_link\">",
"      Mechanisms of benefit of lipid-lowering drugs in patients with coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/53/26456?source=related_link\">",
"      Nutritional antioxidants in coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?10/48/11011?source=related_link\">",
"      Patient information: High cholesterol (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?6/4/6212?source=related_link\">",
"      Patient information: High cholesterol and lipids (hyperlipidemia) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/23/6522?source=related_link\">",
"      Structure and function of the insulin receptor",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f17_45_18139="Uses for vagal maneuvers";
var content_f17_45_18139=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F67134&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F67134&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Conditions in which vagal maneuvers may be useful diagnostically or therapeutically",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Tachyarrhythmias",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Narrow, regular supraventricular tachycardias",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sinus tachycardia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Atrial fibrillation and flutter",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ventricular tachycardia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Conduction abnormalities",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2:1 AV block",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Bundle branch blocks",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pre-excitation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Other cardiovascular uses",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Carotid sinus hypersensitivity",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Coronary artery disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Angina",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pulmonary edema",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Peter J Zimetbaum, MD and Daniel Frisch, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_45_18139=[""].join("\n");
var outline_f17_45_18139=null;
var title_f17_45_18140="Mgmt antiviral resist HBV";
var content_f17_45_18140=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F68845&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F68845&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Management of antiviral-resistant HBV",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"2\">",
"        Prevention",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"2\">",
"        Avoid unnecessary treatment",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"2\">",
"        Initiate treatment with potent antiviral that has high barrier to drug resistance or with combination therapy if drugs with low barrier to resistance are used",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"2\">",
"        Switch to alternative therapy in patients with primary non-response",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"2\">",
"        Monitoring",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"2\">",
"        Test for serum HBV DNA (PCR assay) every 3-6 months during treatment",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"2\">",
"        Check for medication compliance in patients with virologic breakthrough",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"2\">",
"        Confirm antiviral resistance with genotypic testing",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"2\">",
"        Treatment",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        Lamivudine or telbivudine-resistance &rarr;",
"       </td>",
"       <td>",
"        Add adefovir*, switch to&nbsp;tenofovir",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Stop lamivudine, switch to Truvada&bull;&Delta;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"3\">",
"        Adefovir-resistance &rarr;",
"       </td>",
"       <td>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Stop adefovir, switch to Truvada&bull;&Delta;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Switch to or add entecavir&Delta;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Entecavir-resistance &rarr;",
"       </td>",
"       <td>",
"        Switch to tenofovir or Truvada&Delta;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        Tenofovir-resistance&loz; &rarr;",
"       </td>",
"       <td>",
"        Switch to entecavir",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Stop tenofovir, switch to Truvada",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * In countries where tenofovir is not available.",
"     <br>",
"      &bull; Truvada = combination pill with emtricitabine 200 mg and tenofovir 300 mg.",
"      <br>",
"       &Delta; Not approved for non HIV infected persons.",
"       <br>",
"        &loz; Clinical data not available.",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Adapted with permission from: Lok ASF, McMahon BJ. Chronic hepatitis B: Update 2009. Hepatology 2009; 50:661. Available online at file://publish.aasld.org/Pages/Default.aspx. Accessed September 8th 2009. Copyright &copy; 2009 American Association for the Study of Liver Diseases.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_45_18140=[""].join("\n");
var outline_f17_45_18140=null;
var title_f17_45_18141="Bacterial meningitis adult antibiotic dosing";
var content_f17_45_18141=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F60707&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F60707&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Recommended intravenous dosages of antimicrobial therapy for adults with bacterial meningitis who have normal renal and hepatic function",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Antimicrobial agent",
"       </td>",
"       <td class=\"subtitle1\">",
"        Dose (adult)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Amikacin",
"       </td>",
"       <td>",
"        5 mg/kg every 8 hours*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ampicillin",
"       </td>",
"       <td>",
"        2 g every 4 hours",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Aztreonam",
"       </td>",
"       <td>",
"        2&nbsp;g every 6 to 8 hours",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cefepime",
"       </td>",
"       <td>",
"        2 g every 8 hours",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cefotaxime",
"       </td>",
"       <td>",
"        2&nbsp;g every 4 to 6 hours",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ceftazidime",
"       </td>",
"       <td>",
"        2 g every 8 hours",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ceftriaxone",
"       </td>",
"       <td>",
"        2 g every 12 hours",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Chloramphenicol",
"       </td>",
"       <td>",
"        1 to 1.5 g every 6 hours",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ciprofloxacin",
"       </td>",
"       <td>",
"        400 mg every 8 to 12 hours",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Gentamicin",
"       </td>",
"       <td>",
"        1.7&nbsp;mg/kg every 8 hours*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Meropenem",
"       </td>",
"       <td>",
"        2&nbsp;g every 8 hours",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Moxifloxacin",
"       </td>",
"       <td>",
"        400 mg every 24&nbsp;hours",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Nafcillin",
"       </td>",
"       <td>",
"        1.5 to 2&nbsp;g every 4 hours",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Oxacillin",
"       </td>",
"       <td>",
"        1.5 to 2 g every 4 hours",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Penicillin G potassium",
"       </td>",
"       <td>",
"        4 million units every 4 hours",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Rifampin",
"       </td>",
"       <td>",
"        600 mg every 24 hours",
"        <sup>",
"         &loz;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Tobramycin",
"       </td>",
"       <td>",
"        1.7&nbsp;mg/kg every 8 hours*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Trimethoprim-sulfamethoxazole (cotrimoxazole)",
"       </td>",
"       <td>",
"        5 mg/kg every 6 to 12 hours",
"        <sup>",
"         &sect;&yen;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Vancomycin",
"       </td>",
"       <td>",
"        15 to 20 mg/kg every 8&nbsp;to 12 hours",
"        <sup>",
"         ������",
"        </sup>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    MRSA: methicillin-resistant",
"    <em>",
"     Staphylococcus aureus",
"    </em>",
"    <div class=\"footnotes\">",
"     * Dose based on ideal body weight or dosing weight, except in underweight patients. A calculator for ideal body weight and dosing weight is available in UpToDate.&nbsp;Dosage and interval must be individualized to produce a peak serum concentration of 7-9 mg/L and trough &lt;1-2 mg/L for gentamicin or tobramycin and a peak of 25-40 mg/L and trough &lt;4-8 mg/L for amikacin. For additional information, see the topic review on aminoglycosides.",
"     <br>",
"      &bull;&nbsp;The higher dose is recommended for patients with pneumococcal meningitis.",
"      <br>",
"       &Delta;&nbsp;No data on optimal dosage needed in patients with bacterial meningitis.",
"       <br>",
"        &loz;&nbsp;For the treatment of MRSA meningitis, the Infectious Diseases Society of America (IDSA)&nbsp;suggests a rifampin dose of 600 mg orally once daily or 300 to 450 mg twice daily.",
"        <sup>",
"         [1]",
"        </sup>",
"        <br>",
"         &sect;&nbsp;Dosage is based on the trimethoprim component.",
"         <br>",
"          &yen;&nbsp;For the treatment of MRSA meningitis, the IDSA suggests a trimethoprim-sulfamethoxazole dose of 5 mg/kg (based on the trimethoprim component) IV twice or three times daily.",
"          <sup>",
"           [1]",
"           <br/>",
"          </sup>",
"          &Dagger;&nbsp;The vancomycin dose should not exceed 2 g per dose or a total daily dose of 60 mg/kg.&nbsp;Adjust dose to achieve vancomycin serum trough concentrations of 15 to 20 mcg/mL.",
"          <sup>",
"           [1]",
"          </sup>",
"         </br>",
"        </br>",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Modified with permission from: Tunkel AR, Hartman BJ, Kaplan SL, et al. Practice guidelines for the management of bacterial meningitis. Clin Infect Dis 2004; 39:1267. Copyright &copy; 2004 University of Chicago Press.",
"     <br>",
"      <em>",
"       Additional data from:",
"       <br/>",
"      </em>",
"      [1] Liu C, Bayer A, Cosgrove SE, et al. Clinical Practice Guidelines by the Infectious Diseases Society of America for the Treatment of Methicillin-Resistant Staphylococcus Aureus Infections in Adults and Children: Executive Summary. Clin Infect Dis 2011; 52:285.",
"     </br>",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.journals.uchicago.edu/\">",
"      file://www.journals.uchicago.edu/",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_45_18141=[""].join("\n");
var outline_f17_45_18141=null;
var title_f17_45_18142="TMLR improvement angina";
var content_f17_45_18142=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F72331&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F72331&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Improvement in angina is greater with transmyocardial laser revascularization",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 436px; height: 261px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Among 275 patients with NYHA class IV refractory angina who were randomized to transmyocardial laser revascularization (TMLR) or medical therapy (MT), improvement in angina at 3, 6, and 12 months was better with TMLR than MT (p &lt;0.001 for the comparison between TMLR and MT at all three points in time). Patients initially assigned to receive MT who met the criteria for treatment failure and subsequently underwent TMLR (crossover) also had a significant improvement in angina.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Allen KB, Dowling RD, Fudge TL, et al. N Engl J Med 1999; 341:1029.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_45_18142=[""].join("\n");
var outline_f17_45_18142=null;
var title_f17_45_18143="Back leg raise exercise";
var content_f17_45_18143=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F61047&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F61047&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Strength exercise: Back leg raise",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 369px; height: 297px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This exercise strengthens your buttocks and lower back. For an added challenge, you can modify the exercise to improve your balance.",
"    <ol>",
"     <li>",
"      Stand behind a sturdy chair, holding on for balance. Breathe in slowly.",
"     </li>",
"     <li>",
"      Breathe out and slowly lift one leg straight back without bending your knee or pointing your toes. Try not to lean forward. The leg you are standing on should be slightly bent.",
"     </li>",
"     <li>",
"      Hold position for one second.",
"     </li>",
"     <li>",
"      Breathe in as you slowly lower your leg.",
"     </li>",
"     <li>",
"      Repeat 10 to 15 times.",
"     </li>",
"     <li>",
"      Repeat 10 to 15 times with other leg.",
"     </li>",
"     <li>",
"      Repeat 10 to 15 more times with each leg.",
"     </li>",
"    </ol>",
"    As you progress, you may want to add ankle weights.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Go4Life. National Institute on Aging at the National Institutes of Health. Available at: file://go4life.niapublications.org (Accessed December 2, 2011).",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_45_18143=[""].join("\n");
var outline_f17_45_18143=null;
